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hearing: anatomy and physiology
Of all the human senses, hearing is the most astounding achievement of evolution. Sound, 
be it spoken language or originating from another source, reaches the tympanic membrane 
by travelling through the external auditory meatus (ear canal) (Figure 1). The sound waves 
are propagated by the tympanic membrane (eardrum) that passes its vibrations on to the 
ossicles, the three smallest bones of the human body: the malleus (hammer), incus (anvil) 
and stapes (stirrup). The footplate of the stapes, which is inserted into the oval window, 
serves as a piston so that the mechanical energy is transferred into the cochlea, which 
houses the sensory receptors of hearing.
The	 cochlea	 (from	 the	Greek	 κοχλιασ	 (kokhlias)	meaning	 snail)	 is	 a	 bony	 structure	 that	
coils around its own axis. In humans it has approximately 2.5 turnsfootnote1. It contains three 
fluid-filled	 compartments	of	which	 the	outer	 two,	 the	 scala	vestibuli	and	 scala	 tympani,	
are connected in the helicotrema at the apex of the cochlea. The middle compartment, the 
Figure 1. Schematic illuStration oF the outer, middle and inner ear.
1: auricle (pinna), 2: external auditory meatus (ear canal), 3: tympanic membrane (eardrum), 4: the three auditory ossicles (malleus 
or hammer, incus or anvil, and stapes or stirrup), 5: oval window with the footplate of the stapes, 6: cochlea. Picture courtesy of S.B. 












cochlear duct (or scala media), contains the structure that houses the sensory receptors of 
hearing: the organ of Corti (Figures 2 and 3).
Vibration	 of	 the	 stapes	 creates	 a	 traveling	 wave	 in	 the	 fluid	 (perilymph)	 of	 the	 scala	
vestibuli	and	scala	tympani.	This	results	in	displacement	of	the	floor	(basilar	membrane)	
of the cochlear duct, onto which the organ of Corti is located. The location of maximum 
displacement depends on the sound frequency: high frequencies are detected in the basal 
turn, whereas lower frequencies are detected in the more apically located turns. The organ 
of Corti contains the hair cells: in humans, it consists of one row of inner hair cells (~3,500 
cells) and three rows of outer hair cells (~12,000 cells) [1]. If the displacement of the basilar 
membrane is large enough, mechanosensitive transduction channels in the stereocilia of the 
hair	cells	are	opened.	The	fluid	of	the	cochlear	duct	(endolymph)	is	rich	in	potassium,	which	
is	secreted	by	the	stria	vascularis,	and	opening	of	the	transduction	channels	causes	an	influx	
of potassium ions leading to depolarization of the hair cells. Here, the mechanical energy 
is converted into an electrochemical signal as the hair cell activates the connecting nerve 
endings (synapses) of the spiral ganglion neurons by releasing neurotransmitters. Inner hair 




transmitters of information: upon neurotransmitter release by the hair cells, spiral ganglion 
Figure 2. Schematic repreSentation oF a midmodiolar 
tranSection oF the adult human cochlea.
1: cochlear nerve, 2: spiral ganglion, 3: scala vestibuli, 4: scala 
tympani, 5: cochlear duct / scala media.  B1: lower basal turn, 
B2: upper basal turn, M1: lower middle turn, M2: upper 
middle turn, A: apex. Picture courtesy of S.B. Blankevoort.
Figure 3. Schematic illuStration oF the cochlear duct and 
Surrounding StructureS.
1: inner hair cell, 2: outer hair cells, 3: nerve fibers innervating 




neurons depolarize and generate action potentials that travel along the cochlear nerve (i.e., 
the cochlear branch of the 8th	cranial	nerve)	to	the	brainstem.	Efferent	connections	to	hair	




the otic placode arises, which is destined to develop into the inner ear (Figure 4). The otic 
placode invaginates to form the otic vesicle (or otocyst) during the 6th week of gestationfootnote2 
[2]. In the subsequent weeks, the otic vesicle polarizes and transforms into the membranous 
labyrinth,	a	 continuum	of	fluid	filled	 canals	and	chambers	of	both	 the	vestibular	organ	
Figure 4. the otic placode.
A specialized area of the surface ectoderm called the otic 
placode is destined to form the otic vesicle and forms the basis 
of the cochlea. Early in development, it can be recognized as 
a thickened group of ectodermal cells (red) located near the 
hindbrain. Around Carnegie stage 13 (ca 6th week of gestation), 
the placode invaginates and pinches off from the surface to 
form the otic vesicle. 
Figure 5. human Fetal cochlea at the 10th week oF 
geStation. 
(A) Hematoxylin-eosin staining of a transection through the 
lower basal turn. Both the epithelium of the cochlear duct (1) 
and the nearby spiral ganglion (2) are visible. Cells from the 
epithelium are microscopically undifferentiated at this stage. 
(B) Higher magnification of the area of the spiral ganglion 
(delineated with white dots). The large round nuclei belong 
to the developing spiral ganglion neurons. The smaller, darker 
and more elongated nuclei belong to the developing glial cells. 












and the cochlea. During a process called delamination, some cells from the otic vesicle/
labyrinth detach from the otic epithelium and migrate into the surrounding mesenchyme, 
and from this group of cells the spiral ganglion neurons originate [3]. The cochlear part of 
the	labyrinth	(the	cochlear	duct)	spirals	around	a	central	axis	and	reaches	its	final	2.5	turns	
at the end of the 10th or at the start of the 11th week of gestation [4, 5]. 
At this stage, the cells forming the epithelial lining of the cochlear duct (all derived from the 
otic	placode/vesicle)	are	microscopically	still	undifferentiated	(Figure	5A).	The	delaminated	
spiral ganglion neurons group together with the peripheral glial cells in the neighbouring 
spiral ganglion (Figure 5B). At the 12th week of gestation, a general developmental aspect 
of	 the	cochlea	can	be	observed:	a	 spatiotemporal	gradient	 in	a	basal-to-apical	direction	
(Figure 6A). The development of the basal turn is ahead of that of the apical turn by one 
or	 two	weeks,	which	 is	 a	 consistent	 finding	 during	maturation	 of	 the	 cochlea.	Also,	 the	
spiral ganglion and the cochlear duct move away from one another, the scala vestibuli and 
tympani	are	formed,	and	the	first	hair	cell	becomes	visible	in	the	epithelial	lining	of	the	basal	
turn	(Figures	6B-C).	At	14	weeks	of	gestation,	
one row of inner hair cells and three rows of 
outer hair cells can be discerned (Figure 7). 
Although the major structures in the cochlea 
are	readily	recognizable,	differentiation	and	
maturation continue through subsequent 
stages of development. Based upon the 
structural development of the human fetal 
cochlea and insights gained from animal 
studies, it has been estimated that the onset 
of cochlear function occurs around 20 weeks 
of gestation [6, 7].
Figure 6. human Fetal cochlea at the 12th week oF geStation. 
(A) Hematoxylin-eosin staining of a midmodiolar transection 
through the entire cochlea. (B) In the lower basal turn, the scala 
vestibuli and tympani have been formed, the distance between 
the spiral ganglion and the cochlear duct is increasing, and (C) 
the first hair cell becomes visible (arrow head). #, tissue artifact; 
B1, lower basal turn; B2, upper basal turn; M1, lower middle 
turn; M2, upper middle turn; A, apex; ScG, Scarpa’s ganglion; 




Worldwide,	360	million	individuals	suffer	from	disabling	hearing	lossfootnote3, which is over 
5%	of	the	world’s	total	population	[8].	Although	this	number	also	includes	patients	suffering	
from conductive hearing loss (the origin of which lies in the external or middle ear), a large 
part is of sensorineural origin. Sensorineural hearing loss (SNHL) is therefore the most 
prevalent	 sensorineural	 disorder	 afflicting	 human	 beings.	 SNHL	 can	 either	 be	 acquired	
or congenital. Of the acquired type, hearing loss due to aging (presbycusis), ototoxicity or 
acoustic	trauma	are	well-known	examples.	Often,	outer	hair	cells	are	primarily	affected	[1].	
Congenital SNHL is the most common congenital disorder with a prevalence of 1 in every 
1000 newborns in the UK and the Netherlands [9, 10]. In many countries, national neonatal 
screening programs to detect SNHL have therefore been implemented. Genetic (hereditary) 
factors	are	implicated	in	over	two-thirds	of	patients	afflicted	by	congenital	SNHL	cases,	
although exact numbers are not available due to our incomplete etiological understanding. 
Hereditary SNHL can be divided into syndromic and nonsyndromic forms. Although the 
search for responsible genes for SNHL is still ongoing, our knowledge has rapidly increased 
during	the	last	few	decades.	Over	130	loci	have	been	mapped	and	over	60	different	genes	
have	been	identified	to	date	(2014)	[11]footnote4. Nonsyndromic forms of hereditary SNHL are 
grouped	into	autosomal	dominant	(DFNA),	autosomal	recessive	(DFNB),	X-linked	(DNFX)	
and	mitochondrial	subtypes.	Unlike	acquired	SNHL,	only	a	minority	of	mutations	affect	the	
hair cells in hereditary SNHL. Mutations have likewise been found in various other cell 
types involved in the function of the cochlea or the cochlear nerve.
Much can be learned from studies 
investigating gene expression 
patterns in experimental animals 
as well as from studies on 
developmental abnormalities 
in animal models of hereditary 
SNHL. However, this knowledge 
does not yet extend to the full 
scale of known mutations causing 
SNHL and only a limited number 
of studies have been performed 
on human tissues. Understanding 
etiologies and pathologies of 
disorders is essential to the 
advancement of therapeutic 
Figure 7. human organ oF corti at the 14th week oF geStation. 
Hematoxylin-eosin staining of a transection through the organ of Corti 
located in the lower basal turn. IHC, inner hair cell; OHCs, outer hair cells; 
H, Hensen’s cells; Cl, Claudius cells; Dcs, Deiters’ cells; opc, outer pillar cell; 
ipc, inner pillar cell; iph, inner phalangeal cell; SpV, spiral vessel; tc, tunnel 

















to	 hearing	 aids,	 varying	 from	 ‘simple’	 types	 worn	 behind	 the	 ear	 to	 cochlear	 implants	
requiring surgery for implantation. However, their function is largely dependent on the 
quality of the remaining cellular structures within the cochlea and the integrity of the 
cochlear nerve. Hair cell loss, strial dysfunction, or neuronal degeneration can severely limit 
the	hearing	aid’s	functionality.	One	remaining	therapeutic	option	is	the	auditory	brainstem	
implant: by bypassing the entire cochlea as well as the cochlear nerve, the brainstem is 
directly stimulated. However, as the quality of hearing with such an implant still remains 
very	low	[12],	a	different	approach	would	be	to	induce	tissue	regeneration,	 i.e.	to	restore	
damaged hair cells or to regenerate the cochlear nerve. This might either improve the 
hearing	aid’s	functionality,	or	could	possibly	restore	hearing	itself.
Several	 different	 approaches	 to	 achieve	 restoration	 of	 damaged	 cochlear	 structures	 are	
currently being investigated. One interesting option involves introducing neurotrophic 
factors (proteins that stimulate growth and survival of neurons) into the cochlea aiming 
to promote spiral ganglion neuron survival or even regrowth of their peripheral processes 
[13]. The authors speculate that application of exogenous neurotrophic factors enhances 
the function of cochlear implants or may even create direct contact between the electrode 
and	the	nerve	fibers	[14–16].
Another approach is gene therapy, for example to generate new hair cells from supporting 
cells. Introduction of viral vectors that induce expression of Atoh1 (the master regulator 
of	 hair	 cell	 differentiation)	 could	 convert	 targeted	 cells	 into	 new	 hair	 cells,	 potentially	
improving	hearing	[17–21].	However,	it	is	difficult	to	target	the	right	cells	without	affecting	
other cell types and disturbing cochlear architecture and function.
Regeneration of degenerated structures by stem cells is yet another, promising, approach. 
The rationale is that stem cells have migratory capabilities allowing them to reach 
appropriate	locations,	and	that	they	subsequently	differentiate	into	the	desired	cell	type.	
Knowledge on the developmental origin of the damaged cell types as well as the factors that 
trigger	differentiation	is	advantageous	in	the	selection	of	the	appropriate	type	of	stem	cell.	
Recently, otic progenitor cells induced from human embryonic stem cells were used in an 




more insight into inner ear development and pave the way 
for transplantation studies using in vitro grown hair cells. 
hearing: the hair folliCle option
The development of stem cell based therapeutic strategies 
for restoration of auditory function starts with the search 
for the appropriate type of stem cell. In 2004 and 2005, 
two groups showed that pluripotent neural crest stem cells 
reside within the bulge of the hair follicle (Figure 8) in 
the whisker pads of adult mice. These cells were capable 
of	 differentiation	 into	 neurons,	 Schwann	 cells	 and	
melanocytes in vitro [24, 25]. Further studies showed that 
these cells could form neurons in vivo and promote axonal 
regeneration [26, 27]. Theoretically, these stem cells could 
be candidates to regenerate or repair the auditory nerve 
or its glial cells.
The use of neural crest stem cells residing in the hair 
follicle has several advantages over the use of other stem cells, such as embryonic or induced 
pluripotent stem cells. They are easily harvested, they are not oncogenic, and there are no 
ethical issues involved. More importantly, hair follicle derived neural crest stem cells reside 
in the adult body (at least in the mouse). Another advantage of these stem cells is that they 
have	a	neural	crest-like	phenotype,	implying	that	they	are	already	committed	to	follow	a	
limited	number	of	cellular	lineages,	thus	reducing	the	risk	of	differentiation	into	unwanted	
cell types. Finally, when used in a therapeutic setting, these cells can be used for autologous 
transplantation without triggering unwanted immune responses in the host.  
aims and sCope of this thesis
The	aims	and	scope	of	this	thesis	are	two-fold:	(1)	To	gain	more	insight	into	the	development	
of the human cochlea and (2) to investigate a possible stem cell strategy for the restoration 
of	hearing.	Although	 these	 two	goals	 share	 little	 common	ground	at	first	 sight,	 they	are	
intimately associated with one another. When one pursues tissue regeneration, it is of huge 
advantage	 to	have	 the	blue	print	 of	 the	 tissue’s	 normal	 development,	 in	 order	 to	 avoid	
‘shooting	in	the	dark’.	Or,	in	other	words,	when	something	is	broken,	one	needs	to	know	how	
it normally functions in order to repair it. Knowing the origin of the degenerated cell type 
aids in selecting the proper replacement, and knowledge of the normal developmental steps 
helps	in	guiding	a	stem	cell	towards	a	specific	cellular	lineage.	
Figure 8. Schematic illuStration oF a 
tranSection through the hair Follicle. 
Neural crest stem cells are thought 
to reside in the hair follicle bulge. 













outline of this thesis
The	first	and	largest	part	of	this	thesis	investigates	the	normal	development	of	the	human	
cochlea. Chapter 2 focuses on the neurosensory epithelium, from which the hair cells develop, 
and its developmental relation with the innervating spiral ganglion neurons. In Chapter 3, 
this investigation is extended towards the third cell type involved in the hair cell and spiral 
ganglion neuron triad: the glial cell. Here, the focus is on the developmental distribution of 
the peripheral glial cells and on the onset of myelination, one of the prerequisites of normal 
hearing. Focusing on one of the most undervalued cochlear structures that are involved 
in hearing, Chapter 4 investigates the development of the stria vascularis and cochlear 
potassium regulation, including its relation to syndromic and nonsyndromic SNHL. 
Chapters	5-7	are	related	to	the	neural	crest	stem	cells	residing	in	the	hair	follicle.	Chapter 
5	serves	as	an	introduction	to	this	part	of	the	thesis	and	as	a	short	summary	of	the	findings	
and implications of Chapter 6, which is solely about skin melanocytes. These insights are 
further elaborated in Chapter 7, where we investigate and identify cells growing in hair 
follicle bulge explant cultures. Chapter 8, the general discussion, combines and discusses 
Chapters	 2-7	 and	 speculates	 on	 one	 of	 the	 most	 intriguing	 aspects	 of	 human	 cochlear	
development: the onset of human hearing.
Footnotes:
1:	The	size	and	number	of	cochlear	turns	differ	between	mammals.	The	whale	cochlea	has	1.5	turns,	
a typical mouse cochlea has 2 turns, whereas the cochlear of elephants (similar to humans) has 2.5 
turns.	The	guinea	pig	rules	them	all:	it	has	3.5-4.5	turns	(for	images	and	other	animals,	see:	http://
csi.whoi.edu/inner-ears-gallery).
2: Gestational age is equivalent to weeks post conception (fetal age) plus two weeks, as gestational 
age	is	measured	from	the	first	day	of	the	last	menstrual	period.
3:	According	to	the	WHO’s	standards,	disabling	hearing	loss	refers	to	a	hearing	loss	greater	than	40	
dB in the better hearing ear in adults and a hearing loss greater than 30 dB in the better hearing ear 
in children.
4: An extensive table on involved genes, their function, gene expression and hearing loss type as well 
as an image showing the location of these genes within the cochlea can be found in Morton and 
Nance, NEJM, 2006. Also, on the Hereditary Hearing Loss Homepage (hereditaryhearingloss.org) an 
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abstraCt
Background: Hearing depends on correct functioning of the cochlear hair cells, 
and their innervation by spiral ganglion neurons. Most of the insight into the 
embryological and molecular development of this sensory system has been derived 
from animal studies. In contrast, little is known about the molecular expression 
patterns and dynamics of signaling molecules during normal fetal development of 
the	human	cochlea.	In	this	study,	we	investigated	the	onset	of	hair	cell	differentiation	
and innervation in the human fetal cochlea at various stages of development.
Results: At 10 weeks of gestation, we observed a prosensory domain expressing 
SOX2 and SOX9/SOX10 within the cochlear duct epithelium. In this domain, 
hair	 cell	 differentiation	 was	 consistently	 present	 from	 12	 weeks,	 coinciding	
with downregulation of SOX9/SOX10 to be followed several weeks later by 
downregulation of SOX2. Outgrowing neurites from spiral ganglion neurons were 
found	penetrating	into	the	cochlear	duct	epithelium	prior	to	hair	cell	differentiation	
and directly targeted the hair cells as they developed. Ubiquitous Peripherin 
expression by spiral ganglion neurons gradually diminished and became restricted 
to the type II spiral ganglion neurons by 18 weeks. At 20 weeks, when the onset of 
human	hearing	is	thought	to	take	place,	 the	expression	profiles	 in	hair	cells	and	
spiral ganglion neurons matched the expression patterns of the adult mammalian 
cochleae. 
Conclusions: Our study provides new insights into the fetal development of 
the human cochlea contributing to our understanding of deafness and to the 













The cochlea houses two of the main cell types responsible for hearing: the hair cells, 
and the spiral ganglion neurons (SGNs). Damage to the cochlea is usually associated 
with degeneration and irreversible loss of these cell types, which ultimately leads 
to permanent sensorineural hearing loss, the most common type of deafness [1, 
2]. In order to develop new therapeutic strategies, it is essential to have a better 
understanding of the normal molecular development of the human cochlea. 
In the human embryo, the otic placode invaginates to form the otic vesicle (or 
otocyst) during week 6 of gestation (W6), equivalent to week 4 of fetal development 
[3]. In the subsequent weeks, the otic vesicle develops into both the vestibular 









human fetus in the region where the OC will form [5]. The OC reaches its gross 
adult morphology around W20, which corresponds to the onset of auditory function 
[9-11].





IHCs and OHCs until 6 to 7 days after birth when a clear distinction between type 
I	and	type	II	ganglion	neurons	takes	place,	just	prior	to	the	onset	of	hearing	(post-
natal week 2) [13, 14]. In humans, penetration of the SGN neurites into the cochlear 
neuroepithelium	has	been	observed	earlier	than	the	first	differentiation	of	hair	cells	
by electron microscopy [5]. The peripheral neurites of the SGNs penetrate the basal 
turn	around	W11,	and	in	the	following	weeks	find	their	way	to	the	developing	hair	
cells and shape their synaptic connections [5, 15]. However, the separation of type I 
neurosensory development
26
and type II SGNs has not been investigated in humans.
Here, we investigated both the dynamics of development of human cochlear 
hair cells and their innervation. The spatial and temporal dynamics of hair cell 
differentiation	was	determined	by	examining	the	expression	of	three	members	of	
the SOX family, a group of genes involved with cell fate decisions: SOX2, SOX9, and 
SOX10.	An	example	of	early	cell	fate	specification	in	the	cochlear	duct	epithelium	
is the spatially restricted expression of SOX2 to the cells of the prosensory domain 
[8]. The functional importance of the SOX2 transcription factor in normal 
cochlear development is further illustrated by failure of the prosensory domain 
establishment	in	loss-of-function	conditions	[8],	and	underdevelopment	of	hair	cells	
in	gain-of-function	conditions	[16].	Sox9 and Sox10 are known to be expressed in 
the	otic	placode	and	the	otic	vesicle	in	frog	and	chick	[17-20].	In	mice,	SOX9	is	also	
expressed in the otic placode and otic vesicle and controls invagination [21], and 
both	SOX9	and	SOX10	have	been	found	in	the	mouse	cochlear	duct	epithelium	[22-
26]. Interestingly, in mice, Sox9 and Sox10 are downregulated before or upon hair 
cell	differentiation,	whereas	Sox2	 is	downregulated	gradually,	although	all	 three	
Sox genes remain expressed in the underlying supporting cells in the OC [8, 22, 23].
In humans, SOX2, SOX9, and SOX10 are likely to play an important role in cochlear 
development, as mutations in all three genes have been shown to cause sensorineural 
hearing	loss	[27-29].	However,	although	SOX10	expression	has	been	reported	in	the	
human otic vesicle [30], expression patterns of these SOX transcription factors, and 
their	dynamics	upon	hair	cell	differentiation,	have	not	previously	been	determined	
in the (developing) human cochlea. In addition, the innervation of the IHCs 
and OHCs was in the current study investigated by comparing the dynamics of 
expression	of	Peripherin	(PRPH),	an	intermediate	filament	protein	that	is	expressed	
in type II SGNs, both in adult mouse and adult human cochleae [13, 31], along 
with the expression of class III β-Tubulin (TUBB3), a general SGN marker. The 
comprehensive description of the molecular and morphological events taking place 
in	 the	 cochlea	 as	 functional	 hearing	 develops	 may	 benefit	 the	 development	 of	













The human prosensory domain is SOX2-positive
To determine whether a prosensory domain also exists during human development, 
we investigated the expression of SOX2 at W10.4 (week 10 and 4 days), a stage when 
the	cochlear	duct	epithelium	showed	no	clear	morphological	hair	cell	specification	
(Fig. 1A). At this point, nuclear SOX2 expression was already restricted to the 
human prosensory domain (Fig. 1B) and no expression was visible in other parts of 
the cochlear duct, except for cytoplasmic SOX2 expression in the lateral wall of the 
cochlear duct epithelium (Fig. 1B, asterisk). At W10.4, SOX9 not only overlapped 
with SOX2 in the prosensory domain, but showed uniform nuclear expression in 
all cells of the cochlear duct epithelium, similar to that described in the developing 
mouse cochlea [23]. SOX9 was also expressed in the Schwann cells of the adjacent 
spiral ganglion (Fig. 1C) and in the cartilage cells of the otic capsule (Fig. 1C).
Differentiating	cochlear	hair	cells	downregulated	SOX9	and	SOX10,	followed	by	
SOX2 
At W12, the openings of the scala vestibuli and the scala tympani were observed, 
respectively, above and beneath the basal turn of the cochlear duct (Fig. 1D). The 
first	morphological	signs	of	hair	cell	differentiation	were	then	visible	exclusively	in	
the basal turn, as a row of single cells that emerged facing the luminal aspect of the 
SOX2-positive	prosensory	domain	(Fig.	1D,	E).	Immunostaining	for	myosin	VIIA	




downregulation of SOX9 (Fig. 1F). 
At	W14	 (2	weeks	 later)	 the	SOX2-positive	prosensory	domain	 is	developing	 into	
the	OC,	with	maturation	progressing	in	a	basal-to-apical	gradient.	In	the	current	
study	we	 found	 that	 solitary	 IHCs	were	 differentiated	 in	 the	 apical	 and	middle	







underneath both IHCs and OHCs remained positive for boeth SOX2 and SOX9 
(Fig.	2A-I).	
In the basal turn of the W19 cochlea, all IHCs and OHCs had become negative 
for both SOX2 and SOX9, in contrast to the supporting cells in the OC and in 
some	of	the	adjacent	cells	in	Kölliker’s	organ,	which	expressed	SOX2	(Fig.	2J,	K),	
acquiring the mature SOX2/SOX9 expression pattern seen in the mouse OC [23, 
32], which has yet to be investigated in the adult human cochlea. In the developing 
hair cells, the dynamics of SOX10 and SOX9 expression were identical (Fig. 3). 
Downregulation	of	SOX10	coincided	directly	with	the	first	hair	cell	specification	at	
W12, and expression was maintained in supporting cells (Fig. 3).
At W12 to W19, in the developing OC, either only the IHCs or the full set of IHCs and 
OHCs (O1, O2, and O3) were visible. Therefore, we next investigated whether the 
OHCs	could	be	derived	from	the	first	differentiated	IHCs	by	cell	division.	However,	
after performing immunostaining for proliferating cell nuclear antigen (PCNA), a 
marker of cycling cells, we found that all cells of the prosensory domain had exited 
the cell cycle at this stage (W10 to W12) (Fig. 4A, B). This strongly suggested that 
cells in the prosensory domain/OC do not proliferate, supporting the idea that the 
OHCs	differentiate	from	cells	in	the	prosensory	domain,	but	are	not	progeny	of	the	
IHCs. At W14, most cells in the cochlear duct, including the OC cells, were PCNA 
negative (Fig. 4C).    
Innervation of the cochlear duct by PRPH-positive neurites precedes hair cell 
differentiation
At	W10.4,	both	PRPH-positive	and	TUBB3-positive	neurites	were	present	at	 the	
distal end of the spiral ganglion in the basal turn directly beneath the prosensory 
domain, but these neurites did not innervate into the epithelium of the cochlear 
duct (Fig. 5A). As there are no hair cells yet at this stage, no cells expressed MYO7A 
(Fig. 5B).
As	at	W10.4,	both	PRPH-positive	and	TUBB3-positive	neurites	where	still	located	
directly below the prosensory domain in the W12 apical turn (Fig. 5C). However, 
high	magnification	scanning	revealed	the	presence	of	PRPH-positive	and	TUBB3-
positive growth cones extending a few micrometers into the cochlear epithelium 
(Fig.	5C’,	white	and	black	arrows,	respectively),	suggesting	that	in	humans	neurites	













In the W12 middle turn, innervation by both PRPH and TUBB3 positive neurites 
advanced further into the epithelium (Fig. 5E). These neurites penetrated the 
basement membrane at multiple positions directly below the reorganizing 





here as IHCs, at multiple positions along its basal side (Fig. 5G, H). Many neurites 
seemed to express both PRPH and TUBB3. Strikingly, single neurites positive for 
both PRPH and TUBB3 invaded the epithelium at a more lateral position, at the 
site of the future OHCs (Fig. 5G, yellow arrow), suggesting that innervation into the 
future	OHC	area	precedes	OHC	differentiation,	just	as	innervation	into	the	IHC	
area	precedes	IHC	differentiation.
PRPH-positive neurites become restricted to the OHC by W20.3 
At W14, the middle turn showed only IHCs (Fig. 6A, B), whereas at W15, the 
middle turn showed the full complement of IHCs and OHCs. In both stages, the 
full	complement	of	IHCs	and	OHCs	was	visible	in	the	basal	turn	(Fig.	6C-F).	At	
W14	 to	W15,	 there	were	observed	abundant	PRPH-positive	and	TUBB3-positive	
neurites targeting basically all the hair cells (IHCs and OHCs) in the middle and 
basal	turns	(Fig.	6A-F).	At	W15,	all	OHCs	(O1,	O2,	and	O3)	were	innervated	by	
neurites that followed the basement membrane, and extended upwards in between 
supporting	cells,	and	these	neurites	ended	in	a	calyx-like	cluster	(Fig.	6E).	Three-
dimensional (3D) reconstructions showed that at W14 and W15, in contrast to W12, 
some	of	these	PRPH-positive	neurites	contacting	the	OHCs	had	already	acquired	
the	 characteristic	 ‘spiral’	 organization,	 rather	 than	 penetrating	 the	 basement	





3D	 reconstruction	 revealed	 the	 increased	 to	 complete	 ‘spiral’	 organization	 of	




Ubiquitous PRPH expression becomes restricted to type II SGNs at W18
To further understand the separation of type I and type II SGNs in humans, 
we mapped the dynamics of PRPH expression in the developing spiral ganglion 
adjacent to the developing prosensory domain/OC. At W10 to W15, both PRPH 





Strikingly, by W18, the spiral ganglion was found to be largely devoid of PRPH 
(Fig. 7D, E). Only some SGNs strongly expressed PRPH (Fig. 7D). Together with 
the	observation	 that	PRPH-positive	neurites	become	 confined	 to	 the	OHCs	and	
their increase in a spiral orientation, this suggests the emergence of bona	fide type 
II SGNs at W18 to W20 in humans.
Initial innervation of the cochlear duct is not conserved between mouse and human
We have described here that innervation of the cochlear duct in humans started 
around	W12	 and	 involved	 the	 simultaneous	 penetration	 by	 PRPH-positive	 and	
TUBB3-positive	 neurites	 into	 the	 cochlear	 epithelium.	 To	 complement	 previous	
mouse	studies	that	focused	specifically	on	the	expression	of	PRPH	at	late	and	post-
natal	stages	of	development	(embryonic	day	18	(E18)	to	post-natal	day	7	(P7))	[13,	
14], we investigated the expression dynamics of PRPH at the start of penetration of 
SGN	neurites	into	the	mouse	cochlear	duct	and	the	onset	of	hair	cell	differentiation.	
At E13.5, TUBB3 was present only beneath the prosensory domain of the basal turn 
of the cochlear duct, as we found in humans at W10 (Fig. 8A, B). However, even 
though some of the neural structures outside the cochlea showed PRPH positivity 
(Fig. 8A, white arrow), as well as type II SGNs in adult mouse cochlea that had 
been	processed	identically	in	order	to	confirm	correct	immunoreactivity	(data	not	















should be noted that in mice (and humans), innervation of the epithelium preceded 
hair	cell	differentiation,	as	only	a	single	MYO7A-positive	IHC	was	detected	in	the	
lower (B1) basal turn (Fig. 8E), but none was seen in the upper (B2) basal turn 





Using	 transmission	 electron	microscopy,	 Pujol	 and	 Lavigne-Rebillard	 previously	
showed	that	the	onset	of	first	hair	cell	differentiation	in	the	human	fetal	cochlea	
starts in W12 of gestation (that is, week 10 of fetal development) [5]. In the current 
study, we consistently observed epithelial reorganization in the prosensory domain 
concurrently with SOX9 downregulation and MYO7A expression in a single row 
of	cells	in	the	prosensory	domain	of	the	basal	turn,	indicating	first	(inner)	hair	cell	
differentiation	at	W12.	However,	in	one	cochlea	from	W11.4,	there	were	identical	
changes in marker expression in one out of three sections of the basal turn (see 





is	 restricted	 to	 cells	 of	 the	 SOX2-positive	prosensory	domain	 [33].	Our	data	are	
in complete agreement with these observations, as we found that the developing 
human	 cochlea	 at	 W10.4	 exhibited	 a	 SOX2-positive	 prosensory	 domain	 in	
which	hair	cell	precursors	subsequently	differentiated	 into	IHCs	and	OHCs	 in	a	
radial and longitudinal gradient. Sox2 has been shown to act on Atoh1, the key 
transcription	 factor	 for	 hair	 cell	 differentiation	 [16].	 Expression	 of	 Atoh1,	 and	
thereby hair cell fate commitment, is also under strict control of the Notch pathway 
[34]. Interestingly, there was downregulation of SOX9 and SOX10 coincident with 
the	moment	of	first	hair	cell	commitment,	which	was	followed	several	weeks	later	
by downregulation of SOX2. The same sequence of events for SOX9 and SOX2 
has been previously reported in the developing mouse cochlear duct [23]. Together 
with our observations, this supports a distinct role for SOX9/SOX10 and SOX2 in 
hair cell fate commitment and an evolutionarily conserved mechanism of hair cell 
differentiation	between	mice	and	humans.	It	is	known	from	studies	in	other	tissues	
that Sox9 is directly controlled by Notch activity, for example in the developing 















supporting	 cells	 in	 the	 human	 cochlea	 up	 to	 the	 final	 stage	we	 investigated,	 at	
W20.3. As it is currently thought that Sox2 expression in supporting cells is linked to 
a	dormant	potential	of	hair	cell	differentiation	[37],	this	validates	(animal)	research	
focusing on this pathway to restore hearing. SOX2 expression in the adult human 
cochlea remains to be investigated. 
Innervation dynamics of the cochlear duct by PRPH-positive neurites
Hair cell development progresses hand in hand with the arrival and shaping of 
afferent	neurites	into	the	cochlear	duct	epithelium	[11].	In	contrast	to	mice,	human	
PRPH was expressed in SGNs prior to hair cell innervation, and the dynamics in 
the spiral ganglion correlated perfectly with the initial steps of innervation within 
the developing OC in humans. We found abundant PRPH expression at W12 and 
W15 in SGN cell bodies and in neurites reaching both the IHCs and OHCs. At 
W18, PRPH expression had become limited to cells generally located at the distal 
end of the spiral ganglion. It is well known that type II SGNs in the adult human 
cochlea are also found mainly in this area [12]. In addition, in the adult human 
cochlea,	type	II	SGNs	represent	less	than	10%	of	the	total	number	of	SGNs	[12],	and	
PRPH expression has been found to be restricted to this cell type [31]. In relation 





positive neurites. The spiral orientation of neurites projecting to OHCs was already 
found at W14 to W15 and was prominently present at W20. These observations are 
in line with adult expression patterns and orientation, providing further support 







prosensory domain exists within the fetal human cochlear duct. Furthermore, 
the results presented here support the notion that SOX2 and SOX9/SOX10 may 
have	 different	 roles	 in	 hair	 cell	 versus	 supporting	 cell	 fate	 determination.	 Our	
investigations	 into	 hair	 cell	 innervation	 have	 shown	 that	 both	 TUBB3-positive	
and	 PRPH-positive	 neurites	 penetrate	 the	 basement	 membrane	 of	 the	 cochlear	
epithelium	as	 early	 as	W12	and	 target	 the	 subsequent	developing	first	 hair	 cell.	
This in contrast to the mouse, in which PRPH expression is detected later. Finally, 
we determined that already by W18 to W20, PRPH expression distinguishes 
between type I and type II SGNs, in contrast to mice and other rodents in which 
this	specialization	occurs	only	during	post-natal	development	of	the	cochlea	[13,	
14, 38]. Together, these results bring us closer to understanding the timing of some 
of	the	essential	steps	and	the	identification	of	some	of	the	key	molecular	players	
during human cochlear development. Thus, we provide a basis for research focused 














The medical ethics committee of the Leiden University Medical Center approved 
this study (protocol 08.087), and informed consent was obtained in accordance with 
the WMA Declaration of Helsinki guidelines.
Tissue samples
In total, 27 human embryonic and fetal cochleae were collected from tissue 
obtained by elective termination of pregnancy (by vacuum aspiration, after 
obstetric ultrasonograpghy to determine gestational age in weeks and days) at 
various	gestational	stages	(W10	to	W20:	W10,	n	=	4;	W11,	n	=	1;	W12,	n	=	4;	W14,	
n	=	4;	W15,	n	=	2;	W16,	n	=	1;	W17,	n	=	4;	W18,	n	=	4;	W19,	n	=	2;	W20,	n	=	1).	
Time between termination and collection was kept to a minimum, ranging from 
one	to	several	hours.	All	cochlear	specimens	were	fixed	in	4%	paraformaldehyde	in	
PBS overnight at 4°C. Cochleae obtained before W14 were dehydrated in ethanol 
and	 embedded	 in	 paraffin	wax	 using	 standard	 procedures.	 Cochleae	 from	W14	
and	later	were	decalcified	for	1	to	3	weeks	in	10%	EDTA	disodium	salt	(pH	7.4)	
(Sigma-Aldrich,	 St	Louis,	MO,	USA)	 in	distilled	water	at	 4°C,	prior	 to	 ethanol	
dehydration	and	paraffin	wax	embedding.	Sagittal	sections	from	E13.5	and	E15.5	
mouse embryos (CBA/Bl6), were a generous gift from the McLaren Laboratry 






(Leica). Sections were dewaxed in xylene, rehydrated in a descending ethanol series 
(100%,	 90%,	 80%,	 70%),	 and	 rinsed	 in	 distilled	 water.	 Hematoxylin	 and	 eosin	
staining was performed by standard procedures to determine the morphology of 




oven and sections were allowed to cool to room temperature. The sections were 
subsequently	blocked	with	1%	bovine	serum	albumin	(BSA,	Sigma-Aldrich)	in	PBS	
containing	 0.05%	Tween-20	 (Promega,	 Leiden,	 the	Netherlands)	 for	 30	minutes,	
and incubated with primary antibodies diluted in blocking solution overnight at 
room	temperature	in	a	humidified	chamber.	The	following	day,	the	sections	were	
incubated with secondary antibodies diluted in blocking solution for 2 hours at room 
temperature.	Nuclei	were	stained	with	4’,6-diamidino-2-phenylindole	(DAPI;	Vector	
Laboratories	Ltd.,	Peterborough,	UK)	or	TO-PRO-3	(Life	Technologies,	Carlsbad,	
CA, USA), and sections were mounted in ProLong Gold (Life Technologies). 
The	primary	antibodies	used	 in	 this	 study	were	mouse	anti-MYO7A	 (1:40;	138-1	
supernatant;	DSHB,	Iowa	City,	IA,	USA),	rabbit	anti-SOX2	(1:200;	ab5603),	rabbit	
anti-PRPH	(1:200;	ab1530)	(both	Chemicon,	Temecula,	CA,	USA);	rabbit	anti-SOX9	




(1:500;	 A-21202),	 488	 donkey	 anti-rabbit	 (1:500;	 A-21206),	 488	 donkey	 anti-goat	
(1:500;	 A-11055),	 568	 donkey	 anti-mouse	 (1:500;	 A-10037)	 and	 568	 donkey	 anti-
rabbit	 (1:500;	A-10042	 (all	 Life	Technologies)).	 For	 antibody	 specificity	 controls,	
primary antibodies were omitted. 
Image acquisition and processing
Sections stained with hematoxylin and eosin were digitized using a Pannoramic 
MIDI scanner (3DHISTECH, Kisvárda, Hungary) and adjusted using Pannoramic 
Viewer (3DHISTECH). Confocal images were taken under a Leica TCS SP5 
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abstraCt
The adult human cochlea contains various types of peripheral glial cells that 
envelop	or	myelinate	the	three	different	domains	of	the	spiral	ganglion	neurons:	
the central processes in the cochlear nerve, the cell bodies in the spiral ganglia, 
and the peripheral processes in the osseous spiral lamina. Little is known about 
the distribution, lineage separation and maturation of these peripheral glial cells 
in the human fetal cochlea. In the current study, we observed immature Schwann 
cells expressing SOX10, SOX9 and S100B as early as 9 weeks of gestation (W9) in 
all three neuronal domains. We propose that these cells are the common precursor 
to both mature Schwann cells and satellite glial cells. Additionally, the immature 
Schwann cells located along the peripheral processes expressed NGFR, indicating 
a phenotype distinct from the immature Schwann cells located along the central 
processes. From W12, the spiral ganglion was gradually populated by satellite 
glial cells in a spatiotemporal gradient. In the cochlear nerve, radial sorting was 
accomplished by W22 and myelination started prior to myelination of the peripheral 
processes. The developmental dynamics of the peripheral glial cells in the human 
fetal	 cochlea	 is	 in	 support	 of	 a	 neural	 crest	 origin.	Our	 study	 provides	 the	 first	
overview of the distribution and maturation of peripheral glial cells in the human 














Schwann cells, the major type of peripheral glial cells (PGCs), envelop and/or 
myelinate the spiral ganglion neurons (SGNs) in the cochlea and are essential to 
normal hearing. Demyelinating diseases of the peripheral nervous system result in 
differences	in	the	velocity	of	action	potential	propagation	between	individual	nerve	
processes [1]. Depending on the degree of demyelination, this loss of neural synchrony 
leads to moderate sensorineural hearing loss or, if there is a complete conduction 
block,	 to	deafness	 [2–4].	One	major	peripheral	neuropathy	affecting	hearing	 is	
Charcot-Marie-Tooth	disease,	a	genetically	and	clinically	heterogeneous	group	of	
disorders	which	includes	mutations	in	genes	that	are	involved	in	myelination	[5–8].	




Based on animal studies, it is commonly accepted that all PGCs derive from the 
neural crest and migrate along peripheral nerves to their target locations [14, 15]. 
There, Schwann cell precursors become immature Schwann cells, which subsequently 
differentiate	into		myelinating	or	non-myelinating	Schwann	cell	phenotypes	(Fig.	
1A).	Individual	processes	of	peripheral	neurons	are	singled	out	by	pro-myelinating	
Schwann cells in a process known as radial sorting. Once ensheathment is 
completed, those Schwann cells will start to produce myelin, becoming myelinating 
Schwann cells [14]. The myelin sheath consists of multiple layers of tightly packed 
myelin surrounding individual nerve processes and functions to increase axonal 
conduction	 velocity	 [16].	Non-myelinating	 Schwann	 cells	will	 envelop	 numerous	
unmyelinated	neuronal	processes,	forming	the	so-called	Remak	bundles	in	which	
the individual nerve processes remain separated by cytoplasmic extensions of the 
non-myelinating	Schwann	cell	[17,	18].	Although	Schwann	cell	differentiation	has	
been investigated extensively, less is known about the development of a third type 
of PGCs, satellite glial cells. Satellite glial cells are thought to play a role in the 
microenvironment, protecting, supporting and communicating with the neuronal 
cell bodies [19, 20]. Avian studies suggest that satellite glial cells and mature 
Schwann cells derive from a common precursor cell expressing the marker S100 [21] 
(Fig.	1A).	The	differentiation	cascade	that	leads	to	the	formation	of	satellite	glial	
cells in humans remains to be investigated. 
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In the adult human cochlea, all three PGC types are intimately associated with 
SGNs.	SGNs	are	bipolar	or	pseudo-unipolar	neurons	that	transmit	electrical	signals	
encoding	sound	from	cochlear	hair	cells	 to	 the	brain.	They	are	usually	classified	
as	 type	 I	 SGNs	 (90-95%	of	 the	 total	 population)	 and	 type	 II	 (5-10%)	 SGNs.	 In	
the adult human cochlea, both processes of the bipolar type I SGNs, the central 
process in the cochlear nerve (CN) and the peripheral process in the osseous spiral 
lamina (Fig. 1B), are enwrapped in myelin sheaths that are produced by myelinating 
Schwann	cells	[22,	23].	The	second	type	of	PGCs,	the	non-myelinating	Schwann	cells	
(Fig. 1B), ensheath but do not myelinate the central and peripheral processes of 
the type II SGNs [24, 25]. Neither type of Schwann cells ensheath the peripheral 
processes (that innervate the cochlear hair cells in the organ of Corti) beyond the 
habenula perforata [26]. In the spiral ganglion (SG), the cell bodies of the SGNs are 
enveloped by the third type of PGCs, the satellite glial cells (Fig. 1B). In contrast to 
most mammalian species, satellite glial cells in the human SG seldom myelinate the 
SGN cell bodies [13, 22, 27, 28]. 
PGCs have been observed using light microscopy in the human SG and along 
the central processes of SGNs from 11 weeks of gestation (W11, i.e. 9 weeks of 
fetal development) onwards [29]. Other reports have looked at earlier stages, but 
failed	 to	 discriminate	 between	 SGNs	 and	 PGCs	 in	 the	 SG	 [30].	Using	 electron-
microscopy, it appeared that myelination of the central processes of the SGNs in 
the CN in humans starts at W20 [31]. At the peripheral processes, a study using 
Woelcke’s	 iron-hematoxylin	method	 [32]	 suggested	 that	myelination	 starts	 in	 at	
W22, although transmission electron microscopy suggested that it commences at 
W24 [33]. However, it cannot be excluded that the onset of myelination of the 
peripheral processes is at an earlier stage, especially since younger specimens were 
not available to these authors. 
In the present study, we investigated the distribution and maturation of PGCs 
in the human fetal cochlea from W9 to W22. Using immunohistochemistry, we 
observed	 immature	Schwann	cells	 in	 the	cochlea	as	early	as	W9	and	we	defined	
their developmental phenotype in the three domains of the SGNs: (1) their 
central processes, (2) their cell bodies, and (3) their peripheral processes. Studies 
on Schwann cell development are not only important to investigate the onset of 
myelination (which is one indicator for the maturation of the auditory system and, 
hence, related to the onset of hearing), but are also needed to better understand the 
relationship of Schwann cells to auditory neuropathies, whether it be congenital 














The use of human fetal material for this study was approved by the Medical Ethical 
Committee of the Leiden University Medical Center (protocol 08.087) and informed 








in	 PBS	 overnight	 at	 4°C,	 decalcified	 and	 embedded	 in	 paraffin	 as	 previously	
described [34]. 
Immunofluorescence	
The	 cochleas	 were	 cut	 (5	 μm	 sections)	 in	 the	 sagittal	 plane	 using	 a	 RM2255	
microtome	 (Leica).	 Sections	were	 deparaffinized	 using	 standard	 procedures	 and	
immunohistochemistry	was	performed	as	previously	described	[34].	Briefly,	sections	
were	treated	12	minutes	at	97°C	with	0.01M	sodium	citrate	buffer	 (pH	6.0)	 for	
antigen	 retrieval,	 blocked	 with	 1%	 bovine	 serum	 albumin	 (Sigma-Aldrich)	 in	
PBS	 containing	 0.05%	 Tween-20	 (Promega),	 and	 consecutively	 incubated	 with	
primary and secondary antibodies diluted in blocking solution. Nuclei were stained 
















Also, in the case of MBP stainings, rabbit immunoglobulin fraction (X0903, DAKO) 
was	used	as	an	additional	negative	control	as	we	observed	cytoplasmic	fluorescence	
by SGN cell bodies at lower dilutions. 
Image acquisition and processing
Confocal images were made with either a Leica TCS SP5 inverted or a Leica 
SP8 upright microscope, operating under the Leica Application Suite Advanced 
Fluorescence software (LAS AF) using Leica objectives (20x/0.5 dry HCX PL 
Fluotar;	 40x/1.3	 oil	HC	PL	Apo;	 63x/1.4	 oil	HC	PL	Apo;	 100x/1.4	 oil	HCX	PL	
Fluotar). Maximal projections were obtained from image stacks that were 
generated	by	scanning	sections	throughout	their	full	depth	with	z-steps	of	0.5	μm,	
or with a sampling density according to the Nyquist rate when image restoration 
(deconvolution) was applied using Huygens Professional version 4.3.1 software 
(Scientific	Volume	Imaging).	Brightness	and	contrast	adjustments	consistent	with	
image manipulation policies were performed either with LAS AF, ImageJ version 
















To our knowledge, the presence of PGCs has not been reported in human fetal 
cochleas younger than W11 [29]. Here, we have investigated the distribution 
and phenotype of PGCs at W9, the youngest cochlear specimen we were able to 
obtain. At W9, the cochlear duct consisted of one full turn, the future basal turn. 
To identify PGCs, we immunostained for SOX10 (a nuclear marker for PGCs 
regardless of developmental stage [35, 36]), S100B (a cytoplasmic marker expressed 




(B1)	and	the	upper	 (B2)	basal	 turn	of	 the	SG	(Fig.	1G).	 In	the	SG,	we	 identified	
SOX10+/S100B+	PGCs	mainly	along	 its	 edge	and	only	a	 few	 in	 its	 center	 (Fig.	
1G). Immunostaining for SOX9, a nuclear neural crest marker [37, 38], revealed a 
similar	pattern	of	expression	to	SOX10	and	S100B	in	PGCs	(Fig.	1H-J),	indicating	
that at W9 the majority of PGCs located along the neuronal processes have passed 
the	SOX9+/SOX10+/S100B-	progenitor	phase	and	have	developed	 into	a	more	
mature	SOX9+/SOX10+/S100B+	phenotype.	Based	on	their	distribution	density,	
these PGCs most likely migrate from the central processes to the peripheral 
processes along the periphery of the SG and may start colonizing the SG giving rise 
to the satellite glial cells. 
SOX9+/	SOX10+/S100B+	PGCs	invade	the	SG	in	a	spatiotemporal	gradient
The developing human cochlea is characterized by distinct temporal and a 
spatial gradients at various levels including hair cell development, organ of Corti 
maturation, and hair cell innervation [34]. Therefore, we investigated whether 
PGCs in the SG displayed a similar developmental pattern within the cochlea. 









processes as far as the most distal tips of those processes, right underneath the 
prosensory	domain	of	the	cochlear	duct	(Fig.	2K-M).	In	addition	to	the	SGNs,	the	
epithelium of the cochlear duct also weakly immunostained for TUBB3, with the 
brightest	fluorescence	in	the	prosensory	domain	(Fig.	2B	and	3B)	or	later	in	the	hair	
cells [34].  
By W12, dense immunostaining for S100B was observed in the lower basal turn (B1) 
of	the	SG	(Fig.	3A-D,	right	arrow	in	D),	suggesting	the	presence	of	many	PGCs.	In	
addition,	a	spatial	gradient	was	visible	in	a	basal-to-apical	direction.	From	B1	to	the	
upper middle turn (M2), S100B immunostaining was progressively less prominent 
in the center of the SG and PGCs were primarily present at the edge of the SG in 
M2	(Fig.	3A-D,	left	arrow	in	D).	In	agreement,	immunostaining	for	SOX9	at	W12	
confirmed	this	basal	to	apical	distribution	of	PGCs	(Fig.	3E-L).	We	concluded	that,	
similar to other aspects of cochlear development, PGCs also show distinct temporal 
and spatial gradients in colonizing the SG of the human fetal cochlea.
 






During the process of envelopment, we also noticed changes in the PGC nuclei. At 
W12, DAPI staining showed that SGN nuclei were generally round whereas the 
nuclei of the enveloping PGCs tended to be more angular or crescent shaped (Fig. 
5Q-R).	At	W14,	this	difference	became	more	prominent.	In	addition,	PGC	nuclei	
started to get organized around and facing the cell bodies of the SGNs and exhibited 
bright	yet	diffuse	DAPI	staining	(Fig.	5S-T).	By	W18,	the	differences	between	the	
PGC nuclei and SGN nuclei were even more pronounced, with round SGN nuclei 
containing	prominent	nucleoli	(Fig.	5U-V),	much	like	the	morphology	in	adults.	At	













The	 low	affinity	nerve	 growth	 factor	 receptor	 (NGFR,	also	 known	as	p75NTR) is 
expressed by Schwann cells at various locations within the adult human cochlea 
[39] and is expressed in mice and rats throughout the neural crest and Schwann cell 
lineages	[14].	Immunostaining	for	NGFR	at	W9	and	W10.4	revealed	two	different	
PGC phenotypes in the developing human cochlea. In the lower basal turn (B1), 
PGCs along the peripheral SGN processes strongly expressed NGFR both at W9 
(Fig.	5A-D)	and	W10.4	(Fig.	5E-I).	NGFR	immunostaining	could	even	be	detected	
along the most distal tips of the peripheral processes just underneath the cochlear 




Since we consistently observed PGCs at the distal tips of the outgrowing peripheral 
processes	(Fig.	2K-M,	inset	5I),	we	investigated	whether	they	would	initially	follow	
the peripheral processes into the cochlear duct epithelium, although Schwann 
cells are known to be absent in the mature organ of Corti [26]. We have previously 
shown that penetration of peripheral processes into the cochlear duct epithelium is 
observed in all turns at W12 and that they targeted and innervated the developing 
(future)	inner	hair	cell	[34].	At	W12	in	the	upper	middle	turn	(M2),	multiple	S100+	
PGCs were located directly outside the cochlear duct epithelium, and although 




PGCs did not extend into the cochlear duct epithelium either. Immunostaining for 
NGFR	confirmed	these	results	(Fig.	6G-H,	bold	arrows).	Expression	of	NGFR	was	
also evident directly underneath the cochlear duct epithelium at W14, both in the 
basal	and	middle	turns	(Fig.	6I-N,	bold	arrows).	Together,	these	findings	indicate	




NGFR is expressed by pillar cells within the developing human organ of Corti.
Interestingly,	just	after	the	onset	of	the	first	hair	cell	differentiation	at	B1	of	W12,	
we also observed weak NGFR expression within the cochlear duct epithelium in 
a group of cells located around the (future) inner hair cell, marked by MYO7A 
expression	(Fig.	6G-H,	thin	arrows).	At	W14,	similar	weak	NGFR	expression	was	
observed	at	M2	(Fig.	6I-J).	At	M1,	expression	was	increased	in	the	cell	lateral	to	the	
inner hair cell, with a bright band at its apical surface, corresponding to the cuticular 
plate	(Fig.	6K-L,	thin	arrows).	At	W14,	the	outer	hair	cells	had	also	differentiated	at	
B1 and strong NGFR expression was observed in the putative outer pillar cell (Fig. 
6M-N,	thin	arrows).	In	contrast	to	the	observed	NGFR	expression,	none	of	the	turns	
at	W12-W14	showed	any	S100B	expression	in	the	developing	organ	of	Corti	(data	
not shown). In the subsequent weeks (i.e., up to W18), similar NGFR expression 
patterns	were	observed,	both	by	the	PGCs	along	the	peripheral	processes	(Fig.	6O-
Q)	and	within	the	organ	of	Corti	(Fig.	6R-S).
Myelination has started in the W22 cochlear nerve
Immunostaining for S100B and TUBB3 demonstrated that PGCs enveloped 
and	 bundled	 groups	 of	 nerve	 fibers	 in	 the	 CN	 as	 early	 as	 W9	 (Fig.	 7A-C).	 At	
W22, immunostaining for S100B and TUBB3 revealed that within the CN many 
individual	TUBB3+	cochlear	nerve	fibers	were	ensheathed	by	S100B+	PGCs	(Fig.	
7	D-G,	 upper	 inset	 in	 7G),	 suggesting	 that	 these	 cells	 had	 differentiated	 into	 a	
promyelinating stage and that radial sorting was completed. In addition, Remak 
bundles,	 the	 final	 developmental	 stage	 of	 non-myelinating	 Schwann	 cells,	 were	
observed in the CN (Fig. 7G, lower inset). To investigate myelination, we analyzed 
the expression of MBP, a major component of the myelin sheath. We were unable 
to detect any MBP expression along the peripheral processes, nor within the SG 
nor within the CN up to W18 (data not shown). At W22, immunostaining for MBP 
revealed	a	few	MBP+	tubular	structures	surrounding	individual	TUBB3+	cochlear	
























On the origin of PGCs in the human cochlea
The assumption that the cells within the cochlea are of dual embryonic origin has 
been	based	on	classic	experiments	using	spotted	salamander	larvae	[40]	and	chick-
quail chimeras [41]. These experiments indicated that whereas most of the SGNs 
are derived from the otic placode, PGCs have a neural crest origin. Recent research 
has	further	confirmed	the	neural	crest	origin	for	PGCs	in	the	mouse	cochlea	[42,	43],	
suggesting that the PGC cell origin is conserved in vertebrates. The pattern of PGC 
distribution	that	we	observed	in	humans	at	the	early	gestational	stages	(W9-12)	is	
in agreement with the hypothesis of a neural crest origin, with neural crest cells or 
early derivatives migrating along the CN into the human cochlea and populating 
the SG. Although the human Schwann cell lineage remains to be fully delineated, 
expression	of	the	calcium-binding	protein	S100	consistently	marks	the	transition	of	
Schwann cell precursors into immature Schwann cells in the rat [44, 45]. As S100B 
was already abundantly expressed at W9, we conclude that the PGCs in the human 
cochlea	at	this	fetal	stage	have	already	differentiated	into	the	immature	Schwann	
cell phenotype. A more extensive descriptive investigation of marker expression (for 
example, as mentioned in [14, 38])) could further validate these results. In addition 
to	S100B	we	have	investigated	glial-fibrillary	acidic	protein	(GFAP),	however	this	
marker was found to be expressed by the SGNs rather than the PGCs (data not 
shown).
In avian embryos, previous studies have shown that both satellite glial cells and 
Schwann	 cells	 are	 derived	 from	 a	 S100+	 common	 precursor	 cell	 [21,	 46].	 Based	
on the onset of association with SGNs, we hypothesize that the satellite glial cell 
phenotype arises in the human cochlea from W12 onwards, as modelled in Fig. 9. 
Before	 this	 stage,	 SOX9+/SOX10+/S100B+	PGCs	 can	be	 found	 in	 and	around	
the SG, matching an immature Schwann cell phenotype. Therefore, as in animals 
















processes	 in	 the	 CN	 have	 a	 different	 phenotype,	 as	 the	 former	 express	 NGFR	
whereas	the	latter	do	not.	NGFR	is	a	low-affinity	receptor	for	all	neurotrophins	
and	can	act	alone	or	 in	conjunction	with	Trk-receptors.	Among	its	functions	are	
programmed cell death (apoptosis), cell survival, neurite outgrowth, myelination 
and	Schwann	cell	migration	as	well	as	modulation	of	synaptic	strength	[48–50].	
Although expression of NGFR has been reported in Schwann cells in the adult 
human cochlea [39], its exact functions in the cochlea remain unknown.
Mouse	models	have	shown	that	deficiencies	or	mutations	in	NGFR	are	linked	to	
progressive hearing loss, but have also indicated that NGFR is not required for 
development	 of	 hearing	 (as	 tested	 by	 auditory-evoked	 brainstem	 responses)	 in	
the	first	postnatal	weeks	[49,	51].	In	a	study	exploring	the	development	of	neural	
innervation in the mouse cochlea in ErbB2 null mutants, a Schwann cell receptor 
involved in survival and myelination, the cochlea was devoid of Schwann cells. 
Interestingly, in these mutant cochleas, the peripheral processes of SGNs did 
overshoot the organ of Corti, their target location [52]. The authors speculated 
that cochlear Schwann cells could normally provide containment signals guiding 
neurite outgrowth. Further evidence for this hypothesis comes from a study using a 
mouse	model	of	peripheral	nerve	injury	that	showed	strong	up-regulation	of	NGFR	
by Schwann cells [53]. The resulting increase in NGFR lowered the amount of 
neurotrophins available to the injured neurons, thereby inhibiting the regenerating 
axons to penetrate from the dorsal root into the spinal cord. 
Our data support the hypothesis of a role for Schwann cells in nerve containment, 
as	we	observed	a	close	relationship	between	NGFR+	Schwann	cells	and	peripheral	
processes, as early as W9. In addition, Schwann cells did not follow when peripheral 
processes started to penetrate and explore the cochlear duct epithelium at W12. 
Whether or not NGFR plays a role in the process of axon guidance within the 
cochlea remains to be investigated.
NGFR expression in the developing organ of Corti
In the adult human organ of Corti, expression of NGFR has not been reported 
[39]. However, studies in mice and rats have detected transient expression of 
NGFR	in	pillar	cells,	disappearing	in	the	first	postnatal	week,	prior	to	the	onset	
of	hearing	in	these	animals	[49,	54–56].	It	is	thought	that	hearing	in	the	human	
foetus	commences	at	W20	or	 later	 [57];	 the	NGFR	expression	we	detected	in	the	
outer pillar cells at W18 support the view of the immaturity of the organ of Corti 
peripheral glia
56
at this stage. It has been proposed that NGFR expression plays a role in the 
differentiation	or	survival	of	hair	and	supporting	cells	and	the	formation	of	the	
tunnel of Corti [54]. Interestingly, we observed the strongest expression of NGFR 
in the cuticular plate of the outer pillar cell, that is exposed to the lumen of the 
cochlear	duct.	It	is	therefore	plausible	that	these	regulatory	effects	of	NGFR	are	
mediated	by	circulating	(pro)neurotrophic	factors	in	the	fluid	of	the	cochlea	acting	
on the cuticular plate.
No transient myelination of SGNs by satellite glial cells
In contrast to other mammalian species, the majority of the cell bodies of the SGNs 
in the adult human are unmyelinated [13, 22, 27, 28]. Transient myelination of 
SGN cell bodies during human fetal development, from W14 onwards, has been 
suggested [29]. In the current study, we did not observe any MBP expression within 
the human SG between W15 and W22. As myelination of SGN cell bodies has also 
not been observed in human neonates or infants [22, 24], it is unlikely that SGNs 
undergo a period of transient myelination during human fetal development.  
The onset of myelination within the human cochlea
In an extensive evaluation of the developing human fetal CN, it was reported that 
myelination of the central processes in the CN starts at W20 [31]. Myelination of 
the peripheral processes has been observed at W24 [33]. We investigated Schwann 
cells along peripheral processes up to W22, but did not detect MBP expression in 
any of the basal and middle turns. However, at W22 we observed MBP in the CN. 
Together, this shows that the onset of myelination of the CN, at W20, precedes 
myelination of the peripheral processes, which occurs between W22 and W24.
In the adult human cochlea, the number of type I SGNs correlates well with the 
number	 of	myelinated	 nerve	 fibers	within	 the	CN	 and	 it	 is	 commonly	 accepted	
that	 the	 unmyelinated	 fibers	 represent	 type	 II	 SGNs	 [25].	 As	 PRPH	 selectively	
immunostains the central processes of type II SGNs in the adult human cochlea 
[58],	 we	 examined	 whether	 all	 MBP+	 structures	 surrounded	 PRPH-negative	
fibers.	Indeed,	most	of	the	fibers	surrounded	by	MBP	did	not	express	PRPH,	but	
few exceptions were observed. This could indicate that some myelinated cochlear 
nerve	fibers	could	be	of	type	II	SGN	origin.	However,	as	all	SGNs	express	PRPH	












these structures represent (immature) type I SGNs in the process of downregulating 
PRPH. 
In conclusion, our data provide a comprehensive overview of PGC development 
in the human fetal cochlea, which may add to our understanding of congenital 
disorders and auditory neuropathies and can be used as a basis to evaluate acquired 
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Figure 1. SoX2 and SoX9 eXpreSSion in human Fetal cochlea around the onSet oF FirSt hair cell diFFerentiation.
(A) Hematoxylin and eosin (H&E) staining of a cochlea at W10.4 (week 10 and 4 days) with higher magnification (right panel) of the basal turn 
cochlear duct. (B) Basal turn of a W10.4 cochlea immunostained for SOX2, and magnification of the prosensory domain (bottom panels). Cell 
nuclei were visualized with TO-PRO-3 (red). (C) Basal turn of a W10.4 cochlea immunostained for SOX9, and magnification of the prosensory 
domain (bottom panels). Cell nuclei were visualized with TO-PRO-3 (red). (D) H&E staining of a W12 (week 12) cochlea with higher magnification 
(right panel) of the basal turn cochlear duct. (E) Basal turn of a W12 cochlea immunostained for SOX2, and magnification of the prosensory 
domain (bottom panels). Cell nuclei were visualized with TO-PRO-3 (red). (F) Basal turn of a W12 cochlea immunostained for SOX9 (green) and 
MYO7A (red), and magnification of the prosensory domain (bottom panels). Cell nuclei were visualized with DAPI (blue). #Tissue artifact; *, 
cytoplasmic SOX2 staining in the cochlear duct; $, SOX9 staining in the otic capsule; bracket, the prosensory domain; white arrow, Schwann cells 
of the spiral ganglion; arrowhead, inner hair cell. Abbreviations: cd, cochlear duct; KO, Kölliker’s organ; sv, scala vestibuli; st, scala tympani. Scale 
bars = 100 μm (all lower magnifications) or 50 μm (all higher magnifications).
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Figure 2. SoX2 and SoX9 eXpreSSion during development oF the human organ oF corti (oc).
(A,B) Apical turn of a W14 cochlea immunostained for (A) SOX2 and (B) SOX9 and magnification of the prosensory domain/OC (A’,B’). Cell 
nuclei were visualized (red) with TO-PRO-3. (C) The prosensory domain/OC in the apical turn of a W14 cochlea immunostained for SOX9 (green) 
and MYO7A (red). Cell nuclei were visualized with DAPI (blue). (D,E) Middle turn of a W14 cochlea immunostained for (D) SOX2 and (E) SOX9, 
and (D’,E’) magnification of the prosensory domain/OC. Cell nuclei were visualized with TO-PRO-3 (red). (F) The prosensory domain/OC in 
the middle turn of a W14 cochlea immunostained for SOX9 (green) and MYO7A (red). Cell nuclei were visualized with DAPI (blue). (G,H) Basal 
turn of a W14 cochlea immunostained for (G) SOX2 and (H) SOX9, and (G’,H’) magnification of the prosensory domain/OC. (I) The prosensory 
domain/OC in the basal turn of a W14 cochlea immunostained for SOX9 (green) and MYO7A (red). Cell nuclei were visualized with DAPI (blue). 
(J,K) Basal turn of a W19 cochlea immunostained for (G) SOX2 and (H) SOX9. Cell nuclei were visualized with TO-PRO-3 (red). *Cytoplasmic 
SOX2 staining in the cochlear duct; bracket, the prosensory domain/OC; arrowhead, inner hair cell. Abbreviations: KO, Kölliker’s organ; IHC, 
inner hair cell; O1, first row of outer hair cells; O2, second row of outer hair cells; O3, third row of outer hair cells. Scale bars = (A–K) 50 μm or 
(A’–H’) 20 μm.
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Figure 4. proliFerating cell nuclear antigen (pcna) and SoX9 eXpreSSion in the baSal turn oF w10.4 to w14 human Fetal cochlea.
(A-C) Basal turn of a cochlea immunostained for PCNA (red) and SOX9 (green) at (A) W10.4, (B) W12 and (C) W14. Cell nuclei were visualized 
with DAPI (blue). Bracket, the prosensory domain/OC; arrowhead, inner hair cell. Abbreviations: KO, Kölliker’s organ. Scale bars = 40 μm.
Figure 3. SoX10 eXpreSSion during human organ oF corti (oc) development.
(A-C) Basal turn of a cochlea immunostained for SOX10 (green) at (A) W10.4, (B) W12 and (C) W19. Cell nuclei were visualized with DAPI (blue). 
Bracket, the prosensory domain/OC; arrowhead, inner hair cell. Abbreviations: KO, Kölliker’s organ. Scale bars = 20 μm.
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Figure 5. dynamicS oF peripherin (prph)-poSitive and claSS iii b-tubulin (tubb3)-poSitive neuriteS during FirSt hair cell diFFerentiation.
(A,B) Basal turn of a W10.4 (week 10 and 4 days) cochlea immunostained for (A) PRPH (green) and TUBB3 (red) and (B) MYO7A (red). 
(C,D) Apical turn of a W12 cochlea immunostained for (C) PRPH and TUBB3 and MYO7A (D). (C’) Magnification of the prosensory domain 
in (C). (E,F) Middle turn of a W12 cochlea immunostained for (E) PRPH and TUBB3 and (F) MYO7A. (G,H) Basal turn of a W12 cochlea 
immunostained for (G) PRPH and TUBB3 and (H) MYO7A. Cell nuclei were visualized with DAPI (blue). Bracket, the prosensory domain/OC; 
arrowhead, inner hair cell; white arrow, PRPH-positive growth cone; black arrow, TUBB3-positive growth cone; yellow arrow, PRPH/TUBB3-
positive neurite. Abbreviations: KO, Kölliker’s organ. Scale bars = (A-C, D-H) 20 μm or (C’) 5 μm.
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Figure 6. dynamicS oF peripherin (prph)-poSitive and claSS iii b-tubulin (tubb3)-poSitive neuriteS during organ oF corti (oc) 
maturation.
(A,B) Middle turn of a W14 (week 14) cochlea immunostained for (A) PRPH (green) and TUBB3 (red) and (B) MYO7A (red). (C,D) Basal turn 
of a W14 cochlea immunostained for (C) PRPH and TUBB3 and (D) MYO7A. (E,F) Basal turn of a W15 cochlea immunostained for (E) PRPH 
and TUBB3 and (F) MYO7A. (G) Basal turn of a W18 cochlea immunostained for PRPH and TUBB3. (H) Basal turn of a W20.3 cochlea 
immunostained for PRPH and TUBB3. Cell nuclei were visualized with DAPI (blue). Bracket, the prosensory domain/OC; arrowhead, inner hair 
cell. Abbreviations: KO, Kölliker’s organ; IHC, inner hair cell; O1, first row of outer hair cells; O2, second row of outer hair cells; O3, third row 
of outer hair cells. Scale bars = 20 μm.
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Figure 7. dynamicS oF peripherin (prph) and claSS iii b-tubulin (tubb3) eXpreSSion in the human Fetal Spiral ganglion.
(A-E) Basal turn spiral ganglion immunostained for PRPH (green) and TUBB3 (red) at (A) W10.4 (week 10 and 4 days), (B) W12, (C) W15 and 
(D) W18. (E) Magnification of the basal turn spiral ganglion marked with a white arrow in (D). Cell nuclei were visualized with DAPI (blue). White 
arrow, PRPH-positive spiral ganglion neurons; black arrow, PRPH-negative and TUBB3-positive nerve fiber bundles. Scale bars = 20 μm.
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Figure 8. peripherin (prph) and claSS iii b-tubulin (tubb3) eXpreSSion in embryonic day 13.5 (e13.5) and e15.5 mouSe cochlea.
(A,B) E13.5 mouse cochlea immunostained (A) for PRPH (green) and TUBB3 (red) and (B) magnification of the prosensory domain of basal 
turn B1. (C-F) E15.5 mouse cochlea (C) immunostained for PRPH and TUBB3, (D) magnification of the prosensory domain of basal turn B1, 
(E) magnification of the prosensory domain of basal turn B1 immunostained for TUBB3 (red) and MYO7A (green), and (F) magnification of the 
prosensory domain of basal turn B2 immunostained for PRPH (green) and TUBB3 (red). Cell nuclei were visualized with DAPI (blue). Bracket, the 
prosensory domain; arrowhead, inner hair cell. Abbreviations: KO, Kölliker’s organ. Scale bars = (A,C) 100 μm or (B, D-F) 10 μm.
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Figure 9. Schematic diagram oF neuroSenSory development in the baSal turn oF the human Fetal cochlea. 
At W10 (week 10), SOX2 identifies the prosensory domain within the SOX9/SOX10+ cochlear duct epithelium. Neurites from the adjoining 
TUBB3+/PRPH + SGNs do not yet penetrate into the epithelium. Penetration starts at W11, prior to hair cell differentiation. At W12, the first 
MYO7A+/SOX9-/SOX10-/SOX2+ (inner) hair cell can be seen, and is contacted by multiple TUBB3+ and PRPH + neurites. Penetrating neurites 
are also found at the location of the future OHCs. At W14, both the IHCs and OHCs have differentiated, and neurites underneath the OHCs 
start to run in a spiral direction. At this stage, hair cells still express SOX2. At W20, SOX2 is downregulated in all hair cells, as opposed to the 
other cells in the organ of Corti. PRPH expression distinguishes between type I (PRPH-) and type II (PRPH+) neurites. Abbreviations: SGN, spiral 
ganglion neuron; IHC, inner hair cell; O1, first row of outer hair cells; O2, second row of outer hair cells; O3, third row of outer hair cells; OHC, 
outer hair cell.
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additional File 1: movie 1
Three-dimensional reconstruction showing the PRPH-positive neurites 
(green) and the nucleus of the inner hair cell (blue) of the prosensory 
domain/developing organ of Corti in the lower basal turn at W12, 
(week 12) corresponding to Figure 5G.
Format: M4V. Size: 3.4MB
additional File 2:  movie 2
Three-dimensional reconstruction showing the Peripherin (PRPH)-
positive neurites (green) and the nuclei of the hair cells (blue) of the 
developing organ of Corti in the lower basal turn at W14 (week 14), 
corresponding to Figure 6C.
Format: M4V. Size: 3MB
additional File 3: movie 3
3D reconstruction showing the PRPH-positive neurites (green) and the 
nucleus of the inner hair cell (blue) of the developing organ of Corti in 
the lower basal turn at W15, corresponding to Figure 6E.
Format: M4V. Size: 3.8MB
additional File 4: movie 4
Three-dimensional reconstruction showing the Peripherin (PRPH)-
positive neurites (green) and the nucleus of the inner hair cell (blue) of 
the developing organ of Corti in the lower basal turn at W18 (week 18), 
corresponding to Figure 6G.
Format: M4V. Size: 4.1MB
additional File 5: movie 5
Three-dimensional reconstruction showing the Peripherin (PRPH)-
positive neurites (green) and the nucleus of the inner hair cell (blue) of 
the developing organ of Corti in the lower basal turn at W20.3 (week 
20.3), corresponding to Figure 6H. 
Format: M4V. Size: 3.3MB
These additional movie files can be accessed online at the journal’s website (www.neuraldevelopment.com)
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additional File 6: Figure S1. the onSet oF hair cell diFFerentiation.
Confocal image of the prosensory domain within the lower basal turn of a W11.4 human fetal cochlea immunostained for MYO7A (red) and 
SOX9 (green). Nuclei were visualized (blue) with DAPI. Bracket, prosensory domain; arrowhead, inner hair cell. Scale bar = 20 μm.
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Figure 1. capturing pgc development in the human cochlea.
(A) Schematic model of PGC development in the human fetal cochlea. Neural crest cells differentiate via a Schwann cell precursor stage into 
S100+ immature Schwann cells. The immature Schwann cells subsequently maturate into myelinating and non-myelinating Schwann cells, and 
(presumably) satellite glial cells. (B) Schematic illustration of the PGCs in the adult human cochlea. Satellite glial cells (green) envelop all SGN cell 
bodies. Non-myelinating Schwann cells (light blue) ensheath both the central and peripheral processes of the type II SGNs (yellow) that innervate 
the outer hair cells (OHC). Myelinating Schwann cells (dark blue) ensheath and myelinate both processes of the type I SGNs (red) that innervate 
the inner hair cells (IHC). Beyond the habenula perforata, in the organ of Corti, neither Schwann cell types ensheath the most distal part of 
the peripheral processes of type I and type II SGNs. (C-G) Confocal images of a cochlea at W9 showing DAPI (C), TUBB3 (D), SOX10 (E), and 
S100B (F) and the  merged image (G). The spiral ganglion is delineated by the dotted line. (H-J) Confocal images of a cochlea at W9 showing the 
cochlear nerve (H), the spiral ganglion in the upper basal turn (I), and the spiral ganglion in the lower basal turn (J), delineated with dotted lines 
and immunostained with antibodies against SOX9 and TUBB3. Cell nuclei were visualized with DAPI. Abbreviations: B1, lower basal turn; B2, 
upper basal turn; SG, spiral ganglion. Scale bar = 100 μm.
Chapter 3, Figure 1
76
Figure 2. pgcS eXpreSSed SoX10, SoX9 and S100b in the w10.4 human Fetal cochlea.
(A-B) Confocal images of the lower basal turn of a W10.4 cochlea immunostained for SOX10 and SOX10 merged with DAPI. (C-D) Confocal 
images of an adjacent section immunostained for SOX9 and SOX9 merged with DAPI. (E-G) Confocal images of the lower basal turn of a W10.4 
cochlea immunostained for S100B (E) and TUBB3 (F) and the merged image with DAPI (G). (H-J) High-magnification view of the center of the 
spiral ganglion. (K-M) Detail of the peripheral processes at their distal end. Abbreviations: cd, cochlear duct; SG, spiral ganglion. Scale bar = 50 
μm (A-G) or 20 μm (H-M).
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Figure 3. a Spatial gradient oF S100+/SoX9+ pgcS in the w12 human Fetal cochlea.
(A-D) Confocal images of a cochlea at W12 showing DAPI (A) TUBB3 (B) and S100B (C) and the merged image (D). In D, the left arrow points to 
the spiral ganglion in the upper middle turn, whereas the right arrow points to the spiral ganglion in the lower basal turn. (E-L) Confocal images 
of a cochlea at W12 immunostained for SOX9 and SOX9 merged with DAPI showing the spiral ganglion at M2 (E-F), M1 (G-H), B2 (I-J) and B1 
(K-L). Abbreviations: B1, lower basal turn; B2, upper basal turn; M1, lower middle turn; M2, upper middle turn. Scale bar = 500 μm (A-D) or 50 
μm (E-L).
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Figure 4. development oF Satellite glial cellS in the Spiral ganglion.
(A-D) Deconvoluted confocal images of the spiral ganglion in the lower basal turn at W12 showing DAPI (A, blue), TUBB3 (B, red), S100B (C, 
green) and the merged image (D). (E-H) High-magnification view of the spiral ganglion. Arrows point to SGN cell bodies that are enwrapped 
by S100B+ satellite glial cells. (I-L) Deconvoluted confocal images of the spiral ganglion in the lower basal turn at W14 showing DAPI (I, blue), 
TUBB3 (J, red), S100B (K, green) and the merged image (L). (M-P) Deconvoluted confocal images of the spiral ganglion in the lower basal turn at 
W18 showing DAPI (M, blue), TUBB3 (N, red), S100B (O, green), and the merged image (P). (Q-V) High-magnification view of cell nuclei (DAPI) 
and S100B+ satellite glial cells within the spiral ganglion at W12 (Q-R), W14 (S-T) and W18 (U-V). Abbreviations: s, satellite glial cell; n, spiral 
ganglion neuron. Scale bar = 10 μm.
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Figure 5. immature Schwann cellS along the peripheral proceSSeS eXpreSS ngFr.
(A-D) Confocal images of the lower basal turn of a cochlea at W9 showing DAPI (A), TUBB3 (B) and NGFR (C) and the merged image (D). The 
spiral ganglion is delineated by the dotted line. The asterisk marks two NGFR+ cells in the center of the spiral ganglion. (E-I) Confocal images of 
the lower basal turn of a cochlea at W10.4 showing DAPI (E), TUBB3 (F), SOX10 (G) and NGFR (H) and the merged image (I). The spiral ganglion 
is delineated by the dotted line. The inset shows a deconvoluted, high-magnification view of TUBB3 and NGFR at the distal tips of the peripheral 
processes. Abbreviations: SG, spiral ganglion. Scale bar = 50 μm or 5 μm (inset in I).
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Figure 6. ngFr eXpreSSion in the cochlear duct epithelium.
(A-C) Confocal images of the cochlear duct epithelium in the upper middle turn of a cochlea at W12 showing TUBB3 (A, red), S100B (B, green) 
and the merged image with DAPI (C). The arrow points to penetrating TUBB3+ peripheral processes. (D-F) Confocal images of the cochlear duct 
epithelium in the lower basal turn showing TUBB3 (D, red), S100B (E, green) and the merged image with DAPI (F). The arrowhead points to the 
first developing (inner) hair cell. (G-H) Confocal images of the cochlear duct epithelium of the lower basal turn of a cochlea at W12 showing NGFR 
(G, green) and the merged image with DAPI (H) and MYO7A (red). The bold arrows point to the NGFR+ Schwann cells. The thin arrows outline 
the epithelial cells that weakly express NGFR. (I-J) Upper middle turn of a cochlea at W14 showing NGFR (I, green) and the merged image (J) with 
DAPI (blue) and MYO7A (red). The bold arrows point to the NGFR+ Schwann cells. (K-L) Lower middle turn of a W14 cochlea immunostained 
for NGFR (K, green) and the merged image with DAPI (blue) and MYO7A (red). The bold arrow points to the NGFR+ Schwann cells. The thin 
arrow points to a bright band of NGFR. (M-N) Lower basal turn of a W14 cochlea immunostained for NGFR (M, green) and the merged image (N) 
with DAPI (blue) and MYO7A (red). The bold arrows point to the NGFR+ Schwann cells. The thin arrow points to a band brightly immunostained 
for NGFR. (O-Q) Confocal images of the spiral ganglion in the lower basal turn of a cochlea at W18 showing TUBB3 (O), NGFR (P, green) and the 
merged image with DAPI (Q). (R-S) Confocal images of the organ of Corti of a cochlea at W18 showing NGFR (R, green) and the merged image 
with DAPI (S). Abbreviations: cd, cochlear duct; m, mesenchyme; B1, lower basal turn; M1, lower middle turn; M2, upper middle turn; SG, spiral 
ganglion; PPs, peripheral processes. * = autofluorescence of erythrocytes. Scale bar = 20 μm (A-N, R-S) or 50 μm (O-Q).
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Figure 7. terminal diFFerentiation oF Schwann cellS in the cochlear nerve.
(A-C) Deconvoluted confocal images of the cochlear nerve at W9 showing TUBB3 (A, red), S100B (B, green), and the merged image with DAPI 
(C). (D-G) Deconvoluted confocal images of an axial transection of the cochlear nerve at W22 showing DAPI (D), TUBB3 (E), S100B (F) and the 
merged image (G). The upper inset in G shows a high-magnification of TUBB3+ cochlear nerve fibers each enveloped by S100B+ Schwann cells, 
the lower inset shows a Remak bundle. (H-K) Deconvoluted confocal images of a sagittal transection of the cochlear nerve at W22 showing DAPI 
(H), TUBB3 (I), MBP (J) and the merged image (K). The inset shows a high-magnification view of a myelinated nerve fiber. Scale bar = 10 μm or 
1 μm (insets in G and K).
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Figure 8. myelination oF Spiral ganglion neuronS at w22.
(A-E) Confocal images of a spiral ganglion in the middle turn of a cochlea at W22 showing DAPI (A), TUBB3 (B), PRPH (C),  MBP (D) and the 
merged image (E). The spiral ganglion is delineated by the dotted line. (F-J) Confocal images of an axial transection of the cochlear nerve at W22 
showing DAPI (F), TUBB3 (G), PRPH (H), MBP (I) and  the merged image (J). (K-O) Deconvoluted confocal images of an axial transection of the 
cochlear nerve at W22 showing DAPI (K), TUBB3 (L), PRPH (M), MBP (N) and the merged image (O). Insets show TUBB3 (left), PRPH (middle) 
and the merge with MBP and DAPI (right) in high-magnifications examples of PRPH-/TUBB3+/MBP+ cochlear nerve fibers (upper inset) and 
PRPH+/TUBB3+/MBP+ cochlear nerve fibers (lower inset). Scale bar = 20 μm or 1 μm (insets in O).
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Figure 9. model oF Satellite glial cell development in the human Spiral ganglion.
Satellite glial cell development and the envelopment of the cell bodies of SGNs both occur in a temporal and spatial gradient within the spiral 
ganglion of the developing human fetal cochlea. W10:  Immature Schwann cells (light green) can be found at the edges of the SG in the upper 
middle turn (M2). In addition, a few Schwann cells are located in between the SGNs (orange) in the lower basal turn. W12: The number of 
Schwann cells in between the SGNs has greatly increased in M2. Satellite glial cells (dark green) in B1 start to envelop the cell bodies of SGNs 
(red). The pattern in M2 at W12 resembles that in B1  at W10. W14: All SGN cell bodies in B1 are enveloped by one or more adjacent satellite 
glial cells. The pattern in M2 resembles that in B1 at W12.  
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Figure 1. capturing cochlear potaSSium homeoStaSiS in mammalS.
(A) A schematic illustration of a cross-section through the adult cochlea. The cochlear duct (or scala media) is filled with endolymph containing a 
high [K+] that is maintained by the stria vascularis. Potassium recycling is postulated to either occur via the supporting cells of the organ of Corti 
and the epithelial lining of the outer sulcus  (Claudius cells and root cells), or through the perilymph of the scala tympani. Picture courtesy of S.B. 
Blankevoort.
(B) A schematic anatomical (upper half) and compartmental (lower half) model of the adult stria vascularis showing the three cellular layers and 
depicting the location of potassium regulating channels. The stria vascularis is electrochemically isolated from neighbouring structures by tight 
junctions (black bars). 
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Figure 2. migration oF melanocyteS into the Stria vaSculariS oF the human Fetal cochlea.
(A-B) A cochlea at W9.1 immunostained for acetylated tubulin (aceTUBA) (red), melan-A (green) and DAPI (blue) (A) or melan-A (green) and 
DAPI (blue) (B). Arrowheads point to melan-A+ cochlear melanocytes. Scale bars = 50 μm. (C) The lower middle turn (M1) of a cochlea at W10.4 
immunostained for aceTUBA (red), melan-A (green) and DAPI (blue). Scale bar = 50 μm. (D) The lower basal turn (B1) of a cochlea at W10.4 
immunostained for aceTUBA (red), melan-A (green) and DAPI (blue). Scale bar = 50 μm. (E) The apical and lower middle turn of cochlea at 
W12 immunostained for aceTUBA (red), melan-A (green) and DAPI (blue). Scale bar = 50 μm. (F-F’) The lower basal turn of a cochlea at W12.2 
immunostained for aceTUBA (red), melan-A (green) and DAPI (blue). The melan-A signal is shown separately in white in (F’). Scale bar = 50 μm. 
(G) Higher magnification of the outlined area in (F). Arrowheads point to melan-A+ melanocytes located in the periotic mesenchyme. Arrows 
point to melan-A+ melanocytes located in between the epithelial lining of the cochlear duct lateral wall (the future marginal cells of the stria 
vascularis). Scale bar = 20 μm. (H-H’) A similar section of the lower basal turn of a cochlea at W12.2 as depicted in (F), here immunostained for 
basement membrane protein laminin (LAM). The LAM signal is shown separately in white in (H’). Scale bar = 50 μm. (I-I’) Higher magnification 
of the developing stria vascularis outlined in (H). The arrowheads point to the smooth and continuous appearance of the basement membrane 
at the location of the bordering Reissner’s membrane and the outer sulcus, as opposed to the irregular pattern observed in at the location of the 
future stria vascularis. The LAM signal is shown separately in white in (I’) Scale bar = 20 μm.
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Figure 3. eXpreSSion oF mitF, SoX10 and kit.
(A) Lateral wall area of the lower basal turn of a cochlea at W12 immunostained for microphthalmia-associated transcription factor (MITF) (red), 
melan-A (green) and DAPI (blue), showing Melan-A+/MITF+ melanocytes in the periotic mesenchyme as well as in the developing stria vascularis. 
Signals are shown separately in white. Scale bar = 20 μm. (B) Lateral wall area of the lower basal turn of a cochlea at W12 immunostained 
for SOX10 (green) and DAPI (blue). Signals are shown separately in white. Arrowheads point to SOX10+ melanocytes located in the periotic 
mesenchyme. Scale bar = 20 μm. (C) Lateral wall area of the lower basal turn of a cochlea at W12 immunostained for MITF (red), KIT (green) 
and DAPI (blue), showing KIT+/MITF+ melanocytes in the periotic mesenchyme as well as in the developing stria vascularis. Signals are shown 
separately in white.  Scale bar = 100 μm. (D) The lower basal turn of a cochlea at W12 immunostained for KIT (green) and DAPI (blue). The KIT 
signal is shown separately in white. The arrowhead points to KIT+ melanocytes in the periotic mesenchyme next to the developing stria vascularis. 
# = Tissue artifact.  Scale bar = 20 μm.
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Figure 4. maturation oF the lateral wall in the human Fetal cochlea.
(A-D) Lateral wall area of the upper middle (M2, (A)), lower middle (M1, (B)), upper basal (B2, (C)), and lower basal (B1, (D)) turn of a cochlea at 
W14 immunostained for acetylated tubulin (aceTUBA) (red), melan-A (green), and DAPI (blue). Scale bars = 20 μm. (E-H) Lateral wall area of the 
upper middle (E), lower middle (F), upper basal (G), and lower basal (H) turn of a cochlea at W16 immunostained for aceTUBA (red), melan-A 
(green), and DAPI (blue). Scale bars = 20 μm. (I) The upper middle turn of a cochlea at W16 immunostained for aceTUBA (red), melan-A (green), 
and DAPI (blue). Arrowheads point to melan-A+ melanocytes located in the periotic mesenchyme at the edges of the otic capsule. Scale bar = 100 
μm. (J) The lower basal turn of a cochlea at W18 immunostained for melan-A (green) and DAPI (blue). Arrowheads point to melan-A+ melanocytes 
located in the periotic mesenchyme at the edges of the otic capsule. st = scala tympani. Scale bar = 100 μm. (K) The lower basal turn of a cochlea 
at W18 immunostained for aceTUBA (red), melan-A (green), and DAPI (blue). Arrowheads point to melan-A positive strial melanocytes around 
developing strial capillaries. Scale bar = 20 μm. (L-N) The lower basal turn of a cochlea at W18 immunostained for basement membrane proteins 
laminin (LAM) (L, green), collagen type IV (COL4) (M, green) and fibronectin (FN) (N, green), and DAPI (blue). Scale bars = 20 μm.
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Figure 5. kcnQ1 eXpreSSion in the human Fetal cochlea.
(A-A’) The lower basal turn of a cochlea at W10.4 immunostained for acetylated tubulin (aceTUBA) (red), voltage-gated potassium channel 
KCNQ1 (green), and DAPI (blue). The KCNQ1 signal is shown separately in white in (A’). Scale bar = 50 μm. (B-B’) The lower basal turn of a 
cochlea at W12.2 immunostained for aceTUBA (red), KCNQ1 (green), and DAPI (blue). The KCNQ1 signal is shown separately in white in (B’). 
Scale bar = 50 μm. (C-C’) The lower basal turn of a cochlea at W14 immunostained for aceTUBA (red), KCNQ1 (green), and DAPI (blue). The 
KCNQ1 signal is shown separately in (C’). The arrowhead points at KCNQ1 signals in the developing Reissner’s membrane, the arrow points at 
KCNQ1 signals at the location of the future root cells. The KCNQ1 signal is shown separately in white in (C’). Scale bar = 50 μm. (D) The upper 
middle (M2) turn of a cochlea at W16 immunostained for aceTUBA (red), KCNQ1 (green), and DAPI (blue). Scale bar = 50 μm. (E-G) Higher 
magnifications of the outlined areas in (D), showing Reissner’s membrane (E), the marginal cells of the stria vascularis (F) and the root cells in 
the outer sulcus (G). Scale bars = 20 μm. (H-H’) The lower basal turn of a cochlea at W18 immunostained for aceTUBA (red), KCNQ1 (green), 
and DAPI (blue). The arrowhead points to Reissner’s membrane. The KCNQ1 signal is shown separately in white in (H’). Scale bar = 20 μm. (I-J’) 
Higher magnifications of the outlined areas in (H). KCNQ1 signals are shown separately in white in (I’) and (J’). Scale bars = 10 μm.
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Figure 6. eXpreSSion oF na+/k+-atpaSe in the human Fetal cochlea.
(A) The lower basal turn of a cochlea at W10.4 immunostained for Na+/K+-ATPase ATP1A1 (red), melan-A (green), and DAPI (blue). The arrow 
points to the location of the future stria vascularis. The ATP1A1 signal is shown separately in white in (A’). * = autofluorescent erythrocytes. 
Scale bar = 50 μm. (B) The lateral wall in the lower basal turn of a cochlea at W12 immunostained for ATP1A1 (red), melan-A (green), and DAPI 
(blue). The ATP1A1 signal is shown separately in white in (B’). Scale bar = 20 μm. (C) The lower basal turn of a cochlea at W14 immunostained 
for ATP1A1 (red), melan-A (green), and DAPI (blue). The ATP1A1 signal is shown separately in white in (C’). Scale bar = 50 μm. (D) Higher 
magnification of the developing stria vascularis in (C). The ATP1A1 signal is shown separately in white in (D’). Scale bar = 20 μm. (E) The 
developing stria vascularis in the lower basal turn of a cochlea at W16 immunostained for ATP1A1 (red), melan-A (green), and DAPI (blue). The 
ATP1A1 signal is shown separately in white in (E’). * = autofluorescent erythrocytes. Scale bar = 20 μm. (F) The lower basal turn of a cochlea at 
W18 immunostained for ATP1A1 (red), melan-A (green), and DAPI (blue). The ATP1A1 signal is shown separately in white in (F’). Scale bar = 
50 μm. (G-H) Higher magnifications of (F), showing the organ of Corti (G) and epithelial lining of the outer sulcus (H). Scale bars = 20 μm. (I-J”) 
Higher magnifications of the stria vascularis in (F), with the separate signals of ATP1A1 (I’ and J’) and melan-A (I” and J”) shown in white. The 
arrow in (I) point to a melan-A+ melanocyte process penetrating towards the lumen of the cochlear duct. The arrowhead in (I) points towards an 
ATP1A1+ structure around a melan-A+ melanocyte cell body. The arrows in (J) point towards ATP1A1+ structures around melan-A+ processes that 
encircle a developing capillary. * = autofluorescent erythrocytes. Scale bars = 20 μm.
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Figure 7. kcnJ10 eXpreSSion in the human Fetal cochlea.
(A) The epithelial lining in the lower basal turn outer sulcus of a cochlea at W16 immunostained for the inwardly-rectifying potassium channel 
KCNJ10 (green) and DAPI (blue). The KCNJ10 signal is shown separately in white in (A’). Scale bar = 50 μm. (B) The lower basal turn of a 
cochlea at W18 immunostained for sodium/potassium-transporting ATPase ATP1A1 (red), KCNJ10 (green), and DAPI (blue). The KCNJ10 signal 
is shown separately in white in (B’). Scale bar = 50 μm. (C) Higher magnification of the outer sulcus area in (B). The KCNJ10 signal is shown 
separately in white in (C’). Scale bar = 50 μm.
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Figure 8. epithelial eXpreSSion oF gJb2 and gJb6 in the cochlear duct.
(A-B) The lower basal turn cochlea at W10.4 immunostained for gap junction proteins GJB2 ((A), green) and GJB6 ((B), green) and DAPI (blue). 
GJB2 and GJB6 signals are shown separately in white in (A’) and (B’), respectively. The bracket outlines the prosensory domain. Scale bars = 50 μm. 
(C-D) The lower basal turn cochlea at W12.2 immunostained for GJB2 ((C), green) and GJB6 ((D), green) and DAPI (blue). GJB2 and GJB6 signals 
are shown separately in white in (C’) and (D’), respectively. The bracket outlines the prosensory domain. Scale bars = 50 μm. (E-F) The lower basal 
turn cochlea at W14 immunostained for GJB2 ((E), green) and GJB6 ((F), green) and DAPI (blue). GJB2 and GJB6 signals are shown separately 
in white in (E’) and (F’), respectively. The bracket outlines the developing organ of Corti. KO = Kölliker’s organ. Scale bars = 50 μm. (G-H) The 
lower basal turn cochlea at W14 immunostained for GJB2 ((G), green) and GJB6 ((H), green) and DAPI (blue). GJB2 and GJB6 signals are shown 
separately in white in (G’) and (H’), respectively. The arrowheads points to the developing root cells. The bracket outlines the developing of Corti. 
KO = Kölliker’s organ. Scale bars = 50 μm. (I-J) The lower basal turn cochlea at W14 immunostained for GJB2 ((I), green) and GJB6 ((J), green) 
and DAPI (blue). GJB2 and GJB6 signals are shown separately in white in (I’) and (J’), respectively. The arrowheads points to the developing root 
cells. The bracket outlines the organ of Corti. * = autofluorescent erythrocytes. Scale bars = 50 μm.
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Figure 9. gJa1 iS eXpreSSed by type i FibrocyteS in the human Fetal cochlea.
(A) The lower basal turn of a cochlea at W14 immunostained for the gap junction protein GJA1 (green) and DAPI (blue). The dotted line outlines 
the group of spiral ligament fibrocytes expressing GJA1. The GJA1 signal is shown separately in white in (A’). Scale bar = 50 μm. (B) The lower 
basal turn of a cochlea at W18 immunostained for GJA1 (green) and DAPI (blue). The dotted line outlines the group of spiral ligament fibrocytes 
expressing GJA1. The GJA1 signal is shown separately in white in (B’). Scale bar = 50 μm. (C) Hematoxylin and eosin staining of a similar section 
as shown in (B). The dotted line represents the area of GJA1-expressing fibrocytes in (B). Scale bar = 50 μm.
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Figure 10. gJe1 eXpreSSion dynamicS during cochlear development in the human FetuS.
(A) The lower basal turn of a cochlea at W10.4 immunostained for the gap junction protein GJE1 (green) and DAPI (blue). The GJE1 signal is 
shown separately in white in (A’). Scale bar = 50 μm. (B) The developing stria vascularis in the lower basal turn of a cochlea at W12 immunostained 
for GJE1 (green) and DAPI (blue). The GJE1 signal is shown separately in white in (B’). Scale bar = 10 μm. (C) The developing stria vascularis in the 
lower basal turn of a cochlea at W14 immunostained for GJE1 (green) and DAPI (blue). The GJE1 signal is shown separately in white in (C’). Scale 
bar = 50 μm. (D) The developing stria vascularis in the lower basal turn of a cochlea at W16 immunostained for GJE1 (green) and DAPI (blue). 
The GJE1 signal is shown separately in white in (D’). Scale bar = 50 μm. (E) The developing stria vascularis in the lower basal turn of a cochlea 
at W18 immunostained for GJE1 (green) and DAPI (blue). The GJE1 signal is shown separately in white in (E’). Scale bar = 50 μm. (F) Higher 
magnification of the area outlined in (E). The GJE1 signal is shown separately in white in (F’). Scale bar = 20 μm.
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Figure S1. what iS the embryonic origin oF human cochlear melanocyteS?
(A) Overview of a cochlea at W9.1 immunostained for class III beta-tubulin (TUBB3) (red), acetylated tubulin (aceTUBA) (red), melan-A (green), 
and DAPI (blue). The dotted lines outline the region of the developing otic capsule. The arrowheads points to melan-A+ cells. Question marks 
point to melan-A+ signals of unknown origin. The left inset is a higher magnification of the nervous structure shown in the upper left corner. 
The right image is a higher magnification of melan-A+/TUBB3+ melanocytes migrating through the otic capsule.  Scale bar = 100 μm, or 10 μm 
(insets). (B) Hematoxylin and eosin staining of a consecutive section as shown in (A). Scale bar = 100 μm.
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Figure S2. baSement membrane proteinS in the developing human Fetal cochlea.
(A-C) The lower basal turn of a cochlea at W9.4 immunostained for laminin (LAM) ((A), green), collage type IV (COL4) ((B), green), fibronectin 
(FN) ((C), green) and DAPI (blue). The LAM, COL4 and FN signals are shown separately in white. The lower panels show higher magnifications 
of the developing lateral wall. Scale bars = 20 μm. (D-F) As in (A-C), here at W12. Scale bars = 20 μm. (G-I) As in (A-C), here at W14. Scale bars = 
20 μm. (J-L) As in (A-C), here at W16. Scale bars = 20 μm.
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Figure S3. baSement membrane proteinS in the human Fetal cochlea at w18.
(A-C) The lower basal turn of a cochlea at W18 immunostained for laminin (LAM) ((A), green), collagen type IV (COL4) ((B), green), fibronectin 
(FN) ((C), green) and DAPI (blue). The LAM, COL4 and FN signals are shown separately in white. Scale bars = 50 μm. (D-E) Higher magnification 
of the stria vascularis (D) and outer sulcus (E) areas of (A). Scale bars = 50 μm.
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Figure S4. Slc2a1 eXpreSSion in the human Fetal cochlea. 
(A) The lower basal turn of a cochlea at W12 immunostained for the glucose transporter SLC2A1 (green) and DAPI (blue). The SLC2A1 signal is 
shown separately in white. The arrows point to the medial and lateral edges of expression of SLC2A1 on the luminal membrane of the epithelial 
cells. vs = vas spirale (spiral vessel). Scale bar = 20 μm. (B) As in (A), here at W14. The SLC2A1 signal is shown separately in white. Scale bar = 
20 μm. (C) As in (A), here at W16. The SLC2A1 signal is shown separately in white. Scale bar = 50 μm. (D) Higher magnification of the organ of 
Corti and lateral epithelial cells at W16. The SLC2A1 signal is shown separately in white. IHC = inner hair cells, O1 = first row of outer hair cells, 
O2 = second row of outer hair cells, O3 = third row of outer hair cells, vs = vas spirale (spiral vessel), H = Hensen’s cells. Scale bar = 20 μm. (E) 
Higher magnification of the lateral wall and spiral ligament at W16. Asterisks point to auto-fluorescent erythrocytes (red) inside strial capillaries. 
The SLC2A1 signal is shown separately in white. Scale bar = 20 μm. (F) As in (A), here at W18). The SLC2A1 signal is shown separately in white. 
Scale bar = 50 μm.
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These interactive PDF files can be accessed online at the journal’s website (http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1932-846X)
interactive pdF File 1. irregular lateral wall 
baSement membrane at w12.
Interactive three-dimensional reconstruction of 
the lateral wall of the basal turn of a cochlea at 
W12 immunostained for laminin (LAM), as shown 
in Figure 2H-I and Figure S2D. Cell nuclei in the 
epithelium are shown in light blue, nuclei in the 
mesenchymal area as shown in dark blue. The LAM 
of the lateral wall basement membrane is shown in 
green, that of vasculature in the mesenchymal area 
in red. The irregular appearance of the lateral wall 
basement membrane at the location of the future 
stria vascularis is shown in View1, in contrast to the 
smooth appearance of the basement membrane at 
other parts of the cochlear duct, such as the outer 
sulcus shown in View2.
interactive pdF File 2. the lateral wall at w18.
Interactive three-dimensional reconstruction of the 
lateral wall of the basal turn of a cochlea at W18 
immunostained for laminin (LAM), as shown in 
Figures 4L and S3D. Cell nuclei in the epithelial 
compartment are shown in light blue, nuclei in the 
mesenchymal area as shown in dark blue. The LAM 
of the lateral wall basement membrane (View1) and 
capillaries in the stria vascularis (View2) is shown in 
green, that of vasculature in the mesenchymal area 
in red. View3 shows the spiral prominence, View4 
shows Reissner’s membrane.
interactive pdF File 3. the outer SulcuS at w18.
Interactive three-dimensional reconstruction of 
the outer sulcus area of the basal turn of a cochlea 
at W18 immunostained for laminin (LAM), as 
shown in Figure S3E. Cell nuclei in the epithelial 
compartment are shown in light blue, nuclei in the 
mesenchymal area as shown in dark blue. The LAM 
of the epithelial basement membrane is shown in 
green, that of vasculature in the mesenchymal area 
in red. View1 shows the smooth appearance of the 
epithelial basement membrane at this location.
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Figure 1. in vivo eXpreSSion oF  melanocytic and neuronal markerS in the human Skin. 
Confocal images of immunohistochemistry performed in 5 μm skin sections against various melanocytic and neuronal proteins. (A) Melanocytes 
express both melan-A and TUBB3. TUBB3, but not melan-A, is also expressed by dermal and epidermal nerve fibers. (B,C) Although most 
melanocytes do not express nestin, a few exceptions can be found, both in the hair follicle (B) and in the epidermis (C). (D) Melanocytes, but not 
neurons, express both melan-A and SOX9. The dashed line indicates the border between the dermis and the epidermis. In the merges, nuclei  were 
stained blue with DAPI. Scale bar = 100 μm (A and D) or 10 (B and C). 
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Figure 1. in vivo eXpreSSion oF tubb3 in human epidermal and hair Follicle melanocyteS.
Immunohistochemistry was performed on deparaffinized sections of human adult and fetal scalp skin using antibodies to identify melanocytes 
(melan-A, DCT) and class III B-tubulin (TUBB3). (A) Adult epidermis stained for melan-A and TUBB3. (B) Adult epidermis immunostained for 
DCT and TUBB3. (C) Fetal epidermis immunostained for melan-A and TUBB3. Arrows: dendritic structure within the epidermis expressing both 
melan-A and TUBB3. Asterisk: TUBB3+ nerve fiber within the dermis. (D) Fetal epidermis immunostained for DCT and TUBB3. (E) Fetal hair 
follicle immunostained for melan-A and TUBB3. DP: Dermal papilla. Arrowheads: melan-A-/TUBB3+ cells (F) Fetal hair follicle immunostained 
for DCT and TUBB3. Arrowheads: DCT-/TUBB3+ cells. (A-F) White dotted lines indicate the basal layer of the skin (A-D) or the transition 
between the hair follicle matrix and medulla (E-F). Nuclei were stained blue with DAPI. Merge: overlay of fluorescent images. Scale bars = 20 μm.
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Figure 2. in vitro eXpreSSion oF tubb3 in human epidermal and hair Follicle melanocyteS.
Immunostaining was performed on cultures of human fetal scalp skin using antibodies to identify melanocytes (TYRP1 and melan-A) and class 
III B-tubulin (TUBB3). (A) Cultured epidermal melanocytes immunostained for TYRP1 and TUBB3. Asterisks identify TYRP1-/TUBB3+ cells. 
(B) Cultured hair follicle melanocytes immunostained for TYRP1 and TUBB3. Asterisks identify TYRP1-/TUBB3+ cells. (C) Cultured cells 
immunostained for melan-A and TUBB3. White dotted lines outline hair follicle bulb (B). (A-C) Nuclei are stained blue with DAPI. Merge: overlay 
of fluorescent images. Phase contrast: phase contrast microscopy. Bright field: bright field microscopy. Scale bars = 20 μm.
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Figure 3. immunoStaining oF tubb3 in the mouSe melanocyte lineage.
TUBB3 expression was investigated in two immortalized murine melanogenic cell lines. Melb-a cells are clonal, nonpigmented melanoblasts. 
Melan-Ink4a2 cells cultures contain both nonpigmented and pigmented melanocytes. (A) Cultured melb-a cells immunostained for TUBB3. 
(B) Cultured melan-Ink4a2 cells immunostained for TUBB3 without bleaching. Arrows identify a selection of non-pigmented, fluorescent 
(white arrows) and pigmented, non-fluorescent (black arrows) melanocytes. The graph depicts intensity values over identical lines plotted in the 
magnified areas. Red line: TUBB3 fluorescence intensity; Black line: intensity measured under bright field microscopy. Scaling on the vertical axis 
is normalized to maximum intensity. (C) Similar to figure B, but after bleaching with potassium permanganate and oxalic acid (see Materials and 
Methods). Table: black rectangle = without bleaching; white rectangle = with bleaching; ‘minus sign’ = non-fluorescent cells, ‘plus sign’ = bright 
fluorescent cells. (A-B) Nuclei are stained blue with DAPI.. Phase contrast, phase contrast microscopy. Bright field: bright field microscopy. Scale 
bars = 20 μm.
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Figure 4. weStern blot and Quantitative rt-pcr analySiS oF 
tubb3 eXpreSSion in the melanocyte lineage.
(A) Representative Western blots of TUBB3 expression in melb-a and 
melan-Ink4a2 cells using two different monoclonal antibodies, TUJ1 
and 2G10. Both antibodies recognize the C-terminal end of the protein. 
TUBB3 has a molecular weight of ~50 kDa. GAPDH was used as 
loading control. (B) Quantitative RT-PCR analysis of melb-a and melan-
Ink4a2 cell lysates. The figure shows the expression levels of RNA from 
two genes regulating melanogenesis, Mitf and DCT, as well as the RNA 
levels for TUBB3. All PCR products are normalized against averages 
of Hprt and Gapdh controls, and shown as relative expression levels 
against melb-a RNA. *p < 0.05; **p < 0.01.
Figure 5. weStern blot analySiS oF dct and tubb3 
eXpreSSion aFter a-mSh Stimulation in normal human 
melanocyteS.
(A) Representative Western blots showing DCT and TUBB3 
expression in human melanocytes after stimulation with 
a-MSH for 6, 24 and 48 hours. The same blots were incubated 
with a monoclonal antibody against B-actin to correct for equal 
loading. (B) The intensity of the bands in (A) was measured 
using Quantity One 1-D analysis and the resulting change in 
expression is given in percentage of the unstimulated control, 
corrected for loading. 
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Figure S1. melan-a immunoreactivity without and with bleaching.
(A) Cultured melan-Ink4a2 cells immunostained for Melan-A, without bleaching, and (B) with bleaching. (A-B) Phase contrast: phase contrast 
microscopy. Bright field: bright field microscopy. Scale bars = 20 μm.
Figure S2.  hypotheSized model oF tubb3 Function in melanoSome tranSport. 
Melanin containing melanosomes are transported by kinesins towards the plus end of microtubules composed of B-tubulin and TUBB3 dimers. 
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Figure S3. tubb3 tranScriptS in mice and humanS.
(A) In mice, only one protein transcript is known. (B) In humans, there are five known protein transcripts with additions MC1R/TUBB3 chimeric 
transcripts. Figures are taken from Ensembl (Flicek et al., 2012).
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Figure S4. double immunoStaining oF 2g10 and tuJ1 antibodieS.
(A) Human skin stained both with 2G10 and TUJ1. Both monoclonal anti-TUBB3 antibodies stain identical structures within the dermis (nerve 
fiber with Schwann cell nucleus) and the epidermis (melanocytes). Nuclei are stained blue with DAPI. Scale bar = 20 μm.
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Figure S5. preSence oF tubb3 in mitotic SpindleS oF both non-pigmented and pigmented melanocyteS.
(A) Cultured melan-Ink4a2 cells immunostained for both DCT and TUBB3. Arrows point to dividing non-pigmented cells. (B) Similar to figure 
A, but arrows indicate a dividing pigmented melanocyte. (A-B) TUBB3 fluorescence can be observed in surrounding cells, but are barely visible 
here due to the intense emission from the mitotic spindles. Nuclei are stained blue with DAPI. Merge: overlay of fluorescent images. Bright field: 
bright field microscopy. Scale bars = 20 μm.
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Figure 1. neStin-poSitive and tubb3-poSitive cellS migrate From the hair Follicle bulge.
(a) Hair follicle bulge at the start of the culture, showing elongated nestin-positive (NES) cells (green) residing within the explant. (b-c) After four 
weeks in culture, numerous nestin-positive cells (green) are found growing in tracks extending from the bulge explant. (d) Hair follicle bulge 
explants after 4 four weeks of culture immunostain for TUBB3 in a pattern similar to that of nestin. Cell nuclei are stained blue with DAPI. 
Scalebars = 100 μm (a) or 200 μm (b-d).
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Figure 2. tubb3-poSitive hair Follicle bulge cellS co-eXpreSS ngFr and SoX9.
(a-b) Double-immunostaining for TUBB3 (green) and NGRF (red) showing that both proteins are expressed in the same subgroup of cells. (c-d) 
Double-immunostaining for TUBB3 (green) and SOX9 (red). The strong co-expression of SOX9 indicates that the TUBB3-positive cells are of 
melanoglial, rather than neuronal, origin. Cell nuclei are stained blue with DAPI. Scalebars = 50 μm.
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Figure 3. melanocyte and glial marker eXpreSSion oF tubb3-poSitive cellS.
(a) Hair follicle bulge explant after 4 weeks of culture immunostained for TUBB3 (green) and TYRP1 (red), showing weak expression of TYRP1 
in the TUBB3-positive cells. (b) Higher magnification of the lower left area in (a). (c-d) Double-immunostaining for TUBB3 (green) and laminin 
(red) shows a subpopulation of laminin-positive cells largely growing along the same migration patterns of the TUBB3-positive cells. Cell nuclei are 
stained blue with DAPI. Scalebars = 200 μm (a, c), 100 μm (b) or 20 μm (d). 
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abstraCt
Sensorineural hearing loss (SNHL) is one of the most common congenital disorders 
in	humans,	afflicting	one	in	every	thousand	newborns.	The	majority	is	of	heritable	
origin, and can be divided in syndromic and nonsyndromic forms. Knowledge of 
the	expression	profile	of	affected	genes	in	the	human	fetal	cochlea	is	limited,	and	
as	many	of	the	gene	mutations	causing	SNHL	likely	affect	the	stria	vascularis	or	
cochlear potassium homeostasis (both essential to hearing), a better insight into the 
embryological development of this organ is needed to understand SNHL etiologies. 
We present an investigation on the development of the stria vascularis in the human 
fetal	cochlea	between	9	and	18	weeks	of	gestation	(W9-W18),	and	show	the	cochlear	
expression	 dynamics	 of	 key	 potassium-regulating	 proteins.	 At	 W12,	 MITF+/
SOX10+/KIT+	neural-crest-derived	melanocytes	migrated	 into	 the	 cochlea	 and	
penetrated the basement membrane of the lateral wall epithelium, developing into 
the intermediate cells of the stria vascularis. These melanocytes tightly integrated 
with Na+/K+-ATPase-positive	marginal	cells,	which	started	to	express	KCNQ1	in	
their apical membrane at W16. At W18, KCNJ10 and gap junction proteins GJB2/
CX26 and GJB6/CX30 were expressed in the cells in the outer sulcus, but not in the 
spiral ligament. Finally, we investigated GJA1/CX43 and GJE1/CX23 expression, 
and suggest that GJE1 presents a potential new SNHL associated locus. Our study 
helps to better understand human cochlear development, provides more insight 
into multiple forms of hereditary SNHL, and suggests that human hearing does not 















A large part of this hearing loss is of sensorineural nature, making sensorineural 
hearing loss (SNHL) the most prevalent sensorineural disorder in humans. SNHL 




Examples	 of	 syndromic	 SNHL	 include	 Pendred’s	 syndrome	 ([MIM	 274600],	
combining hearing loss and goiter [5, 6]), Waardenburg syndrome (hearing loss and 
pigmentation	abnormalities	[7,	8])	and	Jervell	and	Lange-Nielsen	syndrome	([MIM	
220400 and MIM 612347], hearing loss and cardiac symptoms [9]). In nonsyndromic 
SNHL, associations with obvious abnormalities of the external ear or symptoms 
other than hearing loss cannot be found, but the heterogeneity of loci and genes 
is	high:	over	130	 loci	have	been	mapped	and	over	60	different	genes	have	been	
implicated presently (Van Camp & Smith). Nonsyndromic forms are grouped in 
autosomal	dominant	(DFNA),	autosomal	recessive	(DFNB),	X-linked	(DNFX)	and	
mitrochondrial	subtypes.	The	most	commonly	affected	gene	causing	nonsyndromic	
hearing loss (both in autosomal recessive DFNB1A [MIM 220290] and in autosomal 
dominant DFNA3A [MIM 601544]) is gap junction beta 2 (GJB2, [MIM 121011]), the 
gene encoding the connexin 26 protein (CX26) [11, 12]. Depending on the studied 
population,	20-50%	of	all	recessive	nonsyndromic	SNHL	cases	can	be	attributed	to	
a mutation in GJB2	[13,	14].	For	a	comprehensive	overview	of	other	affected	genes	
we	refer	to	recent	reviews	[15–19].			
In SNHL, the disorder lies either in the cochlea itself, or in any of the retrocochlear 
auditory structures. Cochlear hair cells are responsible for converting sound into 
electrical signals that travel to the brainstem via the cochlear nerve [20]. Hair cell 
function depends on the endocochlear potential, a positive extracellular potential 
(≈80-100	mV	 relative	 to	 perilymph)	 in	 the	 endolymph	 of	 the	 cochlear	 duct	 (or	
scala media), generated by an unusually high concentration of potassium ions (K+) 
[21]. These ions are secreted into the endolymph by specialized cells within the stria 
vascularis, located in the lateral wall of the cochlear duct [22]. The stria vascularis 
is highly vascularized and consists of three layers of distinct cell types: the marginal 
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cells, the intermediate cells (melanocytes), and the basal cells [23, 24]. It is generally 
accepted that the depolarizing K+	flow	causing	hair	cell	activation	in	the	organ	of	
Corti is recycled back to the stria vascularis via the epithelial lining of the cochlear 
duct	and	the	spiral	ligament	fibrocytes,	and/or	through	the	perilymph,	as	depicted	
in Figure 1. To maintain the endocochlear potential, this recycling system requires 
a	specific	distribution	of	cochlear	cell	types	as	well	as	selective	ion	channels	and	
gap-junctions	[25,	26].
Therefore, it is not surprising that many gene mutations causing SNHL either 
result in functional changes of the ion channels involved in K+ homeostasis or 
cause an abnormal cellular morphology in the cochlea. Although progress has 
been made in identifying the genes responsible for SNHL in humans, knowledge on 
their actual expression in the human cochlea is limited and only a few studies have 
investigated the morphological development of the stria vascularis in the human 
fetal cochlea [27, 28]. In this paper, we address both aspects, focussing on the 




studied the expression of K+-regulating	and	gap	 junction	proteins.	Together,	our	
data gives insight in hereditary SNHL and provides a basis for K+-recycling	models	














Human fetal cochleas were collected from tissues obtained by elective abortion 
(healthy subjects, no medical indication) using vacuum aspiration. Prior to the 
procedure, obstetric ultrasonography was used to determine the gestational age 
in weeks and days. Of all collected cochleas, we discarded those which where 
mechanically damaged or showed marked tissue degeneration, upon inspection 
by	light-microscopy.	Cochleas	of	the	following	gestational	ages	were	collected	and	
used: W9, W9.1, W10.4 (2x), W12 (2x), W12.2, W14 (2x), W16 (2x), W18 (3x). The 
cochleas	were	obtained	in	PBS,	fixed	in	4%	paraformaldehyde	in	PBS	overnight	at	
4°C,	decalcified	and	embedded	in	paraffin	as	previously	described	[29].	The	use	
of human fetal material was approved by the Medical Ethical Committee of the 
Leiden University Medical Center (protocol 08.087). Informed written consent was 




as	previously	described	 [29].	Briefly,	antigen	 retrieval	was	performed	 (see	below)	












1:200,	Z009701,	Dako),	 rabbit	 anti-melan-A	 (1:500,	NBP1-30151,	Novus),	mouse	
anti-microphthalmia-associated	transcription	factor	(MITF,	1:100,	M3621,	Dako),	
mouse	 anti-Na+/K+-ATPase	 α1	 (ATP1A1,	 1:200,	 α6F,	 Developmental	 Studies	




Prior to immunostaining for COL4, LAM and FN antibodies, antigen retrieval 
was performed by incubating sections for 5 minutes with 20 µg/ml proteinase K 
(Promega)	in	Tris-EDTA-CaCl2	buffer	(pH8.0).		In	all	other	cases,	tissue	sections	
were	treated	for	12	minutes	at	97	°C	with	0.01M	sodium	citrate	buffer	(pH	6.0)	
and allowed to cool down. The secondary antibodies used were Alexa Fluor (AF) 
conjugated	 immunoglobulins	 (Life	Technologies):	AF	488	donkey	anti-mouse	 (A-
21202),	AF	488	donkey	anti-rabbit	(A-21206),	AF	488	donkey	anti-goat	(A-11055),	
AF	568	donkey	anti-mouse	 (A-10037),	and	AF	568	donkey	anti-rabbit	 (A-10042),	
all	 at	 a	 1:500	dilution.	As	antibody	 specificity	 controls,	 primary	antibodies	were	
routinely omitted (negative control), isotype controls were performed (negative 
control) and immunostainings were performed on adult mouse cochlea (positive 
control). On human fetal tissue, at least three separate immunostaining experiments 
were	 performed	 with	 each	 primary	 antibody.	 To	 further	 verify	 specificity,	 all	
immunostaining	results	were	checked	to	confirm	the	appropriate	cellular	location	
of	the	fluorescent	signals	and	tissue	expression	patterns	were	compared	to	previous	
studies using experimental animals, if available.
Image acquisition and processing
Confocal images were acquired with a Leica SP8 confocal laser scanning microscope 
operating under the Leica Application Suite Advanced Fluorescence software (LAS 
AF) using Leica objectives (40x/1.3 oil HC PL Apo or 63x/1.4 oil HC PL Apo). 
Maximal	projections	were	obtained	from	image	stacks	with	a	z-step	size	of	0.5	μm.	
Brightness and contrast adjustments consistent with image manipulation policies 














Melanocytes invade the lateral wall epithelium at W12 and develop into the 
intermediate cells
The cochlear melanocytes that form the intermediate cell layer of the stria 
vascularis are thought to originate from the neural crest. In order to investigate 
the	 formation	of	 the	 three	cell	 layers	of	 the	 stria	vascularis,	we	first	determined	
the cochlear location of melanocytes and monitored their invasion into the lateral 
wall epithelium during embryonic development of the human fetal cochlea. 
Immunostaining	 for	 melan-A	 ([MIM	 605313],	 a	 marker	 of	 melanocytes)	 and	
acetylated	α-tubulin	(aceTUBA,	which	labels	various	types	of	epithelial	and	neural	
cells) allowed us to visualize melanocyte location and general cochlear architecture. 
At	W9.1,	the	melan-A+	melanocytes	were	located	both	in	the	part	of	the	periotic	
mesenchyme that will develop into the otic capsule (called hereafter: otic capsule), 
and in the part of the periotic mesenchyme that will form the spiral ligament and 
the spiral limbus (called hereafter: periotic mesenchyme), but not in the epithelium 
of	the	cochlear	duct	(Figure	2A-B,	Figure	S1).	More	specifically,	most	melanocytes	
were found in the apical half of the developing cochlea situated above the cochlear 
duct, and only a few could be observed in the periotic mesenchyme bordering the 
lateral wall epithelium, i.e. the future stria vascularis (Figure 2B, right arrowhead). 
Immunostaining for basement membrane proteins laminin (LAM) (Figure S2A), 
collagen	type	IV	(COL4)	(Figure	S2B)	and	fibronectin	(FN)	(Figure	S2C)	at	W9.4	
showed	a	strictly	continuous	and	smooth	basement	membrane,	further	confirming	
the mesenchymal location of the melanocytes. At W10.4, the cochlear duct had 
spiralled	twice	around	the	central	axis	of	the	cochlea	and	melan-A+	melanocytes	
were observed exclusively in the periotic mesenchyme of the future middle and 
basal	turns	(Figure	2C-D,	arrowheads).	When	compared	to	W9.1,	more	melanocytes	
were located close to the lateral wall epithelium. 
At	 W12,	 melan-A+	 melanocytes	 were	 observed	 in	 all	 cochlear	 turns.	 In	 the	
apical and middle turns, melanocytes were still located exclusively to the periotic 
mesenchyme (Figure 2E). However, in the basal turn, melanocytes were observed 
both in the periotic mesenchyme (Figure 2F and arrowheads in Figure 2G) and 
in the lateral wall epithelium of the cochlear duct (the future stria vascularis), 
indicating that they had penetrated through the basement membrane (arrows in 
Figure	2G).	This	finding	is	 in	agreement	with	the	observation	that	the	basement	
stria vasCularis and potassium regulation
120
membrane at this location showed irregular staining patterns for LAM, COL4 
and FN, in contrast to its smooth and continuous appearance near the developing 
Reissner’s	membrane	and	at	the	location	of	the	outer	sulcus	(Figure	2H-I	and	three-
dimensional	reconstruction	provided	in	Interactive	PDF	file	1).	
Melanocytes in the stria vascularis express MITF, SOX10 and KIT
Next, we investigated the expression of two genes, MITF [MIM 156845] and SOX10 
[MIM 602229] that are expressed in the melanocytic lineage. At W12, MITF was 
expressed	in	all	turns	in	both	the	melan-A+	melanocytes	in	the	periotic	mesenchyme	
and in the melanocytes that had invaded the developing stria vascularis (Figure 
3A).	Previously,	we	have	shown	that	SOX10+	cells	are	present	in	the	spiral	ganglion	
and throughout the cochlear epithelium [31]. In the present study, we also detected 
SOX10 expression in the presumptive melanocytes bordering the stria vascularis 
(Figure 3B, arrowheads).
Double immunostaining for MITF and KIT [MIM 164920], the latter protein being 
expressed in both the neural crest and the melanocytic lineage, at W12 showed 
that	 KIT	 was	 expressed	 by	 all	 MITF+	 melanocytes	 (Figure	 3C).	 In	 addition,	
KIT expression was found in the cochlear duct epithelium, in a few remaining 
mesenchymal	cells	within	the	developing	scala	tympani		(Figure	3C-D),	and	in	the	
spiral ganglion (data not shown). 
In the developing stria vascularis, melanocytes integrate with the marginal cells in 
a spatiotemporal order
At W12, we detected a clear spatial gradient in the location of melanocytes, with 
epithelial	 invasion	commencing	in	the	basal	turn	(Figure	2E-F).	To	monitor	this	
development,	 we	 immunostained	 cochleas	 at	 W14,	 W16	 and	 W18	 for	 melan-A	
and	aceTUBA.	At	W14,	melan-A+	melanocytes	were	still	confined	to	the	periotic	
mesenchyme in both the upper middle (M2) and lower middle (M1) turns (Fig 4A, 
B). In the upper basal turn (B2), melanocytes were observed invading the lateral 
wall epithelium (Figure 4C) and in the lower basal turn (B1) most melanocytes 
were found integrating with the developing marginal cells (Figure 4D). At W16, 
integrating melanocytes were found in greater numbers and observed throughout 













along the edges of the otic capsule, here shown in the M2 turn at W16 (Figure 4I, 
arrowheads) and the B1 turn at W18 (Figure 4J, arrowheads). At W18, melanocytes 
were found tightly integrated with the developing marginal cells in the B1 turn, 
and some melanocyte processes were also observed around the developing strial 
capillaries (Figure 4K, arrowheads). Expression patterns of aceTUBA (Figure 4K) 




is clearly emerging, thereby demarcating the stria vascularis from the future root 
cells in the outer at W18. 
Until	W18,	SLC2A1+	basal	cells	were	not	detected	in	the	stria	vascularis
In the stria vascularis, in addition to the marginal cells and the melanocytes, 
we also investigated the formation of the third and innermost strial layer, i.e., 
the basal cells. However, until W18, we were unable to detect any basal cells by 
immunostaining for solute family carrier 2, member 1 (SLC2A1, also known as 
GLUT1, [MIM 138140]), a glucose transporter known to be expressed by the rodent 
cochlear basal cells and vascular endothelial cells [32]. SLC2A1 expression was 
found	in	the	developing	human	stria	vascularis	but	this	expression	was	confined	
to capillaries and erythrocytes (Figure S4). Interestingly, we did observe consistent 
expression of SLC2A1 on the apical (luminal) membranes of all epithelial cells 
between	the	organ	of	Corti	and	the	spiral	prominence	(Hensen’s	cells	in	the	organ	
of	Corti	as	well	as	Claudius’	cells	and	root	cells	in	the	outer	sulcus)	at	all	studied	
stages (from W12 to W18, Figure S4). 
Dynamics of KCNQ1 in the developing human cochlear duct
To investigate the onset of expression and developmental distribution of ion 
channels and enzymes involved in cochlear K+ transport and the generation of the 
endocochlear potential, we immunostained for the K+ channel protein KCNQ1 
[MIM 607542]. At W10.4 (Figure 5A) and W12.2 (Figure 5B), reactivity was observed 
at the basement membrane delineating the lateral wall epithelium. At W14, this 
pattern	had	changed	to	reactivity	in	the	developing	Reissner’s	membrane	(arrowhead	
in Figure 5C) and the future outer sulcus (arrow in Figure 5C). From W16 (Figure 
5D, 5F) to W18 (Figure 5H, 5I) increased KCNQ1 expression was observed at the 
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reactivity	 in	Reissner’s	membrane	or	 in	 the	 root	cells	of	 the	outer	 sulcus.	 It	did,	
however, show identical reactivity in the developing marginal cells at W16 and W18 
(data	not	shown).	Although	we	cannot	explain	this	difference	as	both	antibodies	
should	recognize	the	same	KCNQ1	transcript,	expression	of	KCNQ1	in	Reissner’s	
membrane has been reported previously [33]. 
Dynamics of Na+/K+ ATPase in the developing cochlear duct 
Already	 at	W10.4,	 immunostaining	 for	 the	 alpha-1	 subunit	 of	 Na+/K+-ATPase	
(ATP1A1,	 [MIM	 182310])	 was	 observed	 in	 different	 degrees	 throughout	 the	
entire epithelium of the cochlear duct, with a moderate intensity in the future 
stria vascularis (Figure 6A). However, at W12 ATP1A1 expression increased in 
the developing stria vascularis on the basolateral membranes of the developing 
marginal cells (Figure 6B). At W14 and W16, ATPA1 expression became even 
more prominent and was located in cells adjacent to the increasing numbers of 
invading	 melan-A+	 melanocytes	 (Figure	 6C-E).	 Immunostaining	 diminished	 in	
most parts of the epithelium, and at W18 ATP1A1 expression was found on the 
basolateral membranes of the marginal cells, on the basolateral membranes of 




are not of melanocytic origin (Figure 6G). Focusing on the stria vascularis, we found 
melan-A+	melanocyte	processes	penetrating	between	the	marginal	cells	towards	the	
lumen of the cochlear duct (Figure 6I, arrow). We also observed ATP1A1 expression 
around	the	melan-A+	melanocyte	cell	bodies	(Figure	6I,	arrowhead)	and	around	
melanocyte processes encircling the strial capillaries (Fig 6J, arrows). 
KCNJ10	expression	is	confined	to	the	outer	sulcus	at	W18
From W16 onwards, we observed KCNJ10 in the future root cells cells of the 
outer sulcus (Figure 7). However, we did not observe KCNJ10 expression by strial 












Distribution of GJB2, GJB6, GJA1 and GJE1 in the human fetal cochlea
To investigated the developmental expression of gap junction proteins we 
immunostained for GJB2 (CX26), GJB6 (CX30, [MIM 604418]), GJA1 (CX43 [MIM 
121014]),	all	known	to	be	expressed	in	the	human	cochlea	[34–36],	and	GJE1	(CX23	
[MIM unknown]), which expression pattern has not been investigated previously  in 
the cochlea (see Discussion).
Throughout	the	investigated	stages	(W10.4-W18),	the	GJB2	and	GJB6	expression	
patterns remained identical to each other (Figure 8). At W10, immunostaining for 
GJB2	 and	 for	GJB6	 showed	 a	 diffuse	 and	 punctated	 pattern	 in	 both	Kölliker’s	
organ and the cells of the future outer sulcus (Figure 8A, B). By W12, expression of 
GJB2 and GJB6 had greatly increased and could clearly be observed on both sides 





no expression could be observed in these cells at least up to W18 (Figure 8J). We 
also did not detect expression in the organ of Corti itself.
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Immunostaining	 for	 GJA1	 showed	 weak	 expression	 by	 a	 significant	 subgroup	
of	 spiral	 ligament	 fibrocytes	 at	W14	 (Figure	 9A).	 In	 the	 subsequent	 weeks,	 this	
expression	 became	 more	 prominent	 and	 at	 W18	 could	 be	 clearly	 defined	 as	
belonging	to	the	type	I	fibrocytes	(Figure	9B,	C).
Immunostaining for GJE1 revealed a dynamic pattern of expression during human 
cochlear development. At W10.4 and W12, strong expression of GJE1 was observed in 
the basolateral membranes of the future marginal cells (Figure 10A, B). Interestingly, 
at W14, expression was observed both in the lateral wall epithelium and in some 
of the cells in the adjacent periotic mesenchyme, presumably melanocytes (Figure 
10C). At W16, expression of GJE1 was downregulated by the developing marginal 
cells and became exclusively limited to those adjacent cells (Figure 10D). Double 
immunostaining	at	W18	for	GJE1	and	ATP1A1	confirmed	the	melanocytic	origin	of	
the signal, as no overlap in GJE1 and ATP1A1 was observed (Figure 10E, F).
An overview of the observed spatiotemporal expression patterns of selected proteins 















The developmental pattern of melanocyte distribution observed in the human fetal 
cochlea closely follows that of the mouse, where it is generally accepted that cochlear 
melanocytes	are	derived	from	the	neural	crest	[37–39].	Therefore,	we	suggest	that	the	
melanocytes in the human cochlea are also derived from the neural crest. However, 
in all species analysed so far, the migratory route taken by melanocytes to arrive 
in the cochlea remains unknown. As cochlear development in humans progresses 
slower than in mice (as a rule of thumb, 1 day of rodent cochlear development 
corresponds to 1 week in humans), this permits a more explicit visualization of 
developmental events. Recently, it has been reported that cranial melanocytes can 
arise from Schwann cell precursors migrating together with outgrowing nerves [40, 
41]. As Schwann cell precursors arrive in the cochlea via the cochlear nerve [42], it is 
tempting to propose that melanocytes (precursors) may travel along the same path. 
However, our data on melanocyte migration towards their target location in the 
cochlea, which to our knowledge has not been shown before in such clarity, suggests 
that cochlear melanocytes in humans migrate through the periotic mesenchyme 
from the opposite side. In agreement, several studies in mice embryos show the 
presence of neural crest derivatives or melanocytes near this part of the otic vesicle 
around	 embryonic	 day	 10.5	 [37–39,	 41,	 42].	 Therefore,	 although	 the	 peripheral	
glial cells in the cochlea originate from the migratory wave of neural crest cells 
from rhombomere 4, we now hypothesize that cochlear melanocytes originate from 
a	different	wave	of	neural	crest	cells,	namely	those	delaminating	from	the	region	
at rhombomere 6, at the location of the developing glossopharyngeal nerve (cranial 
nerve IX) and the third pharyngeal arch.
Cochlear melanocytes, a major player in syndromic SNHL
Intermediate	 cells	 in	 the	 stria	vascularis	were	 identified	as	melanocytes	 in	1977,	
although their exact function was unknown at that time [24]. The involvement of 
cochlear melanocytes in generating the endocochlear potential was recognized 
later	in	a	studies	with	‘viable	dominant	spotting’	mouse	mutants,	with	a	mutation	
in the W locus [43, 44]. Shortly hereafter, Kit was found to be the gene product of 
the W	locus	[45,	46],	and	it	was	shown	to	primarily	affect	the	survival	of	migratory	
melanoblasts [47]. In humans, KIT mutations can result in the neurocristopathy (a 
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pathology	affecting	normal	neural	crest	development)	piebaldism	[MIM	172800],	a	
disorder characterized by areas of skin and hair devoid of melanocytes. Although 
most of these patients have a heterozygous mutation, deafness has been observed in 
rare cases of both heterozygous and homozygous mutations [48, 49]. We show that 
KIT is expressed by strial melanocytes in the human fetal cochlea, suggesting that 
SNHL due to KIT mutations in humans is caused by mechanisms similar to those 
in mouse Kit mutants. 
Another	 neurocristopathy	 affecting	 melanocyte	 development	 with	 pigment	
abnormalities and SNHL is the genetically heterogeneous Waardenburg syndrome 
(WS), the most common type of autosomal dominant SNHL in humans. Its four 
subtypes are based on clinical symptoms and multiple causative genes have been 
identified	 [8].	We	 show	 here	 that	 in	 the	 human	 fetal	 cochlea,	MITF	 expression	
is	 confined	 to	melanocytes	 (Figure	 3A,	 3C).	 Therefore,	 it	 is	 likely	 that	 cochlear	
melanocytes are responsible for SNHL in WS with MITF mutations (causing type 
IIa WS [MIM 193510]), and/or PAX3 mutations (a gene regulating MITF, causative 
for type I WS [MIM 193500] and type III WS [MIM 148820]). In addition to MITF, 
mutations in SOX10 can also cause type II WS in next to type IVc WS [MIM 613266] 
[50, 51], whereas SOX10	has	recently	also	been	identified	to	play	a	role	in	Kallmann	
syndrome with deafness (KS, [MIM 147950, 244200, 308700, 610628, 612370, and 
612702]) [52]. SOX10 expression, however, is not exclusively limited to melanocytes 
in the human fetal cochlea (Figure 3B). We recently observed additional expression 
throughout the human fetal cochlear duct epithelium [29] and in all peripheral 
glial cells [31]. Although it is likely that melanocytes play a major role in SNHL 
in WS or KS due to SOX10	mutations,	it	cannot	be	excluded	that	other	SOX10+	
cell types in the cochlea are involved as well. Taken together, the melanocytic 
expression of MITF, SOX10 and KIT in the human fetal cochlea help to explain 
the aforementioned hereditary hearing disorders and underscore the important role 
of this cochlear cell type in syndromic SNHL. 
The endocochlear potential and its relation to hereditary SNHL
Hearing depends on the highly positive endocochlear potential, generated by 
the interplay of various ion channels and transporters in the cell types of the 
stria vascularis (reviewed in [25, 53]). The location of these proteins along the 
membranes	of	the	different	cells	of	the	adult	stria	vascularis	is	depicted	in	Figure	












the stria vascularis or at other locations in the cochlea where they are thought to be 
involved	in	K+	homeostasis	results	in	immediate	SNHL	[54–56].	In	many	cases	of	
both syndromic (as mentioned above) and nonsyndromic SNHL, the endocochlear 
potential	is	likely	to	be	affected.
The	marginal	cells	in	the	stria	vascularis	express	the	voltage-gated	potassium	channel	
KCNQ1 (or KCNE1, [MIM 176261]). Mutations in KCNQ1 cause the autosomal 
recessive	Jervell	and	Lange-Nielsen	syndrome	[MIM	220400],	characterized	by	SNHL	
and cardiac abnormalities (long QT syndrome) [9, 57]. In this syndrome, there is an 
impaired K+ secretion into the endolymph by the KCNQ1/KCNE1 channel complex 
on	the	apical	membranes	of	the	marginal	cells	in	the	stria	vascularis,	as	confirmed	
in a mouse model with the homozygous mutants being completely deaf [58]. Since 
a low number of functional channels still result in normal hearing in heterozygous 
patients [59], it can be surmised that, to cause deafness, mutations in KCNQ1 have 
to inactive the channel complex completely so that the total K+-secretion	is	reduced	
to a minimum. On the basolateral membranes of the marginal cells, K+ uptake 
from	the	intrastrial	space	(the	narrow	fluid-containing	space	between	the	marginal	
cells	and	 the	melanocytes)	 is	mediated	by	 the	 sodium-potassium	pump	Na+/K+-
ATPase [60] and the Na+2Cl-K+ cotransporter (NKCC). Na+/K+-ATPase	is	known	
to be expressed in the adult human stria vascularis [61] and inhibition of Na+/K+-
ATPase directly suppresses the endocochlear potential in guinea pigs [55, 62]. We 
found	first	expression	of	KCNQ1	on	the	luminal	membranes	of	the	marginal	cells	
at W16. At W18, we observed that the cell processes from the developing marginal 
cells (expressing ATP1A1) and the strial melanocytes intermingle and form an 
intricate network together with the capillaries. The developmental expression 
of KCNQ1 and ATP1A1 indicates that both K+ uptake and secretion could be 
mediated	by	marginal	cells	as	early	as	W16-W18.
The pivotal role of strial melanocytes in the generation of the endocochlear 
potential	 is	 to	 secrete	K+	 ions	 into	 the	 intrastrial	 space	and	hence	 they	express	
the	 inward-rectifying	 potassium	 channel	 KCNJ10	 (also	 known	 as	 Kir4.1,	 [MIM	
602208]) [63, 64]. In contrast to the potassium channels of the marginal cells, we did 
not observe any KCNJ10 expression in strial melanocytes up to the last stage we 
investigated, W18. As inhibition of this receptor directly suppresses the endocochlear 
potential [55], it is likely that the endocochlear potential is not yet generated at 
this	stage.	KCNJ10	is	implicated	in	multiple	syndromic	disorders	with	SNHL.	Loss-
of-function	mutations	 in	KCNJ10 cause SESAME syndrome ([MIM 612780], also 
called EAST syndrome), a disorder characterized by SNHL, electrolyte imbalance, 
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seizures, ataxia and mental retardation. Here, the hearing loss is likely due to 
disrupted function of strial melanocytes [65]. KCNJ10 is also implicated in SNHL in 
autosomal	recessive	deafness-4	(DFNB4)	with	enlarged	vestibular	aqueduct	(EVA)	
[MIM 600791], and in autosomal recessive Pendred syndrome [MIM 274600]. In 
Pendred syndrome, SLC26A4 [MIM 605646] mutations account for the majority of 
cases [66]. The dysfunction of its protein, PENDRIN, results in loss of KCNJ10 
expression in the melanocytes of the stria vascularis and subsequent loss of the 
endocochlear potential [67, 68]. However, mutations in KCNJ10 itself have also 
been linked directly to Pendred syndrome [69]. Interestingly, KCNJ10 has also been 
described in the root cells of the outer sulcus, both in the adult rodent and human 
cochlea [64, 70]. Also, the expression pattern of KCNJ10 that we observed in the 
outer sulcus during cochlear development matches the known expression pattern 
of PENDRIN in the outer sulcus of the adult mouse cochlea [67, 71]. This provides 
a striking link between the two proteins and could help to explain the etiology of 
SNHL in Pendred syndrome. 
Several connexins (Cx, gap junction proteins) are expressed at various locations in 
the cochlea and are thought to be implicated in K+ recycling [25, 72]. Mutations in 
connexins are a major cause of hereditary SNHL [18]. The most frequent causative 
gene for nonsyndromatic SNHL is GJB2 (CX26) [18]. Although less frequent, 
mutations in GJB6 (CX30) [73, 74] and GJA1 (CX43) [75, 76] have also been linked 
to SNHL. These gap junction proteins are thought to play a role in maintaining 
cochlear ion homeostasis and the endocochlear potential, as shown in Gjb6-deficient	
mice [56], by passively recycling K+ ions back to the stria vascularis. The observed 
expression in the developing human cochlea is in support of this model. However, 
an interesting note can be made with regard to the observed glucose transporter 
(SLC2A1) expression on the luminal membranes of the outer sulcus cells. As this 
part of the cochlea does not have its own vascularization, one could speculate that 
receptor expression at this luminal location functions to take up glucose circulating 
in the endolymph, suggesting a rather more active role for these cells with regard to 
cochlear K+ homeostasis (with a potential role for the Na+/K+-ATPase?).
Finally, GJE1 has not been previously investigated in the human cochlea. GJE1 
encodes the connexin 23 protein, and should not be confused with CX29/CX30.2, 
which used to be called GJE1 but recently has been renamed to GJC3 [MIM 611925]). 
In the developing human fetal cochlea, we observed dynamic GJE1 expression in 















Maturation of the lateral wall and the onset of human hearing
In many rodent species, development of hearing extends beyond birth and the onset of 
hearing occurs after birth (in an altricial manner). In contrast, hearing development 
in humans progresses at a much slower rate, but the cochlea and hearing function 
are complete before birth (precocial hearing development). Although cochlear size 
and	degree	of	spiralization	differs	between	species,	the	morphological	appearance	
of the various cochlear tissues and structures as well as the subsequent protein 
expression	profiles	are	very	similar.	Therefore,	based	on	similarities	in	morphology	
and protein expression patterns in adult mammalian cochleas, we conclude that 
the human fetal cochlea at W18 demonstrates a nearly adult phenotype, but that 
some essential elements for functionality are still missing. Most notably, strial 
melanocytes do not yet express KCNJ10, basal cells are immunohistochemically 
undefined,	root	cells	have	not	developed	their	root-like	basolateral	processes,	and	
GJB2 and GJB6 are not yet observed in the spiral ligament. This implies that the 
endocochlear potential cannot be generated at this stage and, therefore, that the 
human fetus at W18 is still unable to hear. Although W20 has been proposed by us 
[29,	31]	and	others	[78–80]	as	the	onset	of	human	hearing	based	on	the	maturation	
of the organ of Corti and the cochlear nerve, it is more likely that hearing commences 
a few weeks later, which is in line with otoacoustic emission measurements [81] and 
auditory brainstem responses in preterm infants [82, 83]. 
In mice and gerbils, the appearance of the endocochlear potential has been observed 
just prior to their onset of hearing [43, 84], and coincides with morphological 
maturation of gap and tight junctions. Even although their auditory system does 
not become functional before birth, the sequence of morphological maturation is 
similar	to	what	we	observe	in	human	fetuses.	In	view	of	these	findings,	extrapolation	
of our observations to later fetal stages suggests that the endocochlear potential, 
and therefore hearing, in the human fetus does not emerge before the third trimester 
of pregnancy. 
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ConClusion
We have investigated the complex embryonic development of the lateral wall in the 
human fetal cochlea with respect to the expression of several genes that are known 
to be involved both in syndromic and nonsyndromic SNHL, providing an etiological 
basis for these hearing disorders in humans. Although hereditary SNHL can be 
caused	by	specific	mutations	 in	various	genes	 involved	 in	cochlear	K+ transport, 
we would like to underline the major functional role of melanocytes in the cochlea 
and the generation of the endocochlear potential. We suggest that many cases of 
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supplemental material and methods
Immunohistochemistry
An	 additional	 primary	 antibody	 used	 in	 the	 supplementary	 data	 is	mouse	 anti-
TUBB3 (1:500, 2G10, Ab78078, Abcam).
Image acquisition, processing and reconstruction
Image restoration (deconvolution) was applied to scans shown in Figure S3. These 
maximal projections were obtained from images stacks acquired at sampling 
density according to the Nyquist rate. Deconvolution was performed using Huygens 
Professional	version	4.3.1	software	(Scientific	Volume	Imaging).	Three-dimensional	
(3D) reconstructions were made from deconvoluted image stacks using AMIRA 
5.3.3	(Visage	Imaging),	and	interactive	PDF	files	were	created	using	Adobe	Acrobat	
Pro Extended version 9.5.5. (Adobe Systems). For clarity, erythrocytes present in 
the scala vestibuli and scala tympani were manually masked with black pixels in 
Figure S4F. To generate the image in Figure S1A, ten consecutive tissue sections 
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 Identifying neuronal derivatives of stem cells is essential for both 
basic research and future applications in regenerative medicine targeting 
neurodegenerative	 diseases.	 Erroneous	 identification	 could	 result	 in	 the	
transplantation	of	inappropriate	cell	types,	thus	directly	affecting	clinical	outcome.
	 Stem	cell	and	neurobiology	researchers	widely	regard	the	class	III	β-tubulin	
protein (TUBB3), a member of the microtubule family, as being selectively expressed 
in neuronal cells. Antibodies against this protein are therefore often used to identify 
cells of the neuronal lineage or to quantify neuronal cells within cell cultures. The 
most	renowned	anti-TUBB3	antibody	is	the	monoclonal	TUJ1,	with	other	examples	
including	clones	TU-20	and	2G10.
 Nevertheless, we propose reconsidering the use of TUBB3 as a marker for 
neurons when melanocytes are potentially present or being formed. Why? Research 
in our own lab indicated that melanocytes were formed in studies on neuronal 
differentiation.	 Intrigued,	 we	 investigated	 and	 detected	 high	 TUBB3	 expression	
during	melanocyte	differentiation	in vitro and in vivo [1] in both human foetal and 
adult melanocytes (see Figure 1A for an example in the human skin). In agreement, 
two other articles [2, 3] have described the expression of TUBB3 in chick and mouse 
melanoblasts, indicating that TUBB3 expression is clearly not restricted to neurons 
and	should	therefore	not	be	regarded	as	a	standard	for	neuronal	identification,	but	
rather as a broader marker of the neural lineage (both neural crest and neural tube 
derivatives).
	 Furthermore,	 double-labelling	 combinations	 of	 microtubule-associated	
protein 2 (MAP2) and TUBB3 (used to identify cells as “neurons”) or tyrosine 
hydroxylase (TH) and TUBB3 (used to identify cells as “dopaminergic neurons”) 
are	not	fail-safe	as	melanocytes	can	express	both	MAP2	and	TH.	Melanocytes	can	
also express nestin (considered to be a neural stem cell marker although its presence 
in endothelial cells has also been reported), which together with TUBB3 is often 
used to identify “neuronal precursor cells” (Figure 1B and 1C). Thus, using these 
combinations	of	markers	may	result	in	cells	being	incorrectly	identified	as	neurons.	
The same is true for neurotrophins (NGF, BDNF, NT3 or NT4) and neurotrophic 













 Melanocytes and neurons are both derived from the neural plate (more 
specifically,	all	neurons	from	the	peripheral	nervous	system	and	melanocytes	are	
derived from the neural crest), share morphological features (e.g. an extensive 
dendritic tree) and to a large extent express the same biomarkers. If melanocytes 
are potentially present in the experimental system of interest, another method of 
identification	should	be	sought.	One	option	is	to	rule	out	melanocytes,	for	example	
by taking advantage of markers present in melanocytes but not in mature neurons 
such	as	melan-A	or	sex-determining	region	Y	box	9	(SOX9)	(Figure	1D).	The	other	
option is to irrefutably demonstrate successful derivation of neurons by their true 
neuronal hallmark: the action potential.
 Or is it?
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neural lineage and is therefore often used to identify neurons amongst other cell 
types, both in vivo and in vitro. Melanocytes are derived from the neural crest and 
share both morphological features and functional characteristics with peripheral 
neurons.	 Here,	 we	 show	 that	 these	 similarities	 extend	 to	 class	 III	 β-tubulin	
(TUBB3) expression, and that human melanocytes express this protein both in vivo 
and in vitro.	 In	addition,	we	 studied	 the	expression	of	class	 III	β-tubulin	 in	 two	
murine melanogenic cell lines and show that expression of this protein starts as 
melanoblasts mature into melanocytes. Melanin bleaching experiments revealed 
close proximity between melanin and TUBB3 proteins. In vitro stimulation of 
primary	human	melanocytes	by	α-MSH	indicated	separate	regulatory	mechanisms	
for melanogenesis and to TUBB3  expression. Together, these observations imply 














Over the last several years, there has been a notable increase in interest in the 
culture of skin and skin stem cells, in part for the generation of skin substitutes, in 
part with view to understanding cutaneous pathologies. It is of great importance to 
be	able	to	identify	the	different	skin	cell	subtypes	accurately	in	culture	in	order	to	
fully understand their biology.  A widely used biomarker in this context is class III 
β-tubulin	(TUBB3),	which	is	generally	thought	to	be	expressed	only	in	cells	of	the	
neural lineage. 
Microtubules	 are	 one	 of	 the	 main	 classes	 of	 cytoskeletal	 filaments	 involved	 in	
cellular morphology, motility, division and intracellular transport. They are 
composed	of	assemblies	of	heterodimers	one	α-	and	one	β-tubulin	subunit	 [1,	2].	
There	 are	multiple	 β-tubulin	 isotypes	 and	 their	 expression	 is	 tissue-specific	 and	
depends	 on	 the	 developmental	 stage	 [3].	 Isotype	 TUBB3	 was	 first	 described	 in	
avian and mammalian species [4]. Antibodies directed against TUBB3 epitopes 
distinguished between neurons and glial cells [5, 6], so that it became a standard 
biomarker	for	neuronal	identification.	TUBB3	expression	is	often	used	to	identify	
neuronal	cells	in	skin-derived	and	(epidermal)	stem	cell	cultures.	In vivo it is used to 
trace the dendritic processes of neurons in the dermis and epidermis, of which the 
cell bodies are located elsewhere. 
TUBB3	is	not	exclusively	neuron-specific.	It	is,	albeit	weakly,	expressed	in	testicular	
and a few other tissue types [3, 7]. Recently, it was shown to be present in cultures 
of mesenchymal and epithelial cells [8]. A variety of solid tumors such as ovarian 
tumors, lung tumors and malignant melanomas also express TUBB3 and it has 
been suggested that this tubulin isotype is associated with cellular drug resistance 
[9]. Tubb3 has also been found expressed in developing melanoblasts in mouse and 
chicken	embryo’s	[10,	11].		Interestingly,	in	a	recent	study	positive	immunoreactivity	
for the TUBB3 protein was reported in cells in the basal layer of normal human 
adult epidermis [12]. Although it is suggestive that these cells could be melanocytes, 
no	confirmation	has	been	provided.	This	is	of	importance	as	an	identical	epidermal	
immunostaining pattern can be found in a study on human epidermal innervation 
[13]. A potential TUBB3 expression by melanocytes could therefore mislead 
neuronal	cell	identification	when	using	antibodies	directed	against	TUBB3.	
In the present study, we have resolved this issue by showing that TUBB3 is expressed 




we	 have	 explored	 its	 relation	 to	melanocyte	 differentiation	 and	melanogenesis.	
Because melanocytes do express TUBB3, this has major implications in interpreting 
















female patient. Fetal scalp skin was collected from tissue of 20 weeks gestational 
age obtained by elective abortion. Both cases were approved by the Medical Ethical 
Committee of the Leiden University Medical Center (fetal tissue: P08.087) and 





Fetal scalp skin was mechanically dissociated and cultured for seven days in 
RPMI	1640	(Life	Technologies,	Carlsbad,	CA,	USA)	containing	10%	fetal	bovine	
serum (FBS) GOLD (PAA Laboratories GmbH, Pasching, Austria), 200 nM 
12-O-tetradecanoylphorbol	 13-acetate	 (TPA,	 Sigma-Aldrich,	 Saint	 Louis,	 MO,	
USA),	200	pM	cholera	toxin	(CT,	Sigma-Aldrich),	10	ng/ml	stem	cell	factor	(SCF,	
R&D Systems, Inc., MN, USA), GlutaMAX (Life Technologies) and antibiotic 
antimycotic	 solution	 (Sigma-Aldrich).	 Cultures	were	maintained	 in	 a	 humidified	
incubator	with	5%	CO2 at 37 0C. Medium was changed every third day. 
Melb-a	cells	were	cultured	in	RPMI	with	10%	FBS,	20	ng/ml	SCF,	10	ng/ml	bFGF	
(R&D	Systems,	Inc.),	GlutaMAX	and	antibiotic	antimycotic	solution.	Melan-Ink4a2	
cells	were	 cultured	 in	RPMI	 containing	 10%	FBS,	 200	nM	TPA,	 200	pM	CT,	 10	
ng/ml SCF, GlutaMAX and antibiotic antimycotic solution. Both cell lines were 
maintained	in	a	humidified	incubator	with	10%	CO2	at	37	0C. Medium was changed 
every other day, and cells were passaged using TrypLE Express (Life Technologies) 
upon	reaching	90%	confluency.
Primary	 normal	 human	melanocytes	were	 cultured	 in	Ham’s	 F10	 supplemented	








reaching	 90%	 confluency.	Melanocytes	 were	 stimulated	 with	 109	 U	 alpha-MSH	
(Sigma-Aldrich)	for	6,	24	and	48	hours.	




minutes at 97 0C	using	a	microwave	oven.	Sections	were	blocked	with	1%	bovine	
serum	albumin	(BSA,	Sigma-Aldrich)	in	PBS	containing	0.05%	Tween-20	(Promega,	
Madison, WI) for 30 minutes, and incubated with primary antibodies (appropriately 
diluted	 in	 BSA/Tween-20/PBS)	 overnight	 at	 room	 temperature	 in	 a	 humidified	
chamber.	 Secondary	 antibodies	 were	 diluted	 in	 1%	 normal	 goat	 serum	 (NGS,	
DAKO,	Glostrup,	Denmark)	in	Tween-20/PBS,	and	sections	were	incubated	for	1	
hour	at	room	temperature.	Nuclei	were	stained	with	4’,6-diamidino-2-phenylindole	
(DAPI) and sections were mounted in ProLong Gold (Molecular Probes, Life 
Technologies).	Cultures	were	fixed	in	1%	formaldehyde	in	PBS	overnight	at	4	 0C 




(appropriately	diluted	 in	NGS/Tween-20/PBS)	overnight	at	4	 0C. Next, the cells 
were	 incubated	 with	 fluorochrome-conjugated	 secondary	 antibodies	 (diluted	 in	
NGS/Tween-20/PBS)	 for	 1	 hour	 at	 room	 temperature	 and	 followed	 by	 nuclear	
staining with DAPI added to Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA). Primary and secondary antibodies, and their dilutions, are listed 
in	Table	S1.	 In	all	double	 stainings	with	melanocytic	markers,	monoclonal	anti-
TUBB3 2G10 was used. Due to technical limitations, DCT was used to identify 
the	pigmented	melanocytes	in	deparaffinized	sections	whereas	TYRP1	was	used	to	
identify these cells in culture. These enzymes catalyze subsequent steps in melanin 
biosysthesis.	Human	dermal	fibroblast	cultures	(HDF-a,	ScienCell,	Carlsbad,	CA,	
USA)	 were	 used	 as	 a	 negative	 tissue	 control	 whereas	 in	 specificity	 controls	 the	
primary	antibody	was	omitted.	Brightfield,	phase	contrast	and	fluorescent	images	
were taken with either a DM5500 microscope and camera (Leica Microsystems, 
Rijswijk, the Netherlands) or an Olympus IX70 microscope (Olympus, Zoeterwoude, 












AF software (Leica). Brightness and contrast adjustments and cell counting was 





with 1 mini protease inhibitor cocktail tablet (Roche, Basel, Switzerland) per 10 
ml).	Human	melanocytes	were	harvested	for	Western	analysis	in	lysis	buffer	M-per	
(Thermo	 Scientific,	 Rockford,	 IL),	 supplemented	with	 1	 tablet	 PhosSTOP	 and	 1	




for	 90	minutes	 at	 300	mA.	Membranes	were	 blocked	with	 3%	 non-fat	 dry	milk	
(Elk	 skimmed	 instant	milk	powder;	FrieslandCampina,	 the	Netherlands)	 in	TBS	
containing	0.01%	Tween-20	(TBST,	pH	7.5)	for	1	hour	at	room	temperature	followed	
by incubation with the primary antibodies TUJ1 (1:2000, Covance, Princeton, NJ), 












Primers against Mitf, Dct and Tubb3	were	designed	with	Primer-BLAST	(http://
www.ncbi.nlm.nih.gov/tools/primer-blast).	A	complete	list	of	the	primers	used	can	
be found in Table S2. cDNA was generated by incubating 1 µg RNA with 500 ng 





mixed, incubated at room temperature for 10 minutes, and heated for 50 minutes 
at 45 0C and 10 minutes at 70 0C.	Real-time	PCR	was	performed	using	 the	 IQ5	
Real	Time	PCR	Detection	System	(Bio-Rad)	with	an	 initial	denaturation	step	of	
15 minutes at 95 0C followed by 40 cycles of 15 seconds at 95 0C, 30 seconds at 
60 0C and 30 seconds at 72 0C. Cycle threshold values were attained and relative 
expression levels of mRNA were normalized to the housekeeping genes Hprt and 
Gapdh	and	calculated	by	 the	ΔΔCT	method.	qRT-PCRs	were	performed	on	 two	
independent samples of each cell line and three technical replicas were performed 
for each sample.
Statistical analysis
Results	 are	 expressed	 as	 the	 mean	 ±	 standard	 deviation.	 Two-tailed,	 paired	
Student’s	 t-tests	 were	 used	 to	 determine	 statistical	 significance.	 A	 value	 of	 p	 <	
0.05	was	 considered	 to	 be	 statistically	 significant.	Analysis	was	 performed	using	
Microsoft Excel 2010 (Microsoft, Redmond, WA). 
















TUBB3 is expressed in human epidermal melanocytes in vivo
To	confirm	the	TUBB3	expression	reported	by	Akasaka	et	al.	in	the	basal	layer	of	
human epidermis and to investigate if this was indeed localized to melanocytes, 




as	 tyrosinase-related	protein	2,	TYRP2)	 is	an	enzyme	 involved	 in	melanogenesis	
and	 is	 a	 direct	 target	 of	microphthalmia-associated	 transcription	 factor	 (MITF)	
and	 therefore	 specifically	marks	 the	 early	 and	 terminally	differentiated	pigment	
producing	melancoytes.	 In	 adult	 human	 epidermis,	 most	melan-A+	 and	DCT+	




± 19.3, n = 37). Fetal scalp skin at 20 weeks of gestational age showed a similar 
staining	pattern.	Already,	melan-A+/TUBB3+	and	DCT+/TUBB3+	melanocytes	
were	found	in	the	basal	layer	(Figures	1C	and	1D)	and	the	majority	of	melan-A+	
and	DCT+	cells	 expressed	TUBB3	 (98.0%	±	3.0	 (n	=	50)	and	100.0%	 (n = 27), 
respectively).	Of	the	TUBB3+	cells,	3.9%	±	3.4	(n = 51) did not immunostain for 
melan-A,	whereas	42.6%	±	5.5	(n = 47) were negative for DCT. Taken together, 
these	 data	 show	 that	 normal	 human	 epidermal	 non-pigmented	 and	 terminally	
differentiated	pigmented	melanocytes	express	TUBB3	in vivo.
We	also	observed	TUBB3+	dendritic-like	 structures	 in	 the	epidermis	 (Figure	1C,	
arrow) which we assumed to be epidermal nerve endings and therefore be of 
neuronal	origin.	Interestingly,	many	of	these	structures	were	also	melan-A+	(Figure	
1C,	 arrow).	 Since	 the	 dermal	nerve	fibers	 did	not	 stain	 for	melan-A	 (Figure	 1C,	
asterisk),	we	conclude	that	these	intraepidermal	melan-A+/TUBB3+	structures	are	
melanocytic dendrites rather than free nerve endings. 
Human hair follicle melanocytes express TUBB3 in vivo












follicle	 melanocytes	 also	 expressed	 TUBB3.	 In	 the	 hair	 follicle,	 non-pigmented	
melanocytes	reside	within	the	bulge/sub-bulge	area	and	the	outer	root	sheet	of	the	
infundibulum	[14–16].	They	are	thought	to	be	the	source	of	the	mature	melanocytes	




immunostained	 for	 TUBB3	 (Figures	 1E-1F).	 In	 addition,	 TUBB3	 expression	
was observed in cells of the outer root sheath (Figures 1E and 1F, arrowheads). 
These	TUBB3+	cells,	however,	were	negative	for	melan-A	and	DCT	and	it	could	
be	surmised	that	these	cells	are	non-pigmented	melanocytes	which	are	known	to	
reside in this area. TUBB3 immunostaining was also seen in the hair shaft medulla 
keratinocytes	(Figure	1E-F,	M).	In	summary,	in	the	human	hair	follicle	melan-A+/
TUBB3+	 and	 DCT+/TUBB3+	 melanocytes	 were	 observed	 in	 the	 hair	 matrix,	
whereas	melan-A-/TUBB3+	and	DCT-/TUBB3+	cells	were	found	in	the	outer	root	
sheath of the hair follicle bulb.
Fetal epidermal and hair follicle melanocytes express TUBB3 in vitro
Based on the in vivo expression of TUBB3 in both epidermal and hair follicle 
melanocytes, we anticipated that TUBB3 would also be expressed ex vivo/in vitro in 
these cells. For this purpose, human fetal scalp skin which contained an abundance 
of pigmented hair follicles was mechanically dissociated and cultured for seven days 
in standard culture medium containing additional factors (SCF, TPA and CT, see 
Materials and Methods)	to	support	the	whole	range	of	differentiated	melanocytes,	
including	 the	 non-pigmented,	 early-pigmented	 and	 the	 terminally	 differentiated	
pigmented melanocytes. This resulted in heterogeneous cultures containing 
keratinocytes,	fibroblasts	and	melanocytes.	The	melanocytic	 cells	were	 identified	
by	means	of	different	types	of	light	microscopy.	Using	phase-contrast	microscopy,	
melanocytes could be recognized by their bipolar or multipolar dendrites and the 
halo	 surrounding	 their	 cell	 body	 (Figure	 2).	Bright-field	microscopy	was	used	 to	
detect pigment inclusions (Figure 2). Using both approaches, epidermal and hair 
follicle melanocytes could be distinguished on basis of the criteria formulated 
by	 Tobin	 et	 al.	 [17]	 who	 showed	 that	 cultured	 epidermal	melanocytes	 have	 3-6	
dendrites,	whereas	cultured	hair	follicle	melanocytes	are	mostly	bipolar.	Definite	




As	 expected,	 we	 were	 able	 to	 identify	 TYRP1+/TUBB3+	 pigmented	 epidermal	
melanocytes	 in	 the	 dissociated	 skin	 cultures	 (Figure	 2A).	 Interestingly,	 TYRP1-/
TUBB3+	 cells	 were	 also	 observed	 (Figure	 2A,	 asterisks).	Morphologically,	 these	
non-	 or	 early-pigmented	 melanocytes	 were	 similar	 to	 the	 TYRP1+/TUBB3+	
cells,	 but	 they	were	 less	dark	under	bright-field	microscopy.	Bipolar	hair	 follicle	
melanocytes	were	present	 in	 large	numbers	and	were	TYRP1+/TUBB3+	(Figure	
2B).	 In	 close	 proximity	 to	 these	 cells,	 some	bipolar	TYRP1-/TUBB3+	were	 also	
found	 (Figure	 2B,	 asterisks).	 Melan-A	 staining	 showed	 similar	 results;	 bipolar	
melan-A+/TUBB3+	cells	were	clearly	growing	out	of	the	hair	follicle	bulb	(Figure	
2C).	There	were	no	melan-A-/TUBB3+	cells	with	 similar	morphology,	but	 some	
TUBB3 expression was seen in cells with a morphology reminiscent of keratinocytes 
(Figure 2C, arrowheads). This data show that, as in vivo, both human epidermal 
and hair follicle melanocytes express TUBB3 in vitro and that expression starts 
before initiation of melanogenesis.
Expression	 of	 TUBB3	 starts	 upon	 differentiation	 of	 melanoblasts	 into	 mature	
melanocytes
In neurons of the central nervous system TUBB3 expression decreases as the cells 
mature and can therefore be used to identify young developing neurons. In the 
peripheral nervous system, however, the opposite is found: TUBB3 levels increase 
with neuronal cell maturation in dorsal root ganglia[18]. Our experiments with 
human melanocytes show that TUBB3 is expressed in the end stages of the 
melanocytic	 lineage	 (non-pigmented	 and	 pigmented	 melanocytes).	 However,	
expression	 in	 the	 undifferentiated,	 melanoblast	 stage	 remains	 inconclusive.	 To	
further examine this relationship of TUBB3 expression within the melanocytic 




immature state. Although most cells were negative for TUBB3 (Figure 3A), rare 
TUBB3+	cells	could	be	observed.	Interestingly,	these	TUBB3+	cells	demonstrated	
a	more	 differentiated	 cell	morphology	 by	 the	 presence	 of	 dendrites	 and	 a	 halo	
surrounding	their	cell	bodies.	TUBB3-	cells	were	generally	flat	with	few	and	short	













cells[20].	 Cells	 of	 this	 line	 produce	 different	 amounts	 of	melanin,	 so	 both	 non-
pigmented and pigmented melanocytes are present which can be visualized under 
bright	field	microscopy	(Figure	3B).	TUBB3	immunostaining	showed	a	gradient	of	





all (Figure 3B, black arrows). When we analyzed line plots over areas containing 
large	amounts	of	melanin,	we	indeed	found	a	relation	between	fluorescent	intensity	
(Figure	3B,	graph,	red	line)	and	bright	field	intensity	(graph,	black	line).	
We questioned whether this observed inversed relation of TUBB3 immunostaining 




When we analyzed line plots within cells over areas containing large amounts 
of	melanin,	we	found	a	relation	between	fluorescent	 intensity	 (Figure	3B,	graph,	
red	line)	and	bright	field	intensity	(graph,	black	line),	suggestive	that	the	pigment	
itself	 blocked	 fluorescence.	 Similar	 line	 plot	 profiles	 were	 seen	 with	 secondary	
antibodies	 of	 different	 wavelengths	 (data	 now	 show).	 To	 further	 test	 this,	 we	
treated	 formaldehyde-fixed	 melan-Ink4a2	 cells	 with	 potassium	 permanganate	
and	oxalic	acid	to	bleach	the	melanin	(Figure	3B,	bright	field).	After	subsequent	
immunostaining,	 TUBB3	 fluorescence	 was	 significantly	 increased	 (Figure	 3C).	
Bright	TUBB3	immunostaining	was	present	in	nearly	all	cells	(94.2%	±	3.2,	n = 
142),	whereas	 in	 the	untreated	 samples	only	about	a	quarter	of	 the	 cells	 (25.9%	
± 12.3, n = 192, p	 <	 0.001	 between	 groups)	 were	 clearly	 visible	 (Figure	 3B-C).	
These	data	 indicate	that	TUBB3	is	not	only	upregulated	upon	differentiation	of	





(TUJ1 and 2G10) showed corresponding bands at the predicted molecular weight of 




2G10 showed bands in both cell types with a much higher protein expression in 
the	melan-Ink4a2	cells.	Using	qRT-PCR	we	determined	Mitf, Dct and Tubb3 RNA 
levels (Figure 4B). Mitf and Dct, both key molecules in melanogenesis, were 1.67 ± 





commit	 to	 the	 melanocyte	 lineage	 and	 differentiate	 into	 pigment	 producing	
melanocytes.
α-MSH	 stimulation	 does	 not	 increase	 TUBB3	 expression	 in	 cultured	 human	
melanocytes
As TUBB3 expression in the melanocytic lineage coincides with the induction 
of melanin, we questioned if the melanogenesis pathway could also regulate 
TUBB3 expression. To assess this, we cultured primary human melanocytes and 
stimulated	 the	 cells	 with	 alpha-melanocyte-stimulating	 hormone	 (α-MSH)	 for	 6	
hours, 24 hours or 48 hours. After exposure, we performed quantitative western 
blot	analysis	for	DCT	and	TUBB3	expression	on	the	cell	lysates.	As	α-MSH	binds	
to the melanocortin 1 receptor (MC1R), which in turn promotes transcription of the 
MITF transcription factor, an observed increase in expression of the MITF target 



















In this study, we show that TUBB3 is not only expressed within peripheral neurons 
but also in the melanocytic lineage. In melanocytes, TUBB3 expression was found 
both in human epidermal and hair follicle melanocytes. Using skin sections, 
we	 showed	 that	 nearly	 all	 melan-A+	 and	 DCT+	 melanocytes	 express	 TUBB3.	
Conversely,	TUBB3+	cells	in	the	basal	layer	of	the	epidermis	were	almost	always	
melan-A+,	 although	 many	 did	 not	 express	 DCT.	 Similar	 results	 were	 found	 in	
cultured human fetal epidermal and hair follicle melanocytes. In the melanocytic 
lineage,	melan-A	is	expressed	both	by	non-pigmented	and	pigmented	melanocytes.	
However,	DCT	and	TYRP1	are	not	expressed	before	terminal	differentiation	into	
pigment producing melanocytes. This indicates that TUBB3 is widely expressed 
within the melanocyte lineage, with expression starting before pigment production. 
Indeed, when we investigated TUBB3 expression in mouse melanoblasts and 
melanocytes,	most	melanoblasts	did	not	(as	yet)	express	TUBB3	whereas	both	non-
pigmented and pigmented melanocytes did express TUBB3. This implicates that 
expression of TUBB3 starts around the point of time where melanoblasts commit 
to the melanocyte lineage (Figure 5).
Like peripheral neurons, melanocytes are derived from the neural crest. There are 
also other similarities, both in morphology and functional characteristics. Both cell 
types have small, round cell bodies and multiple dendritic processes. Both can express 
similar receptors (e.g. p75NTR	and	c-Kit)	and	therefore	respond	to	identical	cytokines	
and neurotrophins [21]. Furthermore, both melanins (produced by melanocytes) and 
catecholamines (e.g. dopamine, produced by neurons) are derived from tyrosine, and 
both melanosomes and synaptic vesicle precursors are transported over microtubules 
by kinesins. In turn, melanosomes and neurotransmitters are both released from 
their dendrites or axons. Presently, there is an emerging concept that melanocytes 
could potentially be used to represent neuronal cells in disease model systems. In 
this	light,	the	expression	of	neuron-specific	TUBB3	in	melanocytes	might	not	be	so	
surprising. In the skin, TUBB3 expression is considered to be of neuronal origin, 
whether it be intraepidermal free nerve endings or nerves projecting to Merkel cells, 
Langerhans	cells	or	even	melanocytes	[22–24].	As	we	show	that	at	least	a	part	of	
these endings belong to melanocytes, it is of great interest to further investigate the 
extent of TUBB3 expression by skin melanocytes, examine their relationship with 
surrounding cells and investigate expression of other neuronal biomarkers.
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TUBB3 has now been found expressed in chicken, mouse and human melanocytes. 
This evolutionary conservation is suggestive of an important role of TUBB3 in 
these cells. We observed initiation of TUBB3 expression in the melanocytic lineage 
around	the	time	of	differentiation	into	pigment	producing	melanocytes.	Melanocyte	
development	as	well	as	 the	UV-induced	pigmentation	 response	are	 regulated	by	
the	MITF	transcription	factor	that	modulates	multiple	differentiation	and	melanin	
biosynthesis genes. We questioned whether TUBB3 expression could be regulated 
by	 the	 same	pathway	and	 stimulated	 cultured	human	melanocytes	with	 α-MSH,	
known to induce MITF expression. Whereas expression of the MITF target gene 
DCT	was	induced	by	α-MSH	stimulation,	there	was	no	associated	increase	in	TUBB3	
expression.	Therefore,	TUBB3	does	not	seem	to	be	regulated	by	the	MITF-pathway	
which regulates melanocyte development and pigmentation response. This is in line 
with results of studies examining MITF target genes, which consistently found that 
TUBB3	was	not	among	the	targets	of	this	transcription	[25–27].
Using	 a	 well-established	 bleaching	 protocol,	 we	 show	 that	 fluorescent	 signals	
emitted by TUBB3 stainings are blocked by melanin. This was in contrast to 
control	experiments	with	melan-A	immunostaining	which	did	not	show	this	clear	
relationship	 (Figure	 S1),	 indicating	 that	 the	melanin	 specifically	 interfered	 with	
the	 TUBB3	 fluorescence.	 Therefore,	 we	 conclude	 that	 the	 diminished	 TUBB3	
fluorescence	was	caused	by	specific	co-localization	of	melanin.	This	could	indicate	
a novel role of TUBB3 in melanosomal transport. It is known that mature 
melanosomes are transported by kinesin and dynein motor proteins (Marks & 
Seabra,	2001).	These	proteins	use	microtubule	tracks	to	travel	 in	a	bi-directional	
way	 (Wu	 et	 al.,	 1998).	 Also,	 by	 specifically	 disrupting	microtubules,	 it	 has	 been	
shown that melanosome transport is microtubule dependent [28]. Potentially, 
TUBB3	could	be	the	corresponding	β-unit	isotype	(Figure	S2).	However,	its	role	in	
cellular processes remains to be investigated.
A recent study by Dalziel et al. (2011) showed that TUBB3 is physically located 
immediately downstream of MC1R (Figure S3). This receptor binds to melanocortins 
and	plays	an	important	role	in	melanogenesis	through	its	ability	to	influence	MITF	
transcription. Aside from showing that TUBB3 is located immediately downstream 
of MC1R, in itself suggesting a role within melanocytes, Dalziel and colleagues 
found that chimeric proteins are transcribed by intergenic splicing between these 
two genes. The monoclonal TUBB3 antibodies used in our study, TUJ1 and 2G10, 
both	recognize	the	C-terminus	of	the	TUBB3	protein	(epitopes	EAQGPK	[30]	and	












In chick and mice, Tubb3 has only one protein product. In humans, aside from 
the chimeric proteins, there are four additional TUBB3 isoforms (Figure S3). Both 
antibodies	will	recognize	at	least	isoforms	1	and	2	and	the	chimeric	transcript	RP11-
566K11.2-001.	Currently,	these	antibodies	react	both	with	neuronal	and	melanocytic	
cells.	However,	 it	 could	be	 that	both	 cell	 types	 express	different	 isoforms	of	 the	
TUBB3 protein. It will be interesting to investigate the exact expression of these 
isoforms	in	normal	human	neurons	and	melanocytes	to	find	out	whether	different	
and/or identical isoforms are present in these cell types. Together, our results and 
these	findings	suggest	a	dynamic	role	for	TUBB3	in	multiple	aspects	of	melanocytic	
function. 
Finally, in addition to TUBB3 expression in melanocytes, we have also observed 
its presence in hair follicle medulla keratinocytes in vivo. Expression of TUBB3 in 
the	mitotic	 spindle	of	cultured	keratinocytes	and	fibroblasts	has	been	previously	
reported [8], something we have observed as well in our cultured melanocytes 
(Figure S5). This indicates that this biomarker, especially in the skin, cannot be 
reliably	 used	 to	 differentiate	 between	neuronal	 cells	 and	other	neural	 crest	 and	
ectodermal	cell	types.	Primary	skin	cultures	and	differentiation	studies	on	skin	stem	
cells	or	even	(induced)	pluripotent	stem	cells	might	be	prone	to	this	identification	
issue. Aside from identifying neurons, TUBB3 can be used as a much wider marker 
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to be neuronal cells derived from a local neural crest stem cell. However, TUBB3 
has recently been shown to be expressed in the melanocytic lineage. To evaluate 
the	neural-crest-associated	 immunophenotype	of	TUBB3-positive	cells	 from	hair	
follicle bulge explants, we dissected hair follicle bulges out from mouse whisker 
pads and cultured for one month and assessed outgrowing cells by means of 
immunocytochemistry using the biomarkers TUBB3, nestin, NGFR, SOX9, TYRP1 
and	 laminin.	Large	 amounts	 of	TUBB3-positive	 cells	 could	be	 cultured	 that	 co-
expressed nestin, NGFR, SOX9 and, to a lesser degree, TYRP1, matching a 
melanoglial	 phenotype.	 In	 addition,	 a	 small	 population	 of	 TUBB3-negative	 but	
laminin-positive	cells	was	 found,	which	presumably	are	of	glial	origin.	 It	can	be	
concluded that cells of melanoglial origin can easily be obtained from hair follicle 
bulge explants. These cells may be of use in experimental animal or human disease 
and	wound	healing	models.	Notably,	the	TUBB3-positive	cells	are	of	melanoglial	













Stem cells that are harvested from adult human tissues are considered the gold 
standard	for	autologous	cell-based	therapies[1].	Adult	human	neural-crest-derived	
stem	cells	(NCSCs)	are	promising	candidates	for	the	use	in	regenerative	medicine;	
niches have been described in the dorsal root ganglia, gut epithelium, cornea 
epithelium, heart muscle, inferior turbinate, dental and periodontal tissue, and the 
hair follicle bulge[2]. The advantage of hair follicle bulge stem cells is that they can 
be harvested in a minimally invasive way and that they can be isolated without 
proteolysis. 




However, it has recently been demonstrated that mouse and human melanocytes 
also	express	TUBB3[5–7].	As	melanocytes,	 similar	 to	peripheral	neurons,	derive	
from	the	neural	crest,	we	wondered	whether	the	TUBB3-positive	cells	cultured	from	
hair follicle bulge explants could be such melanocytes. If so, we should be extremely 
reticent	 about	 TUBB3-positive	 cells	 cultured	 from	 hair	 follicle	 bulge	 explants,	
presumed to be committed towards the neuronal lineage.
To address this issue, we investigated the immunophenotype of the cells migrating 








126 hair follicles), which were obtained from the LUMC central Animal Facility. 
Their use was approved by the LUMC Animal Experiments Committee (DEC 
permit 10172).
Cell cultures
Hair follicle bulges were isolated from mouse whisker pads according to a protocol 
previously	 described	 by	 Sieber-Blum	 et	 al.3.	 In	 summary,	 hair	 follicles	 were	
dissected out from the whisker pads, the follicle was transected below and above 
the bulge region and a longitudinal incision was made in the capsule. The bulge 
was	rolled	out	of	the	capsule	and	explants	were	transferred	to	6-well	cell	culture	
plates	pre-coated	with	collagen	l	(Sigma-Aldrich)	and	allowed	to	attach	for	1	hour	
at	 37°C	 in	 a	 humidified	 incubator	 with	 5%	 CO2	 prior	 to	 addition	 of	 culture	
medium.	Culture	medium	consisted	of	alpha	MEM	(Bio-Whittaker)	containing	5%	
chicken	embryo	extract	(Seralab),	10%	fetal	bovine	serum	(Life	Technologies),	1%	
GlutaMAX	 (Life	 Technologies)	 and	 1%	 antibiotic/antimycotic	 solution	 (Sigma-
Aldrich). Medium was refreshed every other day. To allow as many cells as possible 
to migrate out of the explant, cultures were maintained for 4 weeks followed by 





Immunocytochemical protocols were similar to the ones described previously[5]. 
Primary	 antibodies	 used	 in	 this	 study	were	 rabbit	 anti-laminin	 (1:200,	 Z009701,	
Dako),	 mouse	 anti-nestin	 (1:200,	 Biosensis,	 M-1385-100),	 rabbit	 anti-SOX9	
(1:500,	 Millipore,	 AB5535),	 rabbit	 anti-NGFR	 (1:200,	 Millipore,	 07-476),	 mouse	
anti-TUBB3	 (1:200,	 Abcam,	 ab78078)	 and	 rabbit	 anti-TYRP1	 (1:50,	 Santa	 Cruz	












rabbit	 (1:500,	 Invitrogen,	A-11034)	 and	Alexa	Fluor	 555	 goat	 anti-mouse	 (1:500,	
Invitrogen,	A-21422).	To	confirm	secondary	antibody	specificity,	negative	controls	
were included in which the primary antibodies were omitted. Images were made 
with an Olympus IX70 microscope equipped with a Leica DFC340 FX camera using 
LAS AF software (Leica).
Brightness	and	contrast	adjustments	consistent	with	image-manipulation	policies	







At the start of the culture, some cells residing within the hair follicle bulge stained 





on previous immunophenotyping in similar culture experiments, these cells can be 
identified	as	pan-Cytokeratin-	and	cytokeratin15-positive	keratinocytes	(results	not	
shown).
To	 further	 establish	 the	 immunophenotype	 and	 identity	 of	 these	 nestin-	 and	
TUBB3-positive	cells,	we	performed	double	immunostaining	for	TUBB3	together	
with various markers of the early neural crest, Schwann cell and melanocyte 
lineages.	 All	 TUBB3-positive	 cells	 co-expressed	 nerve	 growth	 factor	 receptor	
(NGFR, also often named p75NTR)	(Figs.	2A-B)	and	(sex	determining	region	Y)-box	
9	 (SOX9)	 (Figs.	2C-D),	 indicating	that	 these	cells	are	of	 the	melanoglial	 lineage.	
Double	 immunostaining	 for	 TUBB3	 and	 tyrosinase-related	 protein	 1	 (TYRP1),	
a	protein	 involved	 in	melanin	 synthesis,	 revealed	a	high	degree	of	 co-expression	


















cells migrating out of the hair follicle bulge explant would be melanocytes. Our 
results	 show,	 however,	 that	 the	 TUBB3-positive	 cells	 migrating	 out	 of	 the	 hair	
follicle	bulge	 co-expressed	nestin,	NGFR	and	SOX9,	 indicative	of	a	melanoglial	
identity, notwithstanding their TUBB3 expression which is generally thought to be 
limited to neuronal cells.
To investigate whether these cells were actually committed to either a melanocytic 
or glial cell fate, we performed additional double immunostainings for TUBB3 
together with pertinent lineage markers for each respective cell type, i.e. TYRP1 
for	melanocytes	and	laminin	for	glial	cells,	resulting	in	diverse	findings.	TUBB3-
positive	cells	showed	weak	TYRP1	co-expression	and	the	most	plausible	explanation	
is that these cells belong to a population of intermediate cells, which seem to 
show a tendency to the melanocytic commitment. Double immunostaining with 
antibodies against TUBB3 and laminin revealed a second population consisting 
of	TUBB3-negative	and	laminin-positive	cells,	suggesting	that	these	cells	belong	to	
the Schwann cell lineage. 
The	hair	follicle	bulge	accommodates	several	different	(stem)	cell	populations[8].	In	
addition, in the vibrissae this region is abundantly innervated by multiple sensory 
nerve endings[9, 10]. Given the immunophenotype of the cells in our cultures, we 
hypothesize that both populations originate either from Schwann cells located in 
the	proximal	nerve	stump	or	sensory	nerve	endings[10–12],	or	 from	melanocyte	
stem cells in the bulge[13, 14], both displaying an intermediate status between glial 
and melanocytic cell fate choice.
Recently,	 a	 nestin-positive	 cell	 population	 has	 been	 shown	 to	 reside	 between	
the basal membrane and the outer root sheath in the area just above the bulge, 
exhibiting long processes forming a crown around the whole hair follicle[15]. These 
cells are closely associated with terminal nerve endings and are thought to be 
similar	to	nestin-positive	type-II	terminal	Schwann	cells	of	the	piloneural	collar[12].	
Interestingly,	 the	 first	 paper	 reports	 that	 these	 nestin-positive	 cells	 co-express	
NGFR,	and	that	this	nestin-	and	NGFR-positive	cell	population	shares	histological	
characteristics	 and	 immunological	markers	with	 the	 nestin-positive,	multipotent	
stem	cells	 from	the	bulge-isthmus	region	of	hair	 follicles[4].	The	authors	assume	




cultures originate from the same source, i.e., Schwann cells from the hair follicle 
sensory nerve endings, existing in an intermediate phase between a Schwann cell 





cells located in the hair follicle bulge remains to be elucidated.
Interestingly,	it	has	been	reported	that	nestin-	and	NGFR-positive	cells,	identified	
as	nerve-terminal-	associated	NCSCs	and	 located	around	 the	hair	 follicle	bulge,	
contribute	cells	to	regenerating	dermis	following	skin	injury[17].	These	nestin-	and	
NGFR-positive	cells	are	probably	key	to	wound	healing,	for	it	has	been	shown	that	




positive	 cells	 of	 melanoglial	 lineage,	 which	 sheds	 a	 new	 light	 on	 the	 different	
populations of (stem) cells that have been proposed to reside in the hair follicle 
bulge.	Especially,	the	use	of	TUBB3	as	a	specific	marker	of	neuronal	identity	should	
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On the origin of cell types in the human cochlea
The	first	aim	of	 this	 thesis	was	 to	gain	more	 insight	 into	 the	developing	human	
fetal	 cochlea.	The	adult	cochlea	contains	cells	derived	 from	different	embryonic	
regions: the otic placode, the mesoderm, and the neural crest. To establish the 
exact	origin	of	a	cell	type	one	has	to	perform	lineage-tracing	experiments,	either	
by using the classic, chimeric, transplantation and dye injection approaches or by 
using	more	modern	genetic	fate-mapping	methods.	Although	lineage	tracing	in	the	
human	 fetus	 is	 difficult	 due	 to	 both	 ethical	 and	 technical	 reasons,	 experiments	
on the salamander [1], chicken [2], and rodent [3] have shown similar embryonic 
origins of various cochlear cell types in these three species. All immunostainings 
presented	in	this	dissertation	on	the	human	fetal	cochlea,	as	shown	in	Chapters	2-4,	
match the expression patterns (when available) of the developing cochlea in other 
vertebrate species. This strongly supports the hypothesis that the origin of all cell 
types in the vertebrate cochlea, including the human, is highly conserved. Animal 
data	in	combination	with	the	data	presented	in	Chapters	2-4	result	in	a	model	of	
the origin of cell types in the human cochlea, described in the following paragraphs 













Most of the cochlea is derived from the otic placode and develops via the otic vesicle 
stage into both the vestibular labyrinth and the cochlear duct. It is therefore likely 
that all epithelial cells lining the cochlear duct are derived from the otic placode. 
Counterclockwise (Figure 1), starting at the organ of Corti, these cells are: hair cells 
and	various	types	of	supporting	cells,	Hensen’s	cells,	Claudius’	cells,	outer	sulcus	
root cells, the epithelial cells of the spiral prominence, the marginal cells of the 
stria	vascularis,	the	epithelial	cells	of	Reissner’s	membrane,	interdental	cells,	and	
the	inner	sulcus	cells	(or	Kölliker’s	organ	in	the	fetus).	All	these	different	cell	types	
develop	from	a	more	or	less	undifferentiated	epithelium	which	at	the	10th week of 
gestation (W10) expresses SOX9 and SOX10, with additional SOX2 expression in 
the prosensory domain (Chapter 2).
Spiral ganglion neurons
Spiral ganglion neurons (SGNs) are, like the epithelial lining of the cochlear 
duct, also derived from the otic placode. Proneural cells delaminating from the 
Figure 1. Schematic illuStration oF the cochlear duct / Scala media.
1: hair cells, 2: Hensen’s cells, 3: Claudius’ cells, 4: outer sulcus root cells, 5: epithelial cells of the spiral prominence, 6: marginal 
cells of the stria vascularis, 7: epithelial cells of Reissner’s membrane, 8: interdental cells in the spiral limbus, 9: inner sulcus cells. 
Picture courtesy of S.B. Blankevoort.
disCussion
184
otic vesicle start to form the statoacoustic ganglion, which in humans presumably 
occurs around Carnegie stage 13 (~32 days of fetal age, during the 6th week of 
gestation) [4]. As maturation advances, the cochlear spiral ganglion separates from 
the	vestibular	neurons	(Scarpa’s	ganglion)	and	type-I	and	type-II	SGNs	gradually	
appear. As we could not acquire cochlear specimens of fetal stages before W9, we 
were unable to visualize the key event of delamination. We did, however, shed 
new	light	on	the	onset	of	type-I	versus	type-II	SGN	identity	in	the	human	cochlea,	
as	 from	W18	onwards,	 the	 intermediate	filament	peripherin	became	restrictively	
expressed	in	groups	of	cells	representing	type-II	SGNs,	suggesting	that	they	share	a	
common progenitor (Chapter 2). 
Peripheral glial cells and melanocytes
Presently,	at	least	two	neural	crest-derived	cell	types	are	known	to	be	present	in	the	
cochlea: (1) peripheral glial cells and (2) specialized melanocytes. 
A neural crest origin of the peripheral glial cells in the cochlea has been investigated 
in multiple studies, both recently by genetic tracing studies in the mouse [5, 6] and 
longer ago by tissue transplantation studies in the salamander and chicken [1, 2]. 
As shown in Chapter 3, the distribution and developmental pattern of peripheral 
glial cells in the human fetal cochlea matches with the postulate of a neural crest 
origin. The importance of these glial cells cannot be underestimated, as they (or 
their precursors) not only guide the central processes of SGNs towards their correct 
position within the brain [7], but are also essential for synchronous activity of SGNs 
in the adult cochlea, a prerequisite for normal hearing [8]. An intriguing question 
remaining	to	be	answered	is	the	exact	route	that	is	taken	by	the	neural	crest-derived	
peripheral glial cells to reach and enter the cochlea. The cellular distribution 
pattern we observed at W9 indicates that the peripheral glial cells migrate via 
the vestibulocochlear nerve (the 8th cranial nerve) into the human fetal cochlea. 
However, as SGNs originate from the otic placode, there has to be a moment during 
embryonic development when these two cell populations encounter one another 
for	the	first	time.	Interestingly,	the	vestibulocochlear	ganglion	and	the	geniculate	
ganglion (the ganglion of the facial nerve, n. VII) are in close proximity to one 
another	early	during	development	[9];	also	see	Figure	2).	As	the	facial	nerve	and	
the	geniculate	ganglion	 receive	 their	neural	 crest-derived	cell	population	 from	a	
migratory stream of neural crest cells originating from rhombomere 4footnote1 (Figure 












from this migratory stream of neural crest cells [2, 6, 10, 11].
As	proposed	in	Chapter	4,	cochlear	melanocytes	might	be	derived	from	a	different	
migratory stream of neural crest cells, this one originating from rhombomere 6. This 
is supported by images from several studies in mouse embryos in which, although 
not mentioned by the authors, neural crest (derived) cells are clearly visible on the 
apical side of the developing otic vesicle, i.e. the side facing rhombomere 6 [3, 5, 
6, 12, 13]. In the human fetus at W9.1, melanocytes are present both around the 
nervous tissue at the apical side of the developing cochlea (at this stage likely part 
of the glossopharyngeal nerve (n. IX)), within the developing otic capsule, and 
in the mesenchyme bordering the developing stria vascularis (Chapter 4, Figure 
S1A). The glossopharyngeal nerve itself originates partly from an epibranchial 
placode and partly from delaminating neural crest cells, both of which are derived 
from rhombomere 6 [11, 14]. Taken together, we therefore believe that cochlear 
melanocytes originate from the stream of migrating neural crest cells from 
rhombomere	6	before	travelling	through	the	developing	otic	capsule	and	finding	
Figure 2. SectionS through human FetuSeS at carnegie StageS 14 and 15. 
r4-6: rhombomeres 4-6, G+VCG: geniculate ganglion and the vestibulocochlear ganglion, OV: otic vesicle, n. VII: facial nerve, n. 




their way to the lateral wall epithelium during the early embryonic development. A 
model of these migratory streams of neural crest cells is shown in Figure 3B. Future 
studies are needed to test this model.
Cell types with unknown origin
There are two cell types residing in the cochlea whose the exact embryonic origin 
remains unknown: (1) the basal cells and (2) the interdental cells.
Figure 3. Schematic illuStration oF the hindbrain and otic veSicle in the human FetuS.
(A) Overview showing the otic vesicle (OC) and its position relative to the rhombomeres (r1-7), the developing cranial nerves n. V, 
n. VII/VIII and n. IX and the pharyngeal arches (PA1-4). (B) Migratory streams of neural crest cells delaminating from the regions 













The origin of the basal cells in the stria vascularis remains unknown as little 
research has been done on these cells (the exact location of the basal cells within 
the cochlea is shown in Chapter 4, Figure 1). Theoretically, there are three possible 
sites of origin: (1) they belong to the mesenchymal portion of the cochlea (as do 
the	bordering	fibrocytes	in	the	spiral	ligament),	(2)	they	originate	from	the	neural	





Interdental cells are located in the spiral limbus and most likely play an additional 
role in potassium homeostasis [15] as they express KCNJ10 on their apical (luminal) 
membranes [16]. A recent study in mice traces interdental cells to a shared lineage 
with spiral ganglion neurons, suggesting an otic placode origin [17]. However, 
the same study also groups them with the intermediate cells (melanocytes), which 
clearly	have	a	different	(neural	crest)	origin.	This	contradiction	needs	to	be	resolved	
to	 conclusively	 confirm	 their	 origin.	 Neural	 crest	 lineage-tracing	 studies	 in	 the	
cochlea have never observed cells that migrate to the spiral limbus, which would 
argue against a neural crest origin of the interdental cells. Nonetheless, they would 
have	been	easily	overlooked	as	this	specific	region	has	not	been	investigated	at	the	
proper embryonic or fetal stages, and as multiple lineage markers are expressed in 




Cochlear regeneration using stem cells
The second aim of this thesis was to pursue a possible stem cell strategy for the 
restoration of hearing. To successfully regenerate damaged or lost cochlear structures 
by	means	of	stem	cell-based	therapies,	one	has	first	to	select	the	appropriate	stem	
cell source. Two general approaches may be considered: (1) taking advantage of 
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stem cells residing in the adult cochlea itself, and (2) introducing exogenous stem 
cells into the damaged cochlea.
Cochlear stem cells
There are several lines of evidence suggesting that the adult mammalian cochlea 
still contains stem cells. In the 1980s it was discovered (against expectations) that 
adult birds are able to regenerate hair cells in their damaged basilar papillae, i.e., 
the hearing organ in birds [18, 19]. Later, it became clear that in various vertebrate 
species,	ranging	from	amphibians	to	fish,	hair	cells	are	able	to	regenerate	or	are	
continuously produced [20]. Hair cells in the vestibular organs likewise renew 
throughout	life	in	birds	as	well	as	in	most	other	non-mammalian	vertebrates.	The	
supporting cells in the sensory epithelium were found to be the source of the new 
hair cells. Unfortunately, spontaneous hair cell regeneration in mammals seems 
to have been lost during evolution, except for the limited capability for hair cell 
renewal in the vestibular organs of rodents. Although the exact reason remains 
unknown,	it	is	suggested	that	this	loss	has	been	a	trade-off	with	the	development	
of the unique but intricate architecture of the organ of Corti in which regeneration 
has become too challenging [21]. 
Since the discovery that hair cells in birds can regenerate, numerous studies have 
focused	on	identifying	the	key	regulators	of	hair	cell	specification,	differentiation	
and regeneration in order to induce hair cell (re)generation in mammals. Major 
players	that	have	been	identified	presently	are	the	Notch/Jagged	signaling	pathway,	
transcription factors Atoh1 and Sox2 and cell cycle regulatory protein p27Kip1 [22]. 
Since	 it	 has	 been	 shown	 that	 new	 hair	 cells	 are	 derived	 from	 Sox2-expressing	
supporting cells, an important question is to ask if the human organ of Corti still 
contains	SOX2-positive	cells	supporting	cells.	Experiments	from	Chapter	2	showed	
that these supporting cells in the human fetal cochlea do express SOX2 positive 
up to the latest stage investigated (W19). Whether or not they retain their SOX2 
expression in the adult cochlea remains to be seen. If so, successful experimental 
therapies	in	animal	studies	could	benefit	potential	human	trials.	
Another interesting note is be made regarding regeneration of other cochlear 
structures. At present, there is no evidence whatsoever for regeneration of, for 
example, spiral ganglion neurons or cells in the stria vascularis by means of innate 
cochlear stem cells. Does this mean that there are no such cells? Intriguingly, 












Chapter 4) or in the modiolus (data not shown). Why exactly are those cells present 
at these sites, and are they or could they serve as a local source of stem cells?
Exogenous stem cells
The other stem cell option to consider in cochlear regeneration is the transplantation 
of exogenous stem cells into the damaged cochlea, which should be able to migrate 
to	 the	 appropriate	 site	 and	differentiate	 into	 the	 desired	 cell	 type.	Therefore,	 it	




As	 stem	 cells	 come	 in	 multiple	 flavours,	 extensive	 knowledge	 of	 the	 molecular	
basis of cell fate is a prerequisite for selecting the appropriate stem cell type. For 
example, the transcription factors Pax2 and Pax8 are expressed in the otic placode, 
whereas	cochlear	neural	crest	precursors	express	Pax3.	A	Pax2-/Pax3+/Pax8-	stem	
cell	most	 likely	will	not	differentiate	 into	a	hair	cell,	as	 it	 is	destined	to	develop	
in another cell lineage (more extensively reviewed in [23]). However, this cell type 
could very well be the stem cell of choice for the formation of new peripheral glial 
cells. 
As the otic placode is formed very early during embryological development, the 
most	 likely	 candidates	 for	 otic	 placode-derived	 cell	 induced	 regeneration	 (such	
as hair cell or spiral ganglion cell regeneration) are the pluripotent stem cells. 
Promising	candidate	stem	cells	are	the	induced-pluripotent	stem	cells	(iPSCs)	[24]	
as these cells resemble in many aspects an early embryonic cell type still able to 
differentiate	into	most	cell	lineages.	An	additional	advantage	is	that	iPSCs	can	be	
derived from adult tissue of the patient himself. Another option would be to use 
human embryonic stem cells, which have recently been shown to have a restorative 
effect	 on	 auditory	 function	when	 introduced	 in	 an	 animal	model	with	 auditory	
neuropathy	[25].	Although	transplantation	proved	effective	in	that	study,	immune	
responses can be expected when using such cells in a human transplantation setting. 
Stem	 cells	 such	 as	 patient-specific	 iPSCs	 will	 most	 likely	 not	 have	 this	 adverse	
effect	 if	 used	 autologously.	 Other	 important	 reasons	 to	 consider	 in	 selecting	 a	
stem cell source for regeneration purposes is the tendency of stem cells to form 





deviate from its requested path. To circumvent this problem, a stem cell type could 
be	selected	that	is	more	differentiated	but	retains	stem	cell	characteristics,	such	as	
neural crest stem cells (NCSCs). Evidently in the case of NCSCs, their suitability to 
regenerate hair cells or spiral ganglion neurons is limited, but they could prove to 
be the appropriate choice when it comes to regeneration of peripheral glial cells or 
cochlear melanocytes.
Hair follicle stem cells
Beginning in 2004, researchers began reporting that adult hair follicles contain 
NCSCs [26, 27]. As mentioned previously, this could have an enormous therapeutic 
potential,	as	it	is	thought	that	these	cells	are	still	able	to	differentiate	into	multiple	
important cell lineages and because they can be easily harvested from patients. In 
one of the original studies a Wnt1-cre/R26R	compound	transgenic	mouse	was	used	
[26].	In	hair	follicle	bulge	cultures,	TUBB3-positive	cells	were	found	showing	X-gal	
activity, meaning that these cells (had) expressed Wnt1. The authors mentioned 
that neural crest cells express Wnt1 transiently, and therefore concluded that the 
TUBB3-positive	cells	 (which	were	 identified	as	neurons)	originated	from	NCSCs.	
However,	as	shown	in	Chapters	5-7,	we	suggest	that	there	are	no	bona	fide	NCSCs	
in the adult hair follicle and that the interpretations made in their study were likely 
based on an extended expression of TUBB3 in multiple neural crest derivatives, 
including	 the	melanocytic	 lineage	 (Chapters	5-7).	Furthermore,	Wnt1 is not only 
expressed transiently in the neural crest but also in the melanocytic lineage, where 
it	 controls	differentiation,	proliferation	and	 tumor	 initiation	 [28,	 29].	Therefore,	
an	 alternative	 conclusion	 about	 the	 presence	 of	 TUBB3-positive	 cells	 in	 adult	
hair	follicles	could	be	that	TUBB3-positive	cells	from	those	original	studies	were	
melanoblasts/melanocytes	rather	 than	neurons.	 In	 that	perspective,	 the	TUBB3-
positive cells could originate from melanocyte stem cells residing in the bulge, or 
could	be	dedifferentiated	Schwann	cells	(Chapter	7).	Remarkably,	no	study	so	far	
has	convincingly	shown	expression	of	other	neuron-exclusive	markers	or	recorded	
action potentials (Chapter 5) from in vitro	hair	follicle	bulge-derived	cells.
Even though it seems plausible that there is no true neural crest stem cell located 
in	 the	 hair	 follicle	 bulge	 and	 that	 these	 cells	 do	 not	 differentiate	 into	 neurons,	
hair-follicle	 bulge	 derived	 cells	might	 retain	 their	 therapeutic	 potential	 when	 it	














bulge region, which may act jointly to achieve tissue restoration [30, 31].
Nevertheless,	 whether	 neural	 crest-derived	 neurons	 are	 the	 right	 candidate	 to	
replace damaged SGNs remains an open question. SGNs are derived from the 
otic placode and not from the neural crest like most other neurons from the 
peripheral nervous system. Therefore, cell regeneration with neurons derived from 
neural crest stem cells might not result in cells with the unique morphological and 
electrophysiological characteristics of SGNs.
Although more research is required, it is very likely that both Schwann cells and 
melanocytes can be easily cultured from hair follicle explants (from the mouse 
whisker pad), though it is unclear whether they originate from one multipotent 
stem	cell	or	from	two	different	(stem)	cell	pools	(Chapter	7).	In	the	inner	ear,	such	
cells could potentially be put to use in restoring the peripheral glial cells around the 
SGNs, or to renew melanocytes in the stria vascularis. As etiologic knowledge on 
many types of deafness is still incomplete, future insights may lead to applicability 
of these cell types in treating hearing loss.
the onset of human hearing
In the mouse and rat, hearing develops predominantly after birth [32]. In contrast, 
the development of the cochlea in humans (as well as guinea pigs [33] and chinchillas 
[34])	occurs	during	gestation	(Chapters	2-4).	However,	in	all	mammals,	the	cascade	
of developmental events that leads to hearing is largely identical. At which fetal age 
auditory function starts in the human remains an intriguing question, one that very 
few studies have investigated or have speculated on.
For	simplicity’s	sake,	hearing	can	be	defined	as	the	generation	of	an	action	potential	
in a reaction to sound, which is propageted to the brain (therefore disregarding 
any	 ‘higher’	 features	 such	 as	 synchronicity	 and	 central	 processing,	 which	 likely	
continue to develop after birth). Taking this into account, there are two absolute 
requirements: (1) the right cells should be present at the right location, and (2) 
there should be a functional electrochemical environment. Unfortunately, there is 
a lack of knowledge on both aspects in the human fetal cochlea. Do we understand 




cells for that matter? Also, we do not know the exact contribution of each cell type 
to the cochlear ionic homeostasis. For example, do satellite glial cells play a role 
in potassium regulation (which they likely do)? Or, what are the exact routes of 
potassium recycling? 
Even within these limitations, an educated guess can be made using the following 
assumptions: hearing is possible (1) when the spiral ganglion neurons are connected 
to hair cells, and (2) when there is a functional endocochlear potential (see Chapter 
4	for	an	explanation	of	the	term	‘endocochlear	potential’).
As	 shown	 in	Chapter	2,	 the	first	 contact	between	hair	 cells	and	SGNs	occurs	 in	
the	basal	turn	at	W12,	refining	in	the	weeks	thereafter.	At	W18,	a	configuration	of	
type-I	and	type-II	SGNs	and	inner	and	outer	hair	cells	can	be	found	in	the	basal	
turn that by and large mimics the adult situation. However, the question remains 
whether a positive endocochlear potential is present at 18 weeks of gestation (which 
is, for ethical reasons, impossible to measure in an experimental setting). Based 
upon the morphological development of SGNs and hair cells, we have proposed, as 
have	others,	(Chapters	2-3)	that	hearing	commences	around	W18-20.	However,	this	
statement has been made without taking the endocochlear potential into account 
(Chapter 4). There are several studies measuring auditory responses in preterm 
human neonates. One study measured evoked otoacoustic emissions and observed 
(very weak) activity in neonates born at 28 weeks of gestation [35]. Unfortunately 
presence of these responses was not investigated in all neonates of that particular 
age,	and	younger	subjects	(very	preterm	neonates)	were	not	measured.	In	a	different	
study measuring automated auditory brainstem responses in preterm neonates, a 
bilateral	pass	was	first	observed	at	W27-28,	steeply	increasing	to	W32	where	pass	
rates included almost all subjects [36]. Both studies suggest that the earliest week at 
which hearing in humans commences is around W28. However, as the used auditory 
tests have limitations in their sensitivity, the actual onset of hearing could occur 
earlier. 
In mice and in gerbils, the rise of the endocochlear potential has been studied 
during embryonic development [37, 38]. These studies concluded concluded that a 
certain level of maturation of gap junctions and tight junctions is required before 
the endocochlear potential develops. Data from Chapter 4 studying several key 
potassium channels and other proteins that are thought to play a role in the 
generation	of	 the	endocochlear	potential	 indicate	 that	 this	system	of	potassium-
regulating structures is still immature at W18. For example, the intermediate cells 












study investigating the fetal stria vascularis by means of electron microscopy in a 
few human cochlear samples from stages older than W19 found that basal cells and 
gap junctions could be clearly observed at the end of W24 [39]. When comparing the 
limited amount of human immunohistochemical and electron microscopical data 
from all investigated developmental stages to the timelines of mouse and gerbil 
cochlear development, a clear pattern emerges. Extrapolating the functional onset 
of the endocochlear potential in these animals to the human developmental timeline 
indicates	that	hearing	is	unlikely	to	take	place	in	a	human	cochlea	at	W18-W20.	We	
now speculate that human hearing commences somewhere between W26 and W28 
(in the 7th month of pregnancy, around the start of the third trimester).
future researCh and appliCations
Both basic research investigating physiology and development of auditory function 
and more clinically oriented research in genetics and stem cell therapies help in 
discriminating	 between	 normal	 and	 pathological	 conditions	 and	 in	 finding	 new	
treatment strategies for patients with hearing loss.
Investigating later gestational stages and even adult human cochlear tissue 
could extend the developmental insights gained by this work. However, obtaining 
material	of	sufficient	quality	has	of	course	both	practical	and	ethical	issues.	Other	
investigations could focus on mapping the expression of all genes known to be 
involved in SNHL. This would provide more knowledge on the involved cell types 
and	damaged	structures,	which	in	turn	will	provide	valuable	input	to	the	field	on	
therapeutic interventions. Finally, regardless of whether or when gene or stem cell 
therapies become clinically available, there is much knowledge to be gained by 
investigating the causes of SNHL. For a large portion of hereditary SNHL cases, the 
cause of their hearing loss remains unknown. Further, patients are not yet screened 
for all known mutations. As knowledge on the genetics of hereditary hearing loss 
continues to increase and genetic screening methods become more extensive and 
cheaper, much progress should be expected on this topic within the next decade.
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The embryonic development of the human cochlea (the organ of hearing) has been 
investigated for over one hundred years. Still, little is known about the development 
on a cellular and protein level, which is important to better understand etiologies 




gestation and investigated several aspects of the normal development of the human 
cochlea in Chapters 2-4.
 Chapter 2 investigated the development of the hair cells and the spiral 
ganglion	neurons.	Cochlear	hair	cells	develop	out	of	an	undifferentiated	epithelium.	
We showed that, at the 10th week of gestation (W10), all epithelial cells expressed both 
SOX9 and SOX10 with the addition of SOX2 expression in the prosensory domain. 
We	 found	 the	first	 developing	hair	 cell	 at	W12,	 coinciding	with	downregulation	
of SOX9 and SOX10 in this cell, to be followed later by downregulation of SOX2. 
Markedly, outgrowing neurites from spiral ganglion neurons were found penetrating 
into	the	cochlear	duct	epithelium	prior	to	the	first	hair	cell	differentiation.	These	
neurites directly targeted the hair cells as they developed. Investigating Peripherin 
expression	 (in	 the	 mature	 cochlea	 only	 expressed	 in	 the	 type-II	 spiral	 ganglion	
neurons), showed that all spiral ganglion neurons expressed this protein in early 
stages,	and	that	expression	gradually	diminished	and	became	restricted	to	the	type-
II	spiral	ganglion	neurons	by	18	weeks.	At	20	weeks,	the	expression	profiles	in	hair	
cells and spiral ganglion neurons matched the expression patterns of the adult 
mammalian cochlea.
 Chapter 3 investigated a third cochlear cell type, the peripheral glial cell. 
The	adult	human	cochlea	contains	 three	different	 types	of	peripheral	glial	cells:	
myelinating and unmyelinating Schwann cells and satellite glial cells. In this 
chapter, we focused on the developmental distribution of the peripheral glial cells 
and on the onset of myelination of spiral ganglion neurons, one of the prerequisites 
of normal hearing. We observed glial cells at our earliest investigated stage (W9) 
in all three neuronal domains: both near central and peripheral processes and at 
the location of the SGN cell bodies. Glial cells associated themselves with SGN cell 
bodies from W12 onwards and these satellite glial cells populated the spiral ganglion 
in a spatiotemporal gradient. In the cochlear nerve, radial sorting and myelination 












that the three types of glial cells in the human adult cochlea are all derived from 
the precursor cells observed at W9, and that the observed developmental patterns 
support a neural crest origin of these cells in the human.
 Chapter 4 investigated the development of the stria vascularis and cochlear 
potassium regulation, including its relation to syndromic and nonsyndromic 
sensorineural hearing loss. At W12, melanocytes were found migrating into the 
cochlea and penetrating the basement membrane of the lateral wall epithelium, 
forming the intermediate cellular layer of the stria vascularis. In the following 
weeks, these melanocytes tightly integrated with the developing marginal cells, 
the epithelial cellular layer. We showed the expression of several melanocytic 
proteins (MITF, SOX10, KIT), potassium regulating proteins (Na+/K+-ATPase,	
KCNQ1, KCNJ10), and gap junction proteins (GJB2, GJB6, GJA1, GJE1) in this 
developing	structure.	All	these	proteins	are	known	to	be	involved	in	different	types	
of hereditary sensorineural hearing loss except GJE1, which could therefore be a 
potential	new	associated	locus	for	this	disease.	Based	on	the	data	from	Chapters	2-4	
and literature on development of hearing in animals we propose that hearing in the 
human commences between W26 and W28, later than previously suggested.
 
Chapters 5-7 are related to the neural crest stem cells residing in the hair follicle 
bulge.	These	cells,	first	discovered	a	decade	ago,	are	of	strong	interest	to	stem	cell	
researchers as they could serve as a pool of easy accessible stem cells capable of 
differentiating	 into	 multiple	 cellular	 lineages	 (amongst	 which	 are	 neurons	 and	
glial cells). Potentially, they could be used to regenerate various cochlear tissues. 
However, in Chapter 5 and Chapter 6 we showed that a protein (TUBB3) often 
used in immunochemistry to detect a neuron is also expressed both in skin and hair 
follicle melanocytes in humans. This could indicate that cells from the melanocytic 
lineage	mistakenly	were	identified	as	neural	crest	stem	cells.	This	insight	was	used	
in Chapter 7, where we cultured mouse hair follicle bulge explants to investigate 
expression of TUBB3. Strikingly, cultured cells expressing this protein were not of 
the neural lineage but rather from the melanoglial lineage. Together, this showed 
that the proposed neural crest stem cell residing in the hair follicle bulge might need 
revision. However, as both melanocytes and peripheral glial cells are present and 
have important functions in the cochlea, hair follicle bulge cells remain a suitable 




Al meer dan honderd jaar wordt er onderzoek gedaan naar de embryonale 
ontwikkeling van de humane cochlea (het gehoororgaan). Er is echter nog steeds 
weinig	bekend	over	deze	ontwikkeling	op	een	cellulair	of	gen/eiwit-niveau.	Deze	
kennis is van groot belang om de etiologie en pathologie van verschillende typen van 
sensorineuraal gehoorverlies beter te kunnen begrijpen. Kennis over het normale 
patroon	van	genexpressie	en	celdifferentiatie	in	de	humane	cochlea	draagt	bij	aan	
de ontwikkeling van genetische en op (stam)cel gebaseerde therapieën. 
In	een	serie	van	humane	foetale	cochlea’s	van	verschillende	stadia	van	ontwikkeling	
hebben wij een aantal aspecten van de normale ontwikkeling onderzocht in 
Hoofdstukken 2-4.
 Hoofdstuk 2 onderzocht de ontwikkeling van de haarcellen en de spiraal 
ganglion neuronen (SGN). Cochleaire haarcellen ontwikkeling zich vanuit een 
ongedifferentieerd	epitheel.	We	toonden	aan	dat	in	de	10e	week	van	de	zwangerschap	
(W10) alle epitheliale cellen zowel SOX9 en SOX10 tot expressie brengen met 
daarnaast	ook	SOX2	expressie	in	het	‘prosensory	domain’.	De	eerste	haarcel	zagen	
we zich ontwikkelen in W12, waarbij dit samenging met downregulatie van SOX9 
en SOX10 in deze cel, enige weken later gevold door downregulatie van SOX2. 
Opvallend genoeg vonden we ingroei in het cochleaire epitheel door de neuriten 
van de SGN voorafgaand aan de ontwikkeling van de eerste haarcel. Deze neuriten 
richtten zich gelijk naar de haarcel zodra deze zich ontwikkelde. Het onderzoeken 
van	 Peripherin	 expressie	 (wat	 zich	 in	 de	 volwassen	 cochlea	 alleen	 in	 de	 type-II	
SGN bevindt) toonde aan dat eiwit door alle SGN tot expessie werdt gebracht in 
de vroege embryonale fasen maar dat deze expressie geleidelijk verminderde en 
selectief	werd	voor	type-II	SGN	in	W18.	Het	expressieprofiel	in	de	haarcellen	en	de	
SGN kwam in W20 overeen met het bekende patroon van de volgroeide cochlea bij 
zoogdieren.
 Hoofdstuk 3 onderzocht een derde cel type in de cochlea, de ‘peripheral 
glial	cell’.	De	volwassen	humane	cochlea	bevat	weer	drie	verschillende	typen	van	
deze cel: gemyeliniseerde en ongemyeliniseerde Schwann cellen en ‘satellite glial 
cells’.	In	dit	hoofdstuk	richtten	we	ons	op	de	verspreiding	en	differentiatie	van	deze	
cellen tijdens de ontwikkeling in de cochlea, en op het ontstaan van myeline rondom 
de spiraal ganglion neuronen: een van de vereisten voor een normale functie van 
het gehoor. We zagen al gliale cellen in de jongste fase die we onderzochten (W9) 
in alle drie de neuronale domeinen: zowel rond de centrale en perifere uitlopers als 












aan met de cellichamen van de SGN en werd het spiraal ganglion middels een 
spatiotemporele gradient bevolkt. In de nervus cochlearis ontdekte we ‘radial 
sorting’	en	myelinisatie	in	W22,	voorafgaand	aan	myelinisatie	van	de	perifere	SGN	
uitlopers. Vanwege deze bevindingen achten we het zeer waarschijnlijk dat deze drie 
type gliale cellen in de humane cochlea allen afkomstig zijn van de voorlopercel die 
we zagen in W9, en dat deze observaties ook passen bij een neurale lijst oorsprong 
van deze cellen in de mens.
 Hoofdstuk 4 onderzocht de ontwikkeling van de stria vascularis en de 
cochleaire	kaliumhuishouding,	met	een	verdieping	in	syndromale	en	niet-syndromale	
typen van sensorineuraal gehoorverlies. In W12 zagen we dat melanocyten 
migreerden in de cochlea en dat ze penetreerden door het basaalmembraan van het 
epitheel in de laterale wand, hierdoor zo de intermediare cellulaire laag van de stria 
vascularis vormend. In de hieropvolgende weken integreerde deze melanocyten 
zich sterk met de zich ontwikkelende marginale cellen. Hiernaast toonden we het 
expressieprofiel	aan	van	verschillende	melanocytaire	eiwitten	(MITF,	SOX10,	KIT),	
kalium regulerende eiwitten (Na+/K+-ATPase,	KCNQ1,	KCNJ10)	en	gap	junction	
eiwitten (GJB2, GJB6, GJA1, GJE1). Van al deze eiwitten is het bekend dat ze 
betrokken zijn in verschillende vormen van erfelijke sensorineurale gehoorverliezen 
behoudens GJE1, wat wellicht mogelijk een nieuw geassocieerde locus voor deze 
aandoening zou kunnen blijken. 
	 Gebaseerd	op	alle	data	van	Hoofstukken	2-4	en	kennis	over	de	ontwikkeling	
van het gehoor bij knaagdieren vangt het menselijk gehoor waarschijnlijk pas aan 
tussen W26 en W28, later dan vooralsnog frequent wordt aangenomen.
Hoofdstukken 5-7 hebben betrekking op de neurale lijst stamcellen die zich bevinden 
in de haarfollikel bulge regio. Deze cellen, ruim tien jaar geleden ontdekt, zijn zeer 
interessant voor stamcelonderzoek omdat ze mogelijk kunnen dienen als een zeer 
toegankelijk	bron	van	stamcellen	die	zich	nog	kunnen	differentieren	in	verschillende	
nuttige celtypen (waaronder neuronen en gliale cellen). Potentieel zouden deze 
cellen dan ook kunnen worden ingezet voor het herstel van verschillende cochleaire 
weefsels. Echter, in Hoofdstuk 5 en Hoofdstuk 6 lieten we zien dat veelgebruikt 
eiwit (TUBB3) om neuronen mee aan te tonen middels immunohistochemie ook 
in expressie komt in melanocyten in de huid of haar bij de mens. Dit heeft als 
gevolg	dat	melanocyten	wellicht	vaker	ten	onrechte	zijn	geïdentificeerd	als	neurale	
lijst stamcellen. Dit inzicht hebben we vervolgens gebruik in Hoofdstuk 7 om de 
expressie van TUBB3 te onderzoeken in kweken van de haarfollikel bulge uit de 
muis. Opvallend genoeg liet dit inderdaad zien dat de gekweekte cellen die TUBB3 
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tot expressie brachten niet van neurale maar juist van melanogliale oorsprong zijn. 
Tezamen betekent dit dat het zich bevinden van een neurale lijst stamcel in de 
haarfolikkel heroverwogen zal moeten worden. Echter, omdat zowel melanocyten 
als gliale cellen wel afzonderlijk voorkomen in de haarfollikel en deze celtypen 
belangrijke functies hebben in de cochlea blijft de haarfollikel een interessante 













CD   cochlear duct
CN  cochlear nerve
IHC  inner hair cell
KO	 	 Kölliker’s	organ
NCSC  neural crest stem cell
OC  organ of Corti
OHC  outer hair cell
PGCs  peripheral glial cells
PPs  peripheral processes
SG  spiral ganglion
SGN  spiral ganglion neuron
SNHL  sensorineural hearing loss
ST  scala tympani
SV  scala vestibuli




COL4  collagen type IV
DCT  dopachrome tautomerase
FN	 	 fibronectin
GJA1  gap junction protein, alpha 1 (connexin 43)
GJB2  gap junction protein, beta 2 (connexin 26)
GJB6  gap junction protein, beta 6 (connexin 30)




MBP  myelin basic protein
MITF	 	 microphthalmia-associated	transcription	factor
MYO7A myosin VIIa
NGFR  nerve growth factor receptor (p75NTR)
PCNA  proliferating cell nuclear antigen
PRPH  peripherin
S100B  s100 calcium binding protein B
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1
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